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Preface 
 
The Institute for Prospective Technological Studies (IPTS) was requested by DG 
Enterprise in November 2004 to provide information on academic nanomedicine 
research and commercial activities in Europe, to identify drivers and challenges for 
commercialisation as well as possible socio-economic impacts. This report is the 
outcome of this project, carried out in collaboration with the European Science and 
Technology Observatory (ESTO) network, in particular the VDI Technologiezentrum 
GmbH, Germany, and the Fraunhofer Institute for Systems and Innovation Research, 
Germany, between February 2005 and March 2006.  
 
The IPTS and the ESTO team would like to thank Dr. Rickerby from the JRC Institute 
for Health and Consumer Protection (IHCP), who contributed a thesis paper about 
“Societal and policy aspects of the introduction in Healthcare” and Dr. Vanececk from 
Technology Centre AS, Czech Republic, who analysed nanomedicine activities in the 
Czech Republic. Furthermore, the team would like to thank the experts who took the 
time to participate in interviews.  
 
 

Table of contents
 
5
 
Table of Contents 
 
 
LIST OF TABLES ..................................................................................................................................... 7 
LIST OF FIGURES ................................................................................................................................... 7 
EXECUTIVE SUMMARY........................................................................................................................ 9 
1 INTRODUCTION........................................................................................................................... 15 
2 NANOMEDICINE APPLICATIONS ........................................................................................... 19 
2.1 ADVANCED DRUG DELIVERY SYSTEMS..................................................................................... 19 
2.2 DRUGS AND THERAPIES............................................................................................................. 21 
2.3 IN VIVO IMAGING ...................................................................................................................... 23 
2.4 IN VITRO DIAGNOSTICS............................................................................................................. 25 
2.5 BIOMATERIALS.......................................................................................................................... 27 
2.6 ACTIVE IMPLANTS..................................................................................................................... 29 
2.7 COSMETICS................................................................................................................................ 31 
3 THE NANOMEDICINE SECTOR................................................................................................ 33 
3.1 NANOMEDICINE COMPANIES ..................................................................................................... 33 
3.2 BUSINESS MODELS AND STRUCTURE OF THE INDUSTRY............................................................ 36 
3.3 MARKET .................................................................................................................................... 37 
3.4 DRIVERS FOR DEVELOPMENT .................................................................................................... 39 
3.5 CHALLENGES FOR COMMERCIALISATION .................................................................................. 41 
4 NANOMEDICINE – RESEARCH AND DEVELOPMENT....................................................... 45 
4.1 PUBLICATIONS AND PATENTS.................................................................................................... 45 
4.2 PUBLIC FUNDING AND STRATEGIC INITIATIVES......................................................................... 49 
5 IMPACT OF NANOMEDICINE APPLICATIONS ON HEALTH CARE COSTS................. 53 
5.1 TRENDS IN HEALTH CARE SYSTEMS.......................................................................................... 53 
5.2 COST CONSIDERATIONS FOR NANOMEDICINE APPLICATIONS.................................................... 54 
6 SOCIAL AND ETHICAL ISSUES IN NANOMEDICINE ......................................................... 59 
6.1 HEALTH RISKS OF NANOPARTICLES ........................................................................................... 60 
6.2 CHANGES IN HEALTH CARE DELIVERY ....................................................................................... 60 
6.3 ACCESS TO AND AVAILABILITY OF NANOMEDICINE ................................................................... 61 
6.4 SPECIFIC CHARACTERISTICS OF NANOTECHNOLOGY-BASED DIAGNOSTICS ................................ 62 
6.5 HUMAN ENHANCEMENT ............................................................................................................ 65 
6.6 BLURRING THE BORDERLINE BETWEEN HUMANS AND TECHNICAL ARTEFACTS.......................... 66 
6.7 MILITARY USE .......................................................................................................................... 67 
7 PUBLIC DEBATE .......................................................................................................................... 69 
7.1 PUBLIC PERCEPTION OF NANOTECHNOLOGY AND ITS APPLICATIONS IN MEDICINE .................. 69 
7.2 NON-GOVERNMENTAL ORGANISATIONS – INVOLVEMENT AND POSITIONS ............................... 70 
7.3 DEBATE ABOUT HEALTH AND ENVIRONMENTAL IMPACTS OF NANOPARTICLES........................ 71 
Table of contents 
 
 
 
6 
8 REGULATORY ISSUES ................................................................................................................73 
8.1 TOXICOLOGICAL ASPECTS .........................................................................................................73 
8.2 CLASSIFICATION OF NANOMEDICINE PRODUCTS ........................................................................75 
8.3 REGULATION VERSUS INNOVATION............................................................................................75 
8.4 REIMBURSEMENT.......................................................................................................................76 
9 CONCLUSIONS ..............................................................................................................................77 
10 REFERENCES ............................................................................................................................81 
APPENDIX ...................................................................................................................................................91 
METHODOLOGY APPLIED.......................................................................................................................91 
RESEARCH AND COMMERCIALISATION EFFORTS IN NANOMEDICINE .....................................................94 
NANOMEDICINE PRODUCTS ON THE MARKET ........................................................................................95 
COMPANIES WITH NANOMEDICINE ACTIVITIES......................................................................................99 
 
Table of contents 
 
 
7
List of Tables 
Table 3.1 Companies, products and product pipeline in nanomedicine: Breakdown by medical 
application sectors....................................................................................................................... 35 
Table 3.2 Nanomedicine market 2004 ........................................................................................ 38 
Table 3.3 Examples for commercially successful nanomedicine products................................. 38 
Table 4.1 Publications (cumulative until 2004) and patents (1993-2003) in nanomedicine: 
Breakdown for medical sectors................................................................................................... 46 
Table 9.1 Qualitative comparison of nanomedicine applications in different medical sectors... 77 
 
List of Figures 
Figure 3.1 Nanomedicine Sector: Types of companies and application field breakdown.......... 33 
Figure 3.2 Nanomedicine commercialisation efforts in EU25 countries in 2004: Companies with 
nanomedicine activities, nanomedicine products on the market and in the pipeline .................. 34 
Figure 3.3 Comparison USA and EU25 with regards to nanomedicine research and 
commercialisation efforts............................................................................................................ 35 
Figure 4.1 Nanomedicine publications and patents worldwide .................................................. 45 
Figure 4.2 Area breakdown for nanomedicine publications (1980-2004) and patents (1993-
2003) ........................................................................................................................................... 46 
Figure 4.3 Nanomedicine in Europe: Publications (1980-2004) and patents (1993-2003) for the 
top 15 EU25 countries ................................................................................................................ 47 
Figure 4.4 Share of nanotechnology publications since the 1970s that focus on nanomedicine for 
the top15 EU25 countries............................................................................................................ 47 
Figure 4.5 Nanomedicine companies and leading research groups in the USA identified in this 
study............................................................................................................................................ 48 
Figure 4.6 Nanomedicine companies and leading research groups in the EU identified in this 
study............................................................................................................................................ 49 
Figure 4.7 Nanotechnology public funding of EU25 countries in 2004 ..................................... 50 
 
 

Executive summary
 
9
 
Executive Summary 
Over the past 5 years nanomedicine has taken the shape of an emerging new field of 
nanotechnology applications, encompassing applications of nanotechnology to health. 
By exploiting the improved and often novel physical, chemical, and biological 
properties of materials at the nanometric scale, it aims to provide targeted, site-specific 
therapeutics with reduced adverse effects, novel imaging methods for the early 
diagnosis of diseases, and novel implant materials that support tissue regeneration 
processes. A comprehensive picture of the state-of-the-art of nanomedicine research and 
commercial activities in Europe is currently missing. Against this background a study 
was carried out to provide information on academic nanomedicine research and 
commercial activities in Europe, to identify drivers and challenges for 
commercialisation as well as possible socio-economic impacts. This document 
summarises the results of this study1.  
Research and Development 
Nanomedicine includes several distinct application areas: Drug delivery, drugs and 
therapies, in vivo imaging, in vitro diagnostics, biomaterials, and active implants. In 
these fields, nanomedicine has seen a surge in research activity over the past decade 
with publication numbers rising from some ten per year in the late 1980s to more than 
1200 in 2004. Currently, nanomedicine accounts for about 5% of nanotechnology 
publications worldwide. The dominant research field in nanomedicine is drug delivery 
contributing 76% of the scientific publications followed by in vitro diagnostics with a 
contribution of 11%. EU25 countries account for 36% of all nanomedicine publications 
worldwide, compared to the USA with a contribution of 32% and Asia with 18%. The 
intense research efforts in nanomedicine are driven by significant governmental 
nanotechnology funding programmes worth an estimated EUR 3 billion in 2004. Three 
countries, the USA, Germany and Japan, have recently given clear commitments to 
nanomedicine by establishing focussed nanomedicine research programmes.  
Commercialisation 
Commercialisation efforts in nanomedicine have now started around the world. Of the 
200 companies identified being active in nanomedicine worldwide, 159 are start-ups 
and SMEs that focus on the development of nanotechnology-enhanced pharmaceuticals 
and medical devices. Further, 41 major pharmaceutical and medical device corporations 
have nanomedicine products on the market or run development projects in which 
nanotechnology plays a role. Over the past decade 38 nanotechnology-enhanced 
medical products were placed on the market with estimated total sales of EUR 5.4 
billion in 2004. Based on a pipeline of about 157 products that are in an advanced 
development stage, the market of nanomedicine products is estimated to increase to 
about EUR 15 billion in 2012. Currently, similar to research activities, nanomedicine 
products are dominated by drug delivery systems accounting for about 80% of the 
market. Nanotechnology-based therapies, in vitro diagnostics and imaging agents are 
still in an early development state but it is expected that their importance will 
significantly increase in the future. Although the EU is leading with regards to scientific 
publications it shows less competitiveness when it comes to commercialisation: US 
companies are involved in 46% of the marketed nanomedicine products while EU25 
                                                     
1 See also Wagner V. et al (2006) "The emerging nanotechnology landscape". Nature Biotechnology Vol. 
24, No. 10, p. 1211 - 1217 
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companies have only a share of 37%. Looking at the product pipeline this gap seems to 
widen. This reflects mainly the weak position of EU25-based nanomedicine companies 
in the drug delivery sector, where they represent only 23% of the companies compared 
to 60% for US companies. The share of European companies in the drug delivery sector, 
which is the nanomedicine sector with currently the highest market potential, is about a 
factor of two lower than in the other nanomedicine application areas.  
There are various drivers for nanomedicine product development. On the one hand, 
increased knowledge of molecular processes linked to diseases and advances in 
nanotechnology allowing to manufacture and manipulate materials on the nanoscale 
create a certain scientific-technological push. On the other hand, hitherto unmet medical 
needs, such as the direct targeting of diseased tissue, the early diagnosis of cancer, the 
transport of drugs across the blood-brain barrier and the development of implant 
materials with longer lifespans, create a strong demand for innvovative solutions. 
Nanomedicine sets out to contribute to overcoming these problems in concert with other 
medical technologies such as biopharmaceutical drugs, cell therapy or gene therapy. 
Though likely to be of great importance for medical progress nanotechnology is only 
one of several drivers for innovation in medicine.  
There are a variety of challenges for the development of nanomedicine and a 
particularly important one is the still very moderate interest of the pharmaceutical and 
medical device industry in this emerging technology. Start-ups currently pursue a 
plethora of ideas how to improve disease treatment and diagnosis based on 
nanotechnology, but it is difficult for them to find major pharmaceutical or medical 
devices companies that licence their technology or partner with them to bring their 
novel nanomedicine approaches through the regulatory approval process. This situation 
is not entirely new to the medical sector and reminds of the development of 
biotechnology drugs over the last two decades. Apart from a lack of interest by big 
pharma, experts caution that there is also a structural reason for the slow pace of 
nanotechnology take up in the medical sector, particularly in Europe: The markets of 
major EU25 countries are cost-regulated and experts see this as an important limiting 
factor for the development of innovative high value drugs, including nanomedicine. 
Additionally, much of the improvement for therapy and diagnosis by nanotechnology-
based drugs and contrast agents will be related to their ability to target diseases more 
patient specific and to deliver more specific diagnostic information. This implies 
smaller patient populations and thus smaller markets for nanomedicine products, which 
makes it more difficult to recover development and regulatory approval costs, and 
which may make a development economically unattractive. 
Cost-effectiveness 
In the past, health innovations were mainly assessed with respect to efficacy and 
improved quality of life of patients. Nowadays, health innovations will increasingly be 
assessed also with respect to the costs at which the improvements come. Nanomedicine 
products will have to show cost-effectiveness in comparison to conventional 
alternatives, as health care systems increasingly face cost pressure. Nanomedicine 
innovations are likely to reduce future health care costs if they 
• aim at major cost-causing diseases, such as cardiovascular diseases, diseases of 
the nervous system, musculosceletal diseases, and neoplasms, 
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• reduce personnel costs, e.g. by reducing the required days of inpatient care, for a 
given disease, 
• contribute to "healthy ageing", i.e. in raising the health status of the population. 
On the contrary, nanomedicine innovations are likely to increase future health care costs 
if they come as add-on technology, which offers a measurable, but only small health 
effect at significant costs, so that the cost-benefit-ratio is unfavourable.  
Currently, cost-effectiveness studies for nanomedicine products are scarce. A broader 
set of health economic data was only available for two drugs with nanotechnology-
based drug delivery systems: liposomal amphotericin B and pegylated liposomal 
doxorubicin hydrochloride. Liposomal amphotericin B is an example for a conventional 
drug whose profile of side effects (nephrotoxicity) can be positively changed due to 
liposomal drug delivery. However, the additional positive health effect of reduced 
nephrotoxicity comes at comparatively high costs, which has up to now restricted the 
use of liposomal amphotericin B to exceptional cases. By contrast, pegylated liposomal 
doxorubicin hydrochloride shows a similar or even better effectiveness than the current 
gold standard topotecan for cancer treatment, but shows a different pattern of adverse 
effects. Although there is a high probability that treatment with pegylated doxorubicin is 
cheaper than conventional treatments due to lower treatment costs for adverse effects, 
more studies are required to establish its overall cost-effectiveness. Based on these two 
first generation nanomedicine products, an estimation of (future) cost efficiency of 
nanomedicine as a whole is not possible. Among the 38 products on the market and 
more than 150 in the pipeline are developments that bear the potential to significantly 
reduce costs of medical procedures. For a well-founded assessment of the overall cost-
effectiveness of nanomedicine many more nanomedicine products need to reach the 
market and need to be analysed.  
Social and ethical issues 
The systematic exploration of social and ethical issues of nanotechnology has begun 
only a few years ago. It is hoped that a better understanding of the interaction and 
mutual interdependence of science, technology and society could lead to better informed 
decisions about how to shape the development of nanotechnology, and that mistakes 
that have been made with other technologies, such as biotechnology and genetic 
engineering, might be avoided by dealing proactively with the social and ethical 
embedding of nanotechnology. Until recently, the majority of these analyses related to 
nanotechnologies in their entirety, and were not yet differentiated to specific application 
areas such as nanomedicine. It is striking that in cases nanomedicine applications were 
covered, the discussion of social and ethical issues often dealt with the potentially 
disruptive character of nanotechnologies and futuristic visions, but rarely covered the 
stepwise and incremental innovations which are currently pursued by public and private 
research institutions and companies. In general, there are no completely new social and 
ethical issues arising from nanomedicine applications, but nanomedicine might add new 
dimensions, e.g. molecular diagnostics and monitoring will increase the amount of 
available data  and thus raise the issue of data privacy more urgently. Equal access of 
patients to appropriate diagnostic and therapeutic procedures needs to be ensured and a 
“nano-divide” should be avoided. The just and transparent allocation of scarce health 
care resources might require the integration of health technology assessments and cost-
effectiveness studies in the development of nanomedicine.  
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Public debate 
Also research into the public's attitudes towards nanotechnology has, so far, only 
addressed nanotechnology in its entirety and not looked at subfields, such as 
nanomedicine. The limited social science research done until now indicates that 
attitudes to nanotechnologies are generally positive, and major benefits are anticipated, 
especially from health and environmental applications. However, focus groups and 
citizens' juries also reveal many aspects which are of concern for the layman, e.g. how 
to deal with the inherent uncertainty, and the low trust in governmental bodies as well as 
industry to take decisions for the benefit of the general population. Against this 
background, there is a high demand for effective regulation and control. In addition, 
governance issues are stressed and transparency of and public involvement in 
technology decision-making are called for. 
At the present stage of discussion, only few non-governmental organisations (NGOs) 
have developed a position towards nanotechnology applications and taken a visible role 
in the debate, especially Greenpeace and the ETC group. Whereas the ETC group has 
called for a moratorium of nanotechnology products, Greenpeace stresses the 
importance to clarify on the toxicological potential of nanoparticles but at the same time 
recognes the importance of nanotechnology to overcome current global environmental 
and energy problems. The majority of potentially affected non-governmental 
organisations in the field of biomedical applications of nanotechnologies such as 
consumer organisations or industry unions, are still in an earlier stage of engagement 
and the prevailing activity is the monitoring of developments of nanotechnology.  
Regulatory issues 
Nanoparticles and their potential health and environmental risks are currently the focus 
of discussions at European and international level. At present, no specific regulations 
exist in Europe which refer specifically to the production and use of nanoparticles either 
for workers', consumers' or patients' safety or for environmental protection, so that 
current regulations and operational practices are applied. The need for novel regulations 
for nanotechnology products that takes into account the environmental impact and the 
toxic potential of nanoparticles is currently discussed in governmental committees of 
some of the EU Member States and the European Commission. Prerequisite for such a 
regulation would be more research that clarifies the toxicity of nanoparticles, their fate 
and persistence in the environment and an assessment of the exposure.  
With regard to clinical applications nanomedicine products are currently regulated 
within the conventional regulatory framework of medicinal products and medical 
devices. To obtain market approval, these regulations require a risk assessment and 
management. However, the required knowledge about the behaviour and biological 
effects of nanoparticles is presently patchy and assessment schemes are not specifically 
tailored to assess nanoparticle-specific questions, so that further development and 
amendment might be required. Whether novel regulation is needed to account for 
borderline cases such as implants with drug delivery function or to account for special 
interactions between nanoparticles and biological matter is controversly debated among 
scientists.  
Whereas the regulatory requirements must be sufficiently rigid to ensure safety and 
quality of the medicinal products and medical devices, the possibly negative impacts of 
overly extensive requirements on the introduction of innovative products into the 
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market must also be considered. Against this background, it is being discussed in the 
nanomedicine community whether regulation should be adapted to take into account the 
trend to a more personalised medicine which may imply smaller markets, or whether the 
novel combination of already approved drugs and drug delivery systems should have to 
pass a less restrictive regulatory regime than the newly introduced individual 
components.  
 
Nanomedicine is an emerging field that is now gaining wider attention owing to first 
products on the market and a variety of studies conducted over the past couple of years. 
Nanomedicine has widely been associated with revolutionary new applications. 
However, as this report shows, nanomedicine as currently pursued by the scientific 
community uses nanotechnology as an enabling technology playing an important part in 
the medical innovation process, but there are currently only few examples for 
innovations with breakthrough potential.  
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1 Introduction 
Nanotechnology is emerging as one of the key technologies of the 21st century and is 
expected to enable developments across a wide range of sectors that can benefit citizens 
and improve industrial competitiveness. There is as yet no common definition of 
nanotechnology. In their recent report the UK Royal Society and the Royal Academy of 
Engineering define nanotechnology as “ the design, characterisation, production and 
application of structures, devices and systems by controlling shape and size at the 
nanometre scale” [The Royal Society & the Royal Academy of Engineering, 2004]. The 
nanometre scale is usually set at 1 to 100 nm and nanotechnology makes use of the new 
properties of materials at this scale that differ from those at a larger scale. Recent 
advances in the capabilities to manipulate atoms and molecules have pushed the 
development of nanotechnology. 
Nanotechnology is a generic term used for a broad range of different activities and 
applications ranging from energy production and storage, manufacturing, information 
technologies to medicine. For that reason often the plural form “ nanotechnologies” is 
used. Nanotechnology is rapidly expanding with about EUR 3 billion public R&D 
funding in 2004 worldwide [European Commission, 2005].  
Against this background the European Commission in May 2004 adopted the 
Communication Towards a European Strategy for Nanotechnology, and a related action 
plan for nanosciences and nanotechnologies 2005-2009 in June 2005 [European 
Commission 2004, 2005]. These initiatives aim at a co-ordinated R&D approach to 
nanotechnology to enable reaping the benefits of this new technology and its 
applications. Apart from boosting research funding, technology transfer, and the 
creation of favourable conditions for EU industry to commercialise useful products and 
services, it is stressed that any potential public health, safety and environmental risks 
need to be addressed upfront. This also includes a reassessment of existing EU 
legislation. Furthermore, ethical principles and societal considerations should be 
integrated in the R&D process at an early stage, dialogues with the public are 
considered essential. 
Nanobiotechnology, the convergence of nanotechnology and biotechnology2, and in 
particular its applications in the medical sector are considered as one of the most 
promising and most advanced areas of nanotechnology. Applications include e.g. 
nanoparticles for molecular diagnosis, imaging and therapy as well as complex 
nanostructured surfaces to control tissue repair on a cellular level. It is expected that 
nanobiotechnology applications in medicine will bring significant advances in the 
diagnosis and treatment of disease. This has lead to a steadily increasing research 
activity in this area over the past decade. However, a comprehensive picture of the state-
of-the-art of research and commercial activities in Europe was missing. Furthermore, to 
enable the exploitation of nanobiotechnology and a proactive approach to increase 
European competitiveness, information was needed on future directions of 
                                                     
2 Nanobiotechnology is defined as a field that applies the nanoscale principles and techniques to 
understand and transform living or non-living biosystems and which uses biological principles and 
materials to create new devices and systems integrated from the nanoscale [Roco, 2003]. 
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nanobiotechnology applications and on possible drivers and barriers for its 
development.  
The present document, based on a study carried out between February 2005 and March 
2006, aims to contribute to fill this information gap. It focuses on nanobiotechnology 
applications in medicine, which in the last two years are referred to as “nanomedicine”, 
a term that will also be used in this document. There are many ways of defining 
nanomedicine, in this report we follow the definition used by the European Technology 
Platform on nanomedicine: Nanomedicine is the application of nanotechnology to 
health. It exploits the improved and often novel physical, chemical, and biological 
properties of materials at the nanometric scale [ETP, 2005]. In contrast to the often 
used limitation to size dimensions of 1-100 nm, in nanomedicine size dimensions of 1-
1000 nm are included. This is due to the fact that in medicine nanotechnology aims to 
improve and optimize material properties for their interaction with cells and tissue, to 
allow e.g. passive tumour targeting, crossing of the blood-brain barrier, or to improve 
the bioavailability. This approach makes use of nanoscale materials larger than 100 nm. 
Polymer therapeutics are situated at the borderline between nanotechnology and macro-
molecular chemistry, they are, however, often classified as nanomedicine. On the other 
hand biochips are often considered per se as nanotechnology, regardless if they include 
nanoscale components. In this document biochips are only included if they contain 
nanoscale components. The above given definition of nanomedicine, is therefore 
amended by the following statements: 
1) Nanoparticles for medical applications are defined, as common in 
pharmaceutical sciences, as particles with a size between 1 and 1000 nm.  
2) Biochips are only classified as nanotechnology, if they include nanoscale 
components.  
3) Polymer therapeutics are classified as nanomedicine.  
The study covers several nanomedicine application areas: drug delivery, drugs and 
therapies, in vivo imaging, in vitro diagnostics, biomaterials, and active implants. Tissue 
engineering and regenerative medicine are included as far as biomaterials are 
concerned. Further information on tissue-engineered products is available in two recent 
reports from JRC/IPTS3. Cosmetics are included because the cosmetics sector seems to 
be an early user of new technologies. For example liposomes, which meanwhile are also 
used for drug delivery purposes, have been first used in cosmetic products. 
The study was carried out in collaboration with the European Science and Technology 
Observatory (ESTO) network. The VDI Technologiezentrum GmbH, Germany, 
provided the market analysis, literature and patent search and the analysis of the 
nanomedicine industry4. The Fraunhofer Institute for Systems and Innovation Research 
(ISI), Germany, analysed the impact of nanomedicine products on health care costs and 
                                                     
3 Bock et al (2003) Human tissue-engineered products – Today’s markets and future prospects. Synthesis 
report. EUR 21000 EN; Bock et al (2005) Human tissue-enginered products: Potential socio-economic 
impacts of a new Euroepan regulatory framework for authorisation, supervision and vigilance. Synthesis 
report. EUR 21838 EN 
4 See also Wagner V. et al (2006) "The emerging nanotechnology landscape". Nature Biotechnology Vol. 
24, No. 10, p. 1211 - 1217 
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the environmental, social and ethical issues of nanomedicine applications. This 
document is based on the results of this work.  
Dr. Rickerby from the JRC Institute for Health and Consumer Protection (IHCP) 
contributed a thesis paper about “Societal and policy aspects of the introduction in 
Healthcare” and Dr. Vanececk from Technology Centre AS, Prague analysed 
nanomedicine activities in the Czech Republic. 
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2 Nanomedicine Applications5 
 
2.1 Advanced Drug Delivery Systems 
Advanced drug delivery systems aim to improve bioavailability and pharmacokinetics6 
of pharmaceuticals and to replace invasive by non-invasive routes of administration. 
Examples for advanced drug delivery systems are controlled release formulations or 
pulmonary dosage forms of proteins, such as insulin. Nano drug delivery systems 
(NDDS) are a sub-class of advanced drug delivery systems that consists of drug carriers 
with a size of less than one micrometer and mostly less than 200 nm. Examples for 
NDDS are liposomes, nanosuspensions, polymeric nanoparticles, dendrimers, 
fullerenes, carbon nanotubes, and inorganic nanoparticles. Furthermore, so-called 
"polymer therapeutics" such as polymer-protein conjugates, polymer-drug conjugates, 
polymeric micelles and polymeric drugs are frequently classified as NDDS. Research 
and development on some of these systems, e.g. liposomes, has started as early as the 
1960s. Dendrimers, fullerenes or carbon nanotubes have entered the drug delivery arena 
more recently [Allen et al., 2004; Duncan, 2004; Wagner and Wechsler, 2004]. The 
systems with currently the highest pharmaceutical and commercial potential are 
described in the following: 
Liposomes: Liposome drug delivery systems are nanoscale spheres composed of a 
lipid layer surrounding the drug. First liposomal formulations of the anti-cancer 
drug doxorubicin were launched beginning of the 1990s, such as Doxil®/Caelyx® or 
Myocet®. By using a liposomal formulation the cardiac safety of the drug 
doxorubicin could be improved (see also Chapter 5). There are currently 11 
liposome-enhanced drugs on the market and about 30 in clinical trials.  
Nanosuspensions: Nanosuspensions are dispersions of pure nanosized drug 
particles, which are stabilized by surfactants. By reducing the size of drug particles 
to about 10 to 100 nm (nanonisation) the solubility of the drug can be significantly 
increased. This technology is of interest for about 40% of drugs in the development 
pipeline which are poorly water soluble and therefore cannot be administered. 
There are five drugs on the market and more than ten drugs in clinical trials that are 
formulated with nanosuspension technology [Bushrab, 2003, VDI, 2004; Rabinow, 
2004].  
Polymeric Nanoparticles: Polymeric nanoparticles are either nanosized solid 
particles or capsules which consist of natural or synthetic polymers and to which 
the drug is attached. They are investigated as drug delivery systems for site-specific 
targeting of tumours and for the transport of drugs across biological barriers, 
particularly the blood-brain barrier. At present the number of companies that work 
on polymeric nanoparticle drug delivery systems is quite small; only six companies 
were identified in this study. The anticancer drug Abraxane™, the substance 
paclitaxel stabilised by albumine is the only drug on the market that uses a 
(bio)polymeric nanoparticle drug delivery system. One additional product was 
identified being currently in clinical trials. 
                                                     
5 This chapter is based on the report of Work Package 1 - Current status of medicinal nanobiotechnology 
in Europe, V. Wagner, VDI Technologiezentrum GmbH, 2005. 
6 Pharmacokinetics refer to the processes of absorption, distribution, metabolism, and excretion of a drug 
or vaccine in a living organism. 
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Polymer Therapeutics: The term “polymer therapeutics” describes a family of 
compounds and drug delivery technologies that uses water-soluble polymers as a 
common core component. The term includes polymeric drugs, polymer-drug 
conjugates, polymer-protein conjugates, polymeric micelles, polymeric non-viral 
vectors (see below) and dendrimers. Polymer-protein conjugates using polyethylene 
glycol (PEG) as polymer component are currently the most advanced class of 
polymer therapeutics (six products on the market). They are developed to overcome 
some of the limitations of peptide-, protein- and antibody-based drugs such as a 
short plasma half-life, poor stability and immunogenicity. Examples for 
commercially successful PEGylated protein conjugates are the two PEG-interferon-
α conjugates Pegasys® and PEG-Intron® with sales of EUR 0.8 billion and EUR 0.4 
billion, respectively. About 15 polymer-protein conjugates are currently in clinical 
trials.  
Nanoparticles for Gene Delivery: Viruses are particularly efficient gene vectors 
and are used in more than 70% of gene therapy clinical trials. However, there are 
several concerns regarding the use of viruses, such as their toxicity and their 
potential for generating a strong immune response. Non-viral delivery systems can 
circumvent some of these problems and are emerging as favourable alternatives to 
viral vectors. Polymeric delivery systems (DNA-polymer complexes) and 
liposomal delivery systems are used as nanotechnology-based non-viral gene 
vectors [Mastrobattista et al. 2006].  
According to experts the benefit of NDDS for the patient will be less side-effects and 
improved efficacy of drugs, and the possibility to treat diseases and disease stages that 
currently cannot be treated with conventional drugs. Although drugs which come with 
an additional function of a drug delivery system will be more expensive than the drug 
alone, the expected benefits are hoped to result in an overall reduction of the costs of 
disease treatment.  
Apart from the pharmacological potential, NDDS are also of interest for the 
pharmaceutical industry with regards to the life cycle management of drugs: To defend 
drugs that come off patent against generic products, pharmaceutical companies try to 
develop and patent new galenic formulations7 and thus extend the life cycle of the drug. 
With about 70 products coming off patent per year, few products in the pipelines and 
increasing generic competition, the life cycle management is expected to become an 
important driver for the development of NDDS [VDI, 2004]. 
In the 1970s and 1980s major scientific hurdles were overcome such as the rapid 
clearance of nanoparticles from the blood and the synthesis of suitable biocompatible 
polymers. This paved the way for the first NDDS-enhanced products that were launched 
in the early 1990s. Since then research and patent activities have strongly increased: At 
present the total number of publications is about 800 per year up from 200 in the mid 
1990s and patent filings have increased seven-fold since the mid 1990s to about 1400 in 
2003. This indicates that the interest of the industry in NDDS is picking up worldwide. 
113 companies were identified that work in the field of NDDS, 52% of them are based 
in the USA and 23% in EU25 countries. Currently there are about 23 NDDS enhanced 
                                                     
7 Galenic formulation is named after a 3rd Century AD Greek physician, Claudius Galen, and describes 
the principles of preparing and compounding medicines. 
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drugs on the market, with total sales of estimated EUR 4.2 billion in 2004. This is only 
a tiny share of the worldwide pharmaceutical market that generates sales of about 
EUR 390 billion per year. However the high research activity and the fact that about 98 
NDDS-enhanced drugs are currently in clinical trials indicate that nanoscale drug 
delivery systems will gain more and more importance in the pharmaceutical sector.  
With regards to commercialisation US companies show worldwide the strongest interest 
in NDDS. US companies have developed or co-developed 61 of 98 NDDS-enhanced 
drugs in clinical trials compared to 28 developed or co-developed by EU25 companies. 
Very similar proportions exist for the 23 identified NDDS-enhanced drugs that are on 
the market. US companies are involved in the development and marketing of 17 of 
those drugs compared to 5 drugs that have been developed or co-developed by EU25 
companies.  
Products currently on the market are first generation products. They use early 
development stage NDDS in which nanotechnology is used to increase the solubility or 
to concentrate drugs in the diseased tissue by physical effects. Next generation products 
will try to tailor pharmacokinetic properties of drugs and therewith also their efficacy. 
Further, the whole research field of NDDS is still in its infancy compared to small 
molecule drugs or even biologics8: Scientists are just beginning to understand the 
interaction of NDDS with the immune system, cells, and organs. An improved 
understanding of these interactions over the next years will allow to gradually employ 
the full potential of NDDS to increase the efficacy of drugs.  
 
2.2 Drugs and Therapies 
In addition to drug delivery systems, there are also applications in which nanoparticles 
and nanoscale molecular structures act as pharmaceutically active compounds. 
Molecular nanoscale entities that are used for developing drugs are dendrimers and 
fullerenes. Additionally, nanoparticles are used in novel magnetic or photodynamic 
hyperthermia treatments of cancer and for cell sorting procedures as used in cell 
therapy.  
Dendrimers: Dendrimers are tree-like branched polymeric molecules that can act 
as drugs if they also incorporate certain chemical functionalities. The dendrimer 
drug in the most advanced development status is Vivagel™, a vaginal microbiocide 
to prevent HIV/AIDS infections. Dendrimers are seen as highly promising 
nanoscale molecules for pharmaceutical applications because size and surface 
functionality can be tuned with precision. Thus dendrimers can potentially be 
tailored for optimum activity, mode of action, pharmacokinetics, biocompatibility, 
and stability [BCC, 2004; Starpharma, 2005].  
Fullerenes: Fullerenes are hollow spherical molecules composed exclusively of 
carbon atoms. Fullerenes can very efficiently bind and inactivate radicals that play 
a crucial role in the development of diseases of the central nervous system (e.g. 
Parkinson, Alzheimer) and cardiovascular diseases. Because fullerenes scavenge 
                                                     
8 Biologics are biological and biotechnological medicinal products, including a wide range of products 
such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and 
recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or 
complex combinations of these substances, or may be living entities such as cells and tissues. 
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radicals more efficiently than any other medical antioxidant, there are hopes that 
they could be used as active core structures of a new class of extremely efficient 
drugs to treat radical related diseases. C Sixty, USA, is currently the only start-up 
that works on fullerene-based therapeutics. However, no product is as yet on the 
market or in clinical trials. 
Magnetic Nanoparticles for cell therapy: In cell therapy magnetic nanoparticles 
coupled to antibodies are added to a blood or bone marrow sample that contains the 
target adult stem cells. The magnetic particles bind the target cells, which then can 
be recovered using a magnet. This technique is used in cell therapies to isolate adult 
stem cells that are then retransplanted in the patient e.g. to treat blood disorders or 
cardiac diseases. These cell therapies are applied worldwide at hospitals and 
university clinics on a case by case basis, and reimbursed by insurances for selected 
diseases, such as leukeamia or heart diseases.  
Magnetic Fluid Hyperthermia: In Magnetic Fluid Hyperthermia 
superparamagnetic iron-oxide nanoparticles are used for hyperthermic treatment of 
tumours. The procedure involves the selective concentration of magnetic 
nanoparticles in tumour cells making use of their unique metabolism. Based on the 
aminosilane coating, iron-oxide nanoparticles are incorporated by the tumour cells 
much faster than by healthy cells and the iron nanoparticels become concentrated in 
the tumour cells. By applying a magnetic field the particles are caused to heat 
above 41°C and thus to destroy the tumour cells. The development of nanoparticle-
based hyperthermic methods is spearheaded by the start-up company Magforce, 
Germany. Magforce expects regulatory approval for its tumour therapy as a medical 
device in 2007.  
Phototherapy: Gold nanoshells absorb infrared light at wavelengths for which 
human tissue is transparent. For cancer treatment the nanoshells are conjugated to 
antibodies or other proteins as targeting mechanism to deliver the particles to 
specific cells or tissues. By irradiating the tissue with an external infrared laser the 
shells are heated and the temperature in the tissue raises to about 55°C so that the 
tumor cells are destroyed. Nanospectra Bioscience, USA, is currently the leading 
company, developing this technology for the treatment of lung cancer [BCC, 2004; 
Nanospectra Bioscience, 2005]. 
About 150 publications have been published in the field of nanotechnology-based drugs 
and therapies over the past ten years (1994-2004). This comparatively small number of 
publications is indicative for the still very explorative character of this research field 
that currently is only pursued by a small research community. However, the number of 
publications has been increasing steadily from about ten in the mid 1990s to about 50 in 
the year 2004. Patenting activity is increasing, too, with about 60 patent filings in 2003. 
These developments indicate that this technology field is slowly gaining momentum.  
At present only Vivagel™, a dendrimer-based gel to prevent HIV/AIDS infections 
(Starpharma, Australia), nanoparticle-based Magnetic Fluid Hyperthermia to treat brain 
cancers (Magforce, Germany) and the use of magnetic nanoparticles for stem cell 
therapy for cardiac diseases have proceeded to clinical trials. All other drugs and 
medical therapies that were identified in this study are still in a preclinical development 
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stage. The described novel nanotherapeutic methods are all developed either by small 
technology firms or by start-ups.  
Owing to the early development stage of nanotechnology-based drugs and therapies any 
prediction of the market volume is very speculative. However, many of the companies 
pioneering nanotherapeutic methods see their target market in the range of several 
hundred million euro for the first generation of their products. These numbers add up to 
about one billion euro for dendrimer and magnetic nanoparticle applications. The 
market introduction of fullerene-based therapies is still a long way off, though owing to 
their unrivalled properties they are believed to have blockbuster potential.  
Nanotechnology-based therapeutic approaches have in common that they try to treat 
diseases with radically new drug or treatment concepts. According to experts 
interviewed for this study, nanotechnology-based drugs and therapies have a great 
chance to deliver significant improvements to the patient as these novel approaches bear 
the potential for real progress in certain areas of medical treatment such as cancer, 
infectious and neurological diseases.  
Nanotechnology-based drugs and therapies have also the potential to reduce the cost of 
disease treatment. For example, the treatment costs of nanoparticle-based hyperthermia 
is expected to be just a fraction of the cost of traditional chemotherapeutic treatment of 
solid tumours. Furthermore, this method might overcome the problems of severe side 
effects of chemotherapy.  
 
2.3 In Vivo Imaging 
Progress in genomics and proteomics has led to a much increased knowledge of 
molecular processes linked to diseases that can now be used to develop diagnostic 
procedures to image pathogenic processes on a molecular level. This new diagnostic 
regimen is called molecular diagnostics and it aims to diagnose diseases on a molecular 
level before the development of symptoms [Schaeffter, 2005]. It might be the basis for a 
paradigm shift in healthcare from the treatment of symptoms to the prevention of the 
outbreak of diseases [Li et al., 2004; Wickline and Lanza, 2003]. In vivo imaging aimed 
at molecular diagnostics uses conventional imaging technologies such as ultrasound, 
magnetic resonance imaging, nuclear and optical imaging. To be able to operate these 
techniques on a molecular level (molecular imaging), however, special contrast agents 
are needed and the instrumentation including the software for data analysis needs to be 
adapted accordingly. In the field of in vivo diagnostics nanotechnology is likely to have 
its greatest impact on molecular imaging, as contrast agents need to be designed and 
optimised on the nanoscale level to be able to efficiently target molecular markers for 
diseases.  
Magnetic Resonance Imaging (MRI): As the molecular constituents of 
pathological processes are too small to be imaged directly by MRI, they have to be 
visualised using sensitive, site-targeted contrast agents that accumulate at a 
pathological site. Nanoparticulate systems have emerged as the most successful 
molecular MRI contrast agents to date [Lanza et al., 2004]. For example, iron oxide 
nanoparticles are used as contrast agents, e.g. in the product Resovist®, since 2001 
on the market, that accumulate passively in liver, spleen or lymph nodes depending 
on their size. Furthermore, nanoparticles with an extremely high payload of 
gadolinium ions have been developed to create paramagnetic contrast agents, 
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targeted at specific tissues via antibody ligands. The start-up Kereos, USA, pursues 
this technology with the goal to image tumours as small as 1 mm and unstable 
plaque (deposits in arteries that cause heart diseases). The product is expected to 
enter clinical trials in 2006.  
Nuclear Imaging: In nuclear imaging a radionuclide contrast agents is introduced 
into the body of the patient. The uptake of the radionuclide contrast agents by 
organs depends on their metabolism, thus the contrast agents allow the imaging of 
physiological processes. None of the 12 currently approved nuclear imaging agents 
is based on nanotechnology. However, there are nanoparticle-based contrast agents 
in development. One example is a tumour specific contrast agent developed by the 
start-up company Kereos, USA, that consists of perfluorocarbon nanoparticles 
carrying Technetium-99 [Rollo, 2003].  
Ultrasound Imaging: Ultrasound has an important role in delivering 
morphological information about tissues and organs. Commercial ultrasound 
contrast agents consist of gas-filled microbubbles which typically have a size of 1-2 
µm. At present only a small number of publications describes work on nanosized 
ultrasound contrast agents and none of the described systems seems to have reached 
clinical trials yet. 
Optical Imaging: The most prolific nanotechnology-based optical contrast agents 
are quantum dots (QDs)9. First in vivo studies with QDs in cell lineage-tracing 
experiments with frog embryos were reported in 2002 by Dubertret et al. [2002]. 
Since then QDs have been used to image cell signal transduction [Lidke, 2004], 
cancer markers [Wu, 2003], and tumors in living animals [Gao, 2004]. Researchers 
consider these experiments as an indication for a realistic chance that QD 
technology can be further developed for medical in vivo imaging. However, the 
main roadblock to reaching this goal is the high toxicity of the semiconductor 
materials used for manufacturing QDs.  
MRI and ultrasound methods are likely to profit most from nanotechnology. With 
regards to MRI, nanotechnology is of importance for several reasons: 1) nanoscale iron 
oxide particles are superparamagnetic and give a particularly strong contrast, 2) by 
tuning the size and surface properties of particles loaded with contrast agents, plasma 
half-lifes can be controlled and passive targeting of organs is possible and 3) for 
imaging of molecular targets with gadolinium contrast agents, gadolinium needs to be 
concentrated at the target structure to enhance the contrast and this can only be achieved 
by nanosized particles or molecular structures that contain up to tens of thousands of 
gadolinium atoms. For ultrasound contrast agents nanotechnology is an important tool 
to control and modify the surface parameters of the gasbubbles that eventually will 
allow their application as molecular contrast agents.  
The development of nanotechnology-based imaging agents started about a decade ago. 
Research activity in this field is still relatively low but has significantly increased over 
the past years. From 1980 to 2004 about 350 papers were published and in the period 
1993-2003 about 1250 patents were filed. The only nanotechnology-based contrast 
agents that are at present on the market are nanoparticulate iron contrast agents for MRI 
                                                     
9 Quantum dots are fluorescent semiconductor nanocrystals coated with inorganic materials. The emitted 
wavelengths can be tuned over a wide range by varying the size and composition of quantum dots. 
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(3 products). The leading contrast agent in this class is Resovist®, developed by 
Schering, Germany. Total sales of iron oxide nanoparticle contrast agents were an 
estimated EUR 15 million in 2004. Nanoparticle-based contrast agents currently target 
only a small niche of the imaging market which is valued at about EUR 15 billion. Five 
products were identified being in clinical trials. 
The imaging equipment manufacturers, such as Philips, Siemens and General Electric 
generally show high interest in the field of molecular imaging as documented in 
scientific publications and white papers [Hämisch, 2003]. Their interest is also indicated 
by co-operations with academic institutes and start-ups such as Kereos, USA, or 
Ferropharm, Germany. In the USA molecular imaging receives much governmental 
support with seven molecular imaging centers established since 1999 funded by the 
National Cancer Institute [NCI 1998].  
According to experts interviewed, there are currently no general technological hurdles 
that are likely to block the market entrance of nanotechnology-based contrast agents, 
though the technology is seen as very challenging as the chemistry and physics of 
nanoscale molecules and particles are still very new and need to be better understood. It 
is expected that the first targeted nanoparticulate MRI contrast agents will be available 
for clinical use by the end of the decade. For the other imaging modalities market 
entrance is likely to be later.  
 
2.4 In Vitro Diagnostics 
In the context of in vitro diagnostics nanotechnology is used for the development of 
novel sensors and in vitro tests for many different reasons: To improve and make 
existing tests more sensitive, to allow for point-of-care applications or to develop 
completely new diagnostic test platforms. Nanotechnology applications can be broadly 
divided into two main approaches: 1) the use of nanoparticles as markers for 
biomolecules and 2) novel sensor platforms that use nanomaterials, such as carbon 
nanotubes, lateral nanostructures or nanothin surface layers.  
Nanoparticles: Fluorescent dyes serve as an indispensable tool for detecting 
pathogens, diagnosing cancer or carrying out genetic tests. The currently used 
organic dyes, e.g. in medical laboratory tests, in polymerase chain reaction assays 
and in biochips, are not photostable or suitable for multiplexing. Scientists have 
been investigating for the last ten years inorganic fluorescent nanoparticles as an 
alternative, such as semiconductor nanoparticles (quantum dots), resonance light 
scattering gold labels or nanoparticles doped with rare earth metals 
(nanophosphors) with the aim to : 
• Increase the sensitivity 
• Enable the analysis of multiple analytes 
• Develop cheaper measurement concepts  
• Facilitate mass production 
The most prevalent medical use of nanoparticles are rapid tests such as pregnancy 
testing kits in which gold nanoparticles are used as a colour marker since the 1980s. 
Another important type of nanoparticles are semiconductor nanocrystals coated 
with inorganic materials, so called quantum dots (QDs). As QDs have been 
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successfully used in cell biology research, companies consider now their 
application in clinical diagnostic tests. Regarding research applications, 
nanoparticle tagging systems and respective biochip reader platforms are already on 
the market by Invitrogen (USA), Quantum Dot Corp. (USA), and Evident 
Technologies (USA). A further example for the application of nanoparticles in 
medical analysis are superparamagnetic iron oxide nanoparticles that have become 
the backbone for magnetic separation in several health-care and bioprocessing 
applications, such as cell sorting, nucleic acid extraction/purification and bacterial 
detection. Examples for products are CliniMacs from Miltenyi Biotec, Germany, 
and Dynabeads from Dynal/Invitrogen, Norway/USA. 
Nanotechnology-Based Biosensors: At present, from a commercial point of view, 
biochips with a nanotechnology-enabled electrical detection system are the most 
interesting development in this field. Electrical detection systems allow to detect a 
binding process directly via an electrode, avoiding the need for a complicated 
optical instrumentation. Electrical detection systems in general are expected to be 
superior compared to optical systems with regards to robustness and production 
costs. Companies that work on such approaches are Siemens Medical Solutions, 
Germany, CombiMatrix, USA, and Genefluidics, USA. Market introduction of the 
first systems is expected within the next two years.  
Nanoarrays, nanowire sensors, surface plasmon resonance sensors and cantilever 
sensors are all nanotechnology-based sensor principles that are still in a fairly early 
development status and that currently find applications only in biomedical research. 
However, there are a variety of companies that further develop these systems for 
clinical applications such as Bioforce, USA, Protiveris, USA, or Concentris, 
Switzerland.  
First publications in the field of nanotechnology-based in vitro diagnostics appeared 
only in the late 1980s, although lateral flow tests using gold nanoparticles are on the 
market since the 1980s. Since then about 900 publications have been published and the 
number of publications per year has increased to more than 200 in 2004. Patent filings 
show a similar development: They have increased from about ten in the early 1990s to 
nearly 200 patents in the year 2003. Although the number of publications and patents is 
steadily increasing, the total numbers are still comparatively small and indicate that the 
field is still in an early development state.  
The only nanotechnology-based in vitro diagnostics products that have already reached 
the market are lateral flow tests, containing conjugated gold nanoparticles, and magnetic 
nanoparticles for clinical immunodiagnostics. The market of these nanotechnology-
enabled products is estimated to be EUR 600 million in 2004. All other identified 
biosensors (about 30) are still in development with the first systems likely to enter the 
market in 2006/2007. Estimates for sales for first generation products that are released 
by start-up companies range from about ten to several hundred million euro per year. 
Experts expect that these new diagnostic systems have a good chance to conquer 
significant segments of the evolving multibillion point-of-care diagnostic market.  
Most of the interviewed experts consider nanotechnology as an important part of the 
development of in vitro diagnostic tests with breakthrough potential: Nanotechnology 
allows to develop completely new in vitro diagnostic test designs for mass markets and 
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it also enables the development of novel sensors for cheaper clinical diagnostic tests. 
However there are also many sensor concepts for molecular diagnostics and point-of-
care applications, that come without the use of nanotechnology. Therefore 
nanotechnology is considered as a very important but only one out of several building 
blocks for innovation in the field of in vitro diagnostics.  
 
2.5 Biomaterials 
Over the past decades life expectancy has increased and degenerative diseases affecting 
organs and joints have become a critical issue. Nanotechnology is seen by experts as 
one approach to improve the biocompatibility and lifetimes of implant materials. As 
diverse as implant technology itself are the ways to use nanotechnology to improve their 
performance. Major application fields of nanotechnology are hard tissue implants, bone 
substitute materials, dental restoratives, soft tissue implants, and antibiotic materials:  
Hard Tissue Implants: Crucial for the integration of an implant in the surrounding 
tissue is the cellular recognition of implant surfaces. Since bone is composed of 
constituent nanostructures, it is believed that nanophase materials, with constituent 
features of less than 100 nm, will facilitate the precise control of cell interactions 
with the implant. Scientists and companies currently work on special coatings and 
nanophase bulk materials for implants that improve cell adhesion to the implants. 
Nanocrystalline surfaces are also developed to avoid the generation of wear debris in 
articulating components that decrease the life time of implants by contributing to 
bone cell death [Sato and Webster, 2004].  
Bone Substitute Materials: Current bone substitute materials show good 
biocompatibility, but their degradation is very slow. Since the late 1990s a number of 
research projects have investigated nanocrystalline bone cements with the objective 
to develop more bone-like cements with improved mechanic properties and a higher 
biofunctionality [Tadic et al., 2004]. Vitoss® and Ostim are two examples for 
currently available nanocrystalline bone substitutes based on nanohydroxyapatite, 
that improve bone regeneration.  
Dental Restoratives: Nanoparticles are added to dental restorative materials to 
diminish their polymerisation shrinkage and improve their wear resistance and 
biocompatibility. Furthermore, the so-called nanofillers can contribute to increase the 
modulus of elasticity or to improve the optical properties of the dental composites 
[Moszner and Klapdohr, 2004]. Filtek™ Supreme was the first nanocomposite 
restorative in the market, launched 2002, and is now one of the leading products in 
its segment.  
Soft Tissue Implants: The application of nanotechnology in the field of soft tissue 
implants is still in an embryonic state and has not yet been established as a coherent 
research field. Nanotechnology is used for developing: 
1) Coatings or structuring surfaces to increase the biocompatibility of stents or 
catheters. Further, coatings with drug delivery function are developed to reduce the 
restenosis rate of stents.  
2) Nano-featured scaffolds for tissue engineering to mimic the natural environment 
of cells. This entails approaches such as scaffolds with nanotopographical surface 
patterns and nanofiber schaffolds. The interconnective pores of the nanofibre 
Nanomedicine Applications 
 
 
 
28 
matrices and appropriate mechanical properties make them ideal candidates for 
developing scaffolds that can be customised for specific tissue growth [Norman and 
Desai, 2006].  
3) Nanotechnology engineered membranes for cell therapy, to protect transplanted 
foreign cells from te host immune system. Such membranes with nanopores exclude 
passing of large molecules such as antibodies, but allow the passing of small 
molecules such as nutrients or hormones (e.g. insulin). 
Antibiotic Materials: The antiseptic properties of silver have been known and used 
since a long time. By producing nanoscale silver particles the antibiotic effect of 
silver can be increased and the same antibiotic effect can be achieved with less 
material. Silver nanoparticles can be used for antibacterial coatings of implants, 
catheters, wound dressings and medical instruments. The nano-silver based wound 
dressing Acticoat® is on the market since 1998 [Wagener, 2001].  
Nanotechnology research related to medical implants is documented in about 500 
publications (1980-2004), the first appearing in the early 1990s. There is a strong 
increase in the publication activity since the year 2000, with publication numbers 
doubling every 18 months. In 2004, the number of publications in this field reached 
140, reflecting a growing number of scientists that now work on nanotechnology-based 
implant materials. The patenting activity is increasing too, with first patents appearing 
in the mid 1990s. In 2003, about 180 patents were filed that describe nanotechnology 
applications for medical implant devices. 
Nanotechnology-enabled implant materials as identified in this study had a market of 
about EUR 50 million in 2004. Most of the sales are generated with dental materials (5 
products) and silver nanoparticles-based wound dressing (1 product) with minor 
contributions by bone substitute materials (3 products). To our knowledge there are 
currently no nanotechnology-enabled implants on the market and only four products 
were identified being developed. Thus it is unlikely that nanotechnology-based products 
will have a significant impact on the EUR 8 billion orthopaedic implant market within 
the next 5 years . 
The interest of the industry in nanotechnology-enabled implant materials varies for the 
different application fields. The dental industry shows high interest in this material 
class, as development hurdles are manageable and first products have proven superior 
material properties. Generally, bone cements and orthopaedic implants are mature 
markets with products that meet very high standards, leaving little room for 
breakthroughs. Additionally, according to expert opinion, the generally conservative 
attitude of clinicians and the medical implant industry as a whole results in a 
comparatively slow uptake of new technologies.  
According to experts, nanotechnology-enabled products are not necessarily more 
expensive or at least they do not lead to a significant increase in medical treatment 
costs. Products such as nanotechnology-enabled dental restoratives, wound dressings 
and bone substitute materials that are already on the market show that reimbursement by 
health insurances is not an issue. In case novel orthopaedic implant materials are able to 
significantly increase the lifespan of implants and therewith to reduce revision rates, this 
could lead to reductions of the total costs of disease treatment. 
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All of the interviewed experts see nanotechnology as an important driver for innovation 
in the medical implant industry. However, compared to drug delivery much of the 
development work seems to be in an earlier phase. Research on the impact of 
nanostructured surfaces on the adhesion, proliferation and gene expression of cells has 
just begun and it is likely that this field will gain considerable momentum in the future. 
This will be in particular important for the realisation of regenerative medicine, aiming 
at in situ regeneration of pathological tissue, for which biomaterials will play a crucial 
role [ETP Nanomedicine, 2005]. 
 
2.6 Active Implants 
Active implants are defined as implants with an active electronic function such as neural 
prostheses and implantable electronic drug delivery devices. Examples for neural 
prostheses include retinal and cochlear implants, pacemakers, bladder stimulators and 
brain implants to help patients with Parkinson disease. The development of active drug 
delivery implants is still in its infancy and strongly driven by American research teams. 
At present, nanotechnology certainly does not play a key role in the development of 
active implants, but there are already some examples for the application of 
nanostructured materials for specific components of active implants:  
Retina Implant: The most common degenerative diseases of the retina are macular 
degeneration and retinitis pigmentosa. Both eye diseases cause destruction of the 
rods and cones located in the retina rendering the retina insensitive to light. Since 
the late 1980s several research projects have been initiated to develop retina 
implants. The key element of a retina implant is a chip that substitutes the function 
of the rods and cones and electrically stimulates the ganglion cells. The chip either 
transforms incoming light into electrical pulses or it receives the signal from a 
miniature digital camera located on the patient’s glasses. Nanotechnology is used 
for the production of the electrodes and for the development of biocompatible 
housings for the implant. The first pilot studies with a retina implant were 
conducted by the Retina Implant AG, Germany, in 2005. 
Cochlear Implants: Profound deafness is caused by loss of the sensory hair cells 
in the fluid-filled, snail-shaped inner ear, or cochlea, that transduces sound waves 
into electrical impulses, which are then transmitted to the brain. Profoundly deaf 
individuals who still have an intact auditory nerve have profited from the advances 
made over the past 30 years in the field of cochlear implants. These implants 
consist of a microelectrode array implanted in the cochlea that directly stimulates 
the auditory nerve [Rauschecker, 2002]. According to experts, nanotechnology 
might be used in the future to improve the biocompatibility of cochlear implant 
housings or to add a drug delivery function to the implant that supports the healing 
process of the tissue or that prevents infections after implant surgery.  
Cardiac Implants: A permanent pacemaker sends electrical signals to start or 
regulate heartbeats. These devices are implanted in case the heart’s natural 
pacemaker has a dysfunction and the signals it sends out become erratic. The only 
example of a nanotechnology-enabled component of a pacemaker are electrodes 
with a nanostructured coating (developed by Biotronik, Germany) that improves the 
electrode-tissue interface and thus the electrical sensing and pacing properties. 
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According to experts, there is little additional potential for nanotechnology to 
improve current pacemaker or defibrillator technology.  
Drug Delivery Chips: Drug delivery microchips are developed with the objective 
to precisely control the release rate of drugs for several months or even years. 
Traditionally, drugs are delivered to the human body mainly via oral and 
intravenous means. These delivery routes have several disadvantages: 1) High 
initial concentrations of the drug that are often higher than the therapeutic range 
and cause side effects, 2) the requirement of multiple injections, because only a 
very small percentage of the injected drug reaches the affected area and 3) pulse-
like delivery as required for certain drugs, such as insulin, is not possible. 
Currently, drug delivery microchips are classified as microsystem technology with 
regards to fabrication methods and to their functional parts. However, they might 
also make use of nanotechnology for the design of certain components of the 
implant, such as nanopore membranes or biocompatible implant coatings. 
According to experts, there are currently no drug delivery microchips on the market 
or in clinical trials. 
Coatings Making Implants Save for MRI: MRI cannot be applied to millions of 
patients with certain implants, such as pacemakers or brain electrodes, because the 
scanners can dangerously heat the implant’s metal parts. Biophan, USA, develops 
nanomagnetic particle coatings that are supposed to render biomedical devices safe 
for MRI application and to reduce the interference these devices cause to the 
quality of MR images. The technology is still in a preclinical phase [Biophan, 
2005].  
40 publications (1980 - 2004) and 75 patents (1993 – 2003) were identified covering 
nanotechnology research and applications related to active implants. This shows that 
nanotechnology is not yet a research area of great importance for the development of 
active implants.  
The number of companies considering nanotechnology as an enabling technology that 
might be used to improve the biocompatibility and technical performance of their active 
implants is, however, increasing. There is no information available if this interest has 
already gone beyond the status of pure technology screening. The interest in 
nanotechnology is certainly high if it comes to approach specific technical problems 
such as to enhance the charge transfer at the electrode/tissue interface or to improve the 
biocompatibility of implant materials. In this study five start-ups were identified that 
visibly pursue activities in this field. But only in the case of Biophan’s coating, that 
makes active implants MRI compatible, nanotechnology is the key component and as 
such this technology deserves to be classified as nanotechnology. In all other cases 
nanotechnology has only an enabling function. Electrodes with nanostructured coating 
are the only nanotechnology-enabled active implants that have reached the market.  
Apart from nanotechnology-based coatings nanotechnology is not perceived as to 
deliver major contributions to overcome the problems that are still in the focus of the 
medical device industry, such as cable interfaces or issues concerning the mechanic or 
electronic stability of active implants. Furthermore, there are currently no visible R&D 
activities to use nanotechnology to address single cells at a submicron level and 
according to experts, this will not be an issue for the foreseeable future. 
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2.7 Cosmetics 
Cosmetics have been included in this study because the cosmetic industry sometimes 
appears as an early user of new technology, and innovative products are first introduced 
in the cosmetic market before they enter clinical use. An example for such an 
development was the market introduction of liposome-based anti-aging lotions before 
the first liposomal drugs reached the market. One important trend in the formulation of 
cosmetics is the use of sensitive ingredients such as vitamins or various plant-based 
active substances. These ingredients often need to be delivered to deeper layers of the 
skin to be most effective. Therefore delivery systems that protect and transport these 
active ingredients to the target skin layer increasingly gain importance. Further, 
particles can be used to prevent the penetration of active ingredients into the skin or to 
protect the skin against sensitising organic substances of the cosmetic formulation. 
There are a variety of microsized and nanosized delivery systems available for use in 
cosmetics, such as liposomes, solid lipid nanoparticles, nanospheres and inorganic 
nanoparticles.  
Liposomes: The most common nanoscale carrier system in cosmetics is liposomes, 
which were introduced with the anti-aging lotion Capture by Dior in 1986. Most of 
the commercially available liposomes for cosmetic formulations are produced from 
lecithin, a mixture of phospholipids and triglycerides as extracted from soy beans. 
Small flexible liposomes are used to transport substances in deeper skin layers and 
rigid liposomes function as depots for substances in upper skin layers as they do not 
penetrate the skin. Further, liposome formulations help to protect instable chemicals 
or to reduce skin irritating effects of chemicals [Lasic, 1995]. Experts estimate that 
several hundred cosmetic products containing liposomes are on the market. Most of 
the products are anti-ageing skin creams, such as Capture (Dior), Dermo Expertise 
(L’Oréal) or Liftosome (Guinot).  
Lipid Nanoparticles: Lipid nanoparticles with a typical size of 50 to 1000 nm have 
a similar structure to nanoemulsions. The difference is that the lipid core is solid 
and not liquid. Lipid nanoparticles appear interesting for the formulation of 
cosmetics for three reasons: 1) They improve the stability of chemically unstable 
active ingredients, 2) they allow the controlled release of active ingredients, and 3) 
they improve skin hydration and protection through film formation on the skin. 
Lipid nanoparticles are protected worldwide as Lipopearls® (Lipo Technologies, 
USA) and Nanopearls® (Pharmasol, Germany) [Müller et al., 2004].  
Nanocapsules: Nanocapsules have a core-envelope structure and range between 
130 and 600 nm in size. The liquid core comprises the active component and is 
encapsulated with a polymer membrane. This encapsulation technology stabilises 
sensitive ingredients better than existing emulsion or liposomal technology. The 
nanocapsules are small enough to penetrate through the first layers of the skin. In 
deeper layers the skin’s enzymes dissolve the outer polymer membrane of the 
nanocapsules and the active ingredient is released. This delivery principle is of 
particular value for ingredients such as vitamin A, retinol and beta-carotene that 
must be delivered to the deeper layers of the skin to be most effective. L’Oreal’s 
nanocapsules have been on the market since 1995. They were first used in higher 
end brands such as Lancôme and have since been added to less expensive product 
lines such as Future E and Plénitude [L’Oreal, 2003].  
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Titanium Dioxide and Zinc Oxide Nanoparticles: UV radiation from the sun 
consists of sunburn-causing UV-B (290-320 nm) and longer-wavelength UV-A 
(320-400 nm) radiation. UV-A radiation penetrates deeper into the skin, causing 
skin wrinkling, and promotes premature ageing. UV-A and UV-B radiation is 
believed to act synergistically in causing skin cancer. In Europe 26 organic 
sunscreens are approved. Many of those are basic UV-B filters and often cause 
allergic reactions in sensitive individuals or produce stains on clothing. Titanium 
dioxide (TiO2) and zinc oxide (ZnO) are the most common ingredients of inorganic 
or physical sunscreens. They act as physical blocks to both long- and short-
wavelength UV radiation, but they have the aesthetic shortcoming to appear as a 
white layer on the skin. By using nanosized particles this disadvantage could be 
overcome as light by these particles is no longer scattered. Advantages of these 
sunscreens compared to the organic-based products are the broad-spectrum UV-A 
protection and their good compatibility even with sensitive skin. Therefore TiO2 
and ZnO are used in products for babies and small children. Though TiO2 and ZnO 
nanoparticles in sunscreens are considered save by regulatory bodies there is an 
ongoing scientific debate whether these nanoparticles can penetrate into deeper skin 
layers and cause harm to skin cells [Luther, 2004]. At present organic sunscreens 
account for about 80% of the market, while specialised sunscreens containing TiO2 
and ZnO nanoparticles represent 20% of the market. The share of sunscreens 
containing TiO2 and ZnO is increasing mostly in speciality sunscreen brands, but 
application is also increasing in sensitive skin and baby products and in daily wear 
skin lotions that provide UV protection. Some brands that contain TiO2 and ZnO as 
sun blockers are Suncare SPF 30 (Cellex-C, Canada), Eucerin Ultraschutz 
(Beiersdorf, Germany) and Nivea Sun Age Defence (Beiersdorf, Germany). 
As cosmetics is not a major academic research field it is understandable that only a total 
number of 230 publications that cover nanomaterials for cosmetics has been published 
since the early 1990s. However, over the past decade the number of publications per 
year has increased slowly from less than five to about 30 publications in 2004. The 
cosmetic industry has started to patent formulations containing nanomaterials in the 
1970s. Since then the number of patents has increased to about 280 in 2003. The total 
number of filed patents that include nanotechnology aspects is 2800.  
Experts estimate that about 10% of the EUR 9 billion skin care market are products that 
contain liposomes and that about 20% of all sunscreens contain titanium dioxide and 
zinc oxide nanoparticles. A company that shows strong interest in nanoscale materials is 
L’Oreal that claims that in recent years about 10% of its filed patents are related to 
nanomaterials. Interestingly, cosmetic companies seem to be leaders with regards to the 
commercialisation of nanomaterials as in certain product classes, such as anti-aging 
cremes or sun blockers, nanotechnology-based formulations have already gained two 
digits market shares. One reason for the widespread use of nanomaterials is certainly the 
topical application of cosmetics which raises less issues compared to the uptake and 
metabolism or implantation of nanomaterials in drugs or medical devices.  
Based on the accessible information and the development of nanotechnology 
applications in medicine, the cosmetic sector seems not have a pronounced early user 
role anymore. The following chapters will concentrate on nanomedicine applications. 
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3 The Nanomedicine Sector10 
 
3.1 Nanomedicine Companies 
Commercialisation efforts in nanomedicine are picking up worldwide. In this study 200 
companies with nanomedicine activities were identified. These businesses include 92 
start-ups11 (44%), 67 SMEs12 (32%) and 41 large pharmaceutical or medical device 
companies (21%). A detailed data analysis revealed that the relative proportion of 
corporations, SMEs and start-ups are the same for the USA and the EU25. The 159 
start-ups and SMEs focus either completely (71 companies) or at least to a great part (87 
companies) on nanomedicine. The 41 large pharmaceutical or medical device 
companies run only individual nanomedicine projects or have individual 
nanotechnology-based products on the market, i.e. nanotechnology currently contributes 
only little to the companys’ business activities. Importantly, many of the large 
companies do not release information on their research programmes or products in 
development stages. Those, that openly communicate their activities are likely to be just 
the tip of the iceberg and it is assumed, based on expert interviews, that the majority of 
the major pharmaceutical and medical device corporations pursue R&D projects in 
which nanotechnology plays a role. Nanotechnology has clearly started to infiltrate 
R&D activities in the medical sector on a broad level.  
Most of the companies involved in nanomedicine (56%) develop nano drug delivery 
systems (NDDS) (Fig. 3.1). This is in line with the high proportion of the nanomedicine 
publications in this field (76%) and the share of NDDS of the total nanomedicine 
market of about 80%. 16% of the companies develop nanotechnology-enabled in vitro 
diagnostics and 15% nanotechnology-enabled medical biomaterials for implants.  
 
 
 
 
 
 
 
 
 
Figure 3.1 Nanomedicine Sector: Types of companies and application field breakdown 
Source: VDI Technologiezentrum GmbH 
 
                                                     
10 Information in this chapter is based on Work package 2 - Challenges and drivers for medicinal 
nanobiotechnoloy and its impact on the medical sector, V. Wagner, VDI Technologiezentrum GmbH, 
2005. 
11 A start-up company is defined as a new business venture in its early stage of development, generally 
younger than 5 years 
12 A SME is defined as a company with less than 500 employees. 
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Currently only few companies focus on nanotechnology applications in the field of in 
vivo imaging (6%), drugs and therapies (4%) or active implants (3%).  
Within the EU25, Germany, UK, and France are leading with regards to 
commercialisation efforts. In Germany 39 companies are visibly involved in 
nanomedicine R&D projects, in UK 15 companies and in France 10 companies (Fig. 
3.2). In all other countries less than 5 companies could be identified, independent from 
country size. In Ireland, one comparatively active company was identified, developing 
NDDS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Nanomedicine commercialisation efforts in EU25 countries in 2004: Companies with 
nanomedicine activities, nanomedicine products on the market and in the pipeline 
Source: VDI Technologiezentrum GmbH 
 
 
A breakdown of EU25 nanomedicine companies with regards to medical application 
fields (Table 3.1) shows that in drug delivery with worlwide the highest research and 
commercialistion activities, the share of EU25 companies is 23%, whereas in all other 
fields the share is significantly higher with 40% to 50%. This coincides with the share 
of EU25 products in the pipeline which is also below average with 27%. This indicates 
a relative weakness of the commercialisation efforts in the EU25 in the nanomedicine 
sector with the highest near-term market potential. 
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Table 3.1 Companies, products and product pipeline in nanomedicine: Breakdown by medical 
application sectors 
* If a product is developed by an EU25 company in cooperation with a company based in a non-EU25 
country, this product is counted for each of the two countries). Further information on products is given in 
the appendix. 
 
 Companies 
world-wide 
Share of 
EU25 
Companies 
Products 
world-
wide 
Share* of 
EU25 
Products 
 
Products in 
Pipeline 
world-wide 
Share of 
EU25 
Products in 
Pipeline 
Drug Delivery 113 23 % 23 29 % 98 27 % 
Drugs & 
Therapies 
7 43 % 0 NA 7 29 % 
In vivo Imaging 11 40 % 3 33 %  8 38 % 
In vitro 
Diagnostics 
33 49 % 2 50 % 30 47 % 
Biomaterials 30 47 % 9 55 % 9 55 % 
Active Implants 6 50 % 1 100 % 5 20 % 
Sum 200 35 % 38 37 % 157 34 % 
 
Source: VDI Technologiezentrum GmbH 
 
Compared to the USA the commercialisation efforts in EU25 countries are generally 
less advanced: 46% of all nanomedicine products are developed or co-developed by US 
companies compared to 37% pursued by EU25 companies (Fig. 3.3). The gap seems to 
further widen if we look at products that are currently under development: US 
companies are involved in 54% of nanomedicine products that are worldwide in the 
pipeline compared to 34% for EU25 companies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Comparison USA and EU25 with regards to nanomedicine research and 
commercialisation efforts 
If a product is developed by companies based in two different countries, this product development is 
counted for each of the two countries. Source: VDI Technologiezentrum GmbH 
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In their final report the ESF Forward Look initiative (see Chapter 4.2) comes to the 
same conclusion and states that the timely exploitation of newly emerging medical 
nanotechnologies is an area of general weakness within the European Union [ESF, 
2005].  
 
3.2 Business Models and Structure of the Industry 
The innovation process in nanomedicine is clearly driven by start-ups and SMEs 
whereas in big corporations nanotechnology enabled products are still of comparatively 
little importance. There are three business models apparent for nanomedicine start-ups 
and SMEs:  
1) The development of nanotechnology-enhanced pharmaceuticals or medical 
devices: Start-ups and SMEs with this business model aim to develop a 
proprietary product pipeline and try to bring to market novel or conventional 
drugs delivered with a NDDS or to develop e.g. a novel nanotechnology-based 
diagnostic platform. Examples for companies with this business model are Inex, 
USA; Starpharma, Australia; Idea, Germany; Kereos; USA, or Ambri, Australia. 
After proof of concept has been shown these companies try to partner with 
pharmaceutical or medical device corporations that take the products through the 
clinical trials and that provide the crucial distribution networks. The majority of 
start-ups and SMEs, independent from the medical application field, work with 
this business model.  
2) The development of a nanotechnology platform that can be used to add value to 
second-party products: Such a business model seems to be particularly attractive 
for drug delivery companies. These companies focus on a particular drug 
delivery technology that is licensed out to pharmaceutical companies or the drug 
delivery system is customised and applied to a certain drug in commission of a 
pharmaceutical company. Pharmasol, Germany and Eiffel Technologies, 
Australia, both drug delivery companies, pursue such a business model. 
3) The development and manufacturing of high-value materials for the medical 
device and pharmaceutical industry: Some start-ups and SMEs only provide 
nanomaterials for the production of nanotechnology-enhanced drugs or medical 
devices. Examples for this business model are Bio-Gate, Germany, producing 
silver nanoparticles for medical devices, British Biocell, UK, producing gold 
nanoparticles for lateral flow tests or Raymor Industries, USA, manufacturing 
nanosized titanium powders for implants. 
Few of the major pharmaceutical and medical device companies have shown strong 
commitments to nanotechnology. They prefer to invest in novel technologies once proof 
of concept has been shown; for drugs this typically means after a drug candidate has 
successfully passed pre-clinical trials or phase I clinical trials. The risk of development 
is therefore assumed by start-up companies and SMEs. According to experts this 
approach is not specific for nanomedicine, but can also be observed in the field of 
biopharmaceuticals: The pharmaceutical corporations became interested in protein 
drugs, after their pharmaceutical potential was proven. As smaller companies and start-
ups rely on partnering with big pharma that provide the funding for the clinical trials, 
there are no signs that the structure of the pharmaceutical sector will change 
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significantly by the advent of novel nanotechnology-based drug delivery technologies. 
A further indication that there will be no big changes is the incremental added medical 
value by nanotechnology and the small market volumes of NDDS-enhanced products.  
Novel nanotechnology-based therapies are more likely to introduce change than NDDS, 
at least in certain market segments. There are several approaches for nanoparticle-based 
hyperthermia treatments for cancer. These treatments are, according to experts, 
expected to be significantly cheaper than the currently used chemotherapy. Furthermore, 
they are regulated as medical devices and not as drugs, which implies notably lower 
development costs, manageable by SMEs. These types of novel non-drug therapies of 
cancer might have some impact on the cancer therapy market. 
In the long term, however, also NDDS might impact the structure of the market to some 
degree: Many of the innovative drug delivery systems focus on diseases that occur in 
comparatively small patient groups such as brain or liver cancer, implying smaller 
markets. Experts see here a chance for medium-sized companies, since traditionally, big 
pharma has not shown much interest in niche markets over the past decade. However, if 
a new market segment can be established focusing on a more individualised medicine 
developed and marketed by medium-sized pharma companies remains to be seen. The 
key issue is wether the markets for such drugs are big enough to economically justify 
the high development costs caused by the clinical approval procedure. The orphan drug 
regulations targeted at drugs for rare diseases, in place in the EU and the USA, which 
guarantee market exclusivity for a period of 10 years, might help to bring NDDS-
enhanced drugs to the market.  
 
3.3 Market 
Inherent to nanotechnology is its enabling function that is used to add new functionality 
to products making them more competitive. As it is hardly possible to measure the 
added value of nanotechnology to a product, it has become common praxis in 
nanotechnology business studies to take the total sales of nanotechnology-enhanced 
products as a measure for the economic importance of nanotechnology in an industrial 
sector. Following this procedure, we estimate the total sales of the 38 identified 
nanomedicine products on the market in 2004 generated sales of estimated EUR 5.4 
billion (Table 3.2 and 3.3).  
Drug delivery systems present currently the largest market, accounting for about 80% of 
the sales. Significant sales of several hundred million euro are also generated with 
lateral flow tests based on gold nanoparticles and pacemakers using fractal electrodes. 
Interestingly, none of these two product groups is widely perceived as nanotechnology 
because both have been in use long before it nanotechnology emerged as a buzz-word 
and because nanotechnology accounts only for a tiny fraction of the added value. 
However, at least in the case of lateral flow tests gold nanoparticles are of significant 
functional importance, the reason why it was classified as a nanotechnology-enabled 
product. In the field of in vivo imaging, nanoscale imaging agents with estimated sales 
of about EUR 15 million in 2004 represent only about 1% of the market. Also in the 
sector of medical implants and devices nanotechnology-enhanced products are still of 
low economic importance with a market of estimated EUR 50 million in 2004. There 
are currently no approved nanotechnology-based drugs or therapies on the market.  
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Table 3.2 Nanomedicine market 2004 
Estimates for sales of nanotechnology-enhanced products and product groups in medical market segments 
are based on market analysis in this study. 
 
 Market, Billion € Market Environment, Billion € 
Drug Delivery 4.2 
Drugs and Therapies 0 
390 Drugs 
In vivo Imaging 0.015 15 In vivo diagnostics incl. equipment 
In vitro Diagnostics 0.6 22 In vitro diagnostics 
Biomaterials 0.05 8 Medical implants and devices 
Active Implants 0.5 6 Active Implants (Pacemakers and 
Cochlear Implants) 
Sum 5.4 441  
 
Source: VDI Technologiezentrum GmbH 
 
 
A market report by NanoMarkets, LC, estimates the sales of NDDS to EUR 3.7 billion 
in 2012 [NanoMarkets, 2005]. Based on the assumption that on average 30% of the 
value of a drug is added by a NDDS, it is estimated that NDDS-enhanced drugs with a 
value of about EUR 12.4 billion will be on the market by 2012. Considering also other 
nanomedicine products, and based on the information retrieved in this study, it is 
estimated that in 2012 the total market of nanotechnology-enabled medical products is 
about EUR 15 billion. It is also assumed, based on the product pipelines of the different 
application fields, that the relative importance of in vitro diagnostics and in vivo 
imaging is likely to increase. However, these estimates assume a similar regulatory and 
reimbursement framework as currently being in place in the future.  
 
Table 3.3 Examples for commercially available nanomedicine products 
In case a large number of different products is available that contain a specific nanotechnology 
component only the product class is listed, e.g. lateral flow tests or magnetic nanoparticles for cell 
separation. Listed are those products with highest sales for each medical application field. All of the listed 
products are available in at least one EU25 country.  
 
Pharmaceutical 
Product / Medical 
Device 
Nanotechnology 
Component 
Indication Company 
Drug Delivery    
Ambisome® Liposome Fungal Infections Gilead (USA), Fujisawa 
(Japan) 
Doxil/Caelyx Liposome Cancer ALZA (USA), Schering 
Plough (USA) 
Visudyne® Liposome Eye disease QLT (Canada), Novartis 
(Switzerland) 
Rapamune Nanosuspension Immunosuppresant Elan (Ireland)/Wyeth 
(USA) 
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Pharmaceutical 
Product / Medical 
Device 
Nanotechnology 
Component 
Indication Company 
Neulasta Polymer Protein 
Conjugate 
Febrile neutropenia Amgen (USA) 
Pegasys® Polymer Protein 
Conjugate 
Hepatitis C Hoffmann-La Roche 
(Switzerland), Nektar 
(USA) 
PEG-Intron Polymer Protein 
Conjugate 
Hepatitis C Enzon (USA), Schering-
Plough (USA) 
Copaxone Polymeric Drug Multiple sclerosis TEVA Pharmaceuticals 
(Israel)  
Renagel Polymeric Drug Kidney failure Genzyme (USA) 
In vivo imaging    
Feridex®/Endorem® Iron Nanoparticles Liver tumours  Advanced Magnetics 
(USA), Guerbet (France) 
Gastromark/Lumirem Iron Nanoparticles Imaging of 
abdominal structures 
Advanced Magnetics 
(USA), Guerbet (France) 
Resovist® Iron Nanoparticles Liver tumours Schering (Germany) 
In vitro diagnostics    
Lateral Flow Tests Colloidal gold Pregnancy British Biocell (UK), 
Amersham (UK),  
Nymox (USA) 
Clinical Cell 
Separation 
Magnetic 
Nanoparticles 
Immunodiagnostics Dynal/Invitrogen 
(Norway), Miltenyi 
Biotec (Germany), 
Immunicon (USA) 
Biomaterials    
Acticoat Silver Nanoparticles Antimicrobial wound 
care 
Nycryst (USA) 
Ceram X™ duo, 
EvoCeram®, Filtek™ 
Supreme, Tetric 
Nanoparticles Dental Repair Dentspley (UK), 
3M Espe (Germany), 
Ivoclar Vivadent 
(Liechtenstein) 
Ostim®, Perossal®; 
Vitoss®,  
Nano-hydroxyapatite Bone Defects Osartis (Germany), 
Orthovita (USA), 
Coripharm (Germany) 
Active Implants    
Pacemaker Electrodes with 
nanostructured coating 
Heart failure Biotronik (Germany) 
 
 
3.4 Drivers for Development 
Nanomedicine is partly technology push and partly demand pull driven. The progress in 
genomics and proteomics has led to a much improved knowledge of molecular 
processes linked to diseases and this has led to a redefinition of many diseases. Crucial 
for the diagnosis and treatment of diseases are proteins and DNA, both nanoscale 
biomolecules. Over the past two decades scientists have learned to design, manufacture 
and manipulate nanoscale materials. At the point where nanomaterials meet with a 
molecular understanding of cell function and disease development, nanomedicine 
emerges. Using nanomaterials allows to target cancerous tissue, to transport drugs and 
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imaging agents into cells or to stimulate cell responses supporting the healing process. 
For these applications nanomaterials are unique as their scale corresponds to the scale of 
biomolecules and it is intuitively understandable that nanomaterials could potentially be 
of great value for medical applications [Ferrari, 2005].  
Additionally, there are still important medical needs that need to be met to improve the 
efficacy of disease treatment: Many drugs show adverse side effects, many diseases 
cannot be diagnosed early enough for an effective treatment, biological barriers such as 
the blood-brain barrier cannot be overcome by many drugs, and there is need for more 
biofunctional materials to increase the lifespan of implants.  
Commercialisation of products starts at the cross over of medical needs with novel 
nanomaterials serving these needs. Some examples for drivers for nanomedicines are 
given below: 
• Drug Delivery: Many anticancer drugs have adverse side effects that can have 
severe consequences, in particular for risk patients. Drug delivery systems are 
being developed that concentrate the drug in cancerous tissue and significantly 
reduce the collateral damage caused by the drug. Another driver for new drug 
delivery approaches is the low solubility of many, very effective drug candidates 
which prevents their formulation as drugs. The pharmaceutical industry works 
on nanotechnology approaches (nanosuspensions) that make these drugs 
available for the treatment of patients. A commercial driver for NDDS is the 
extension of  the life cycle of a drug that goes off patent by reformulating the 
drug using NDDS.  
• The development of novel nanotechnology-based drugs and therapies is driven 
by the need to develop therapies that have less side effects and that are more 
cost-effective than traditional therapies, in particular for cancer. 
• An important driver for the development of nanotechnology-based contrast 
agents is the realisation of molecular diagnostics, i.e. the diagnosis of diseases 
on a molecular level. This approach potentially allows earlier diagnosis and 
monitoring of the effects of drugs on an unprecedented short timescale. The 
vision of molecular diagnostics is a major paradigm change from the treatment 
of symptoms to the prevention of the outbreak of diseases. For certain imaging 
modalities nanotechnology will be crucial to realise this vision because 
nanoscale carriers are needed to transport the contrast agents to the site of 
disease.  
• Molecular diagnostics and point-of-care diagnostics are the two most important 
drivers for the development of nanotechnology-based in vitro sensors. 
Nanotechnology contributes to the development of novel sensor systems that are 
highly sensitive, allowing for ultimate miniaturisation. This could make tests 
available for point-of-care diagnostics in doctor’s offices or even at home, which 
currently can only be run by laboratories. Also the pharmacogenetic approach to 
therapy, i.e. a more patient-specific treatment considering the genetic make-up 
of the patient, will make use of nanotechnology. Some methods under 
development use nanotechnology to enable the necessary sensitivity and 
specificity. However, often there are also suitable microscale methods available 
so that nanotechnology is not a unique enabler for molecular diagnostics. 
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• In the field of medical implants the demand pull seems to be not as strong as in 
drug delivery and diagnostics because important types of implants, such as hard 
tissue implants, are in a technologically fairly mature status. Drivers for 
nanotechnology applications are the need for implants with longer lifetimes and 
biodegradable implants that allow the full restoration of tissue. To meet theses 
challenges researchers develop nanostructured, more biocompatible materials.  
 
3.5 Challenges for Commercialisation 
According to experts, there are no general scientific hurdles that block nanomedicine 
products from market entry because many of the technologies pursued are now in a 
fairly mature state, having a development history of more than a decade. However, 
whether a technology is suitable for commercialisation and has chances to survive in a 
competitive market environment must be analysed on a case by case basis. Yet, there 
also seems to be a variety of stumbling blocks for commercialisation that arise from 
external factors, such as availability of capital, technology transfer management by 
universities, the intellectual property landscape, and regulatory issues that are detailed 
below (regulatory issues are discussed in Chapter 8).  
 
Venture Capital 
European start-up managers interviewed were of the opinion that there is considerably 
less venture capital (VC) funding available in Europe compared to the USA. In the USA 
about 52% of the nanotechnology VC has gone to nanobiotechnology start-ups13 [Paull 
et al, 2003]. The high investment into nanobiotechnology start-ups shows that investors 
see nanobiotechnology as a sector with great business potential, promising high returns 
on investments. Within nanobiotechnology the prime interest of the investors was drug 
discovery accounting for 54% of the investments followed by diagnostics (37%), drug 
delivery (5%) and biopharmaceuticals (4%). The worldwide VC investment in 
nanotechnology was EUR 386 million in 2005, that is about 2% of the total globally 
invested VC money [Lux, 2006]. The still abundantly available capital and the more 
advanced entrepreneurial culture in the USA are certainly two important reasons that 
commercialisation efforts are further advanced in the USA compared to the EU25. 
According to European experts, the more restricted private funding situation in Europe 
is slowing commercialisation efforts in the field of nanomedicine in Europe.  
 
Training and Education for Scientist and Entrepreneurs 
Nanomedicine is a research field in which material science is of great importance and 
many of the ideas for novel nanomedicine applications come from material scientists. 
However, many of these scientists are not familiar with the biological and 
pharmaceutical world and hence there is a tendency to underestimate 1) the complex 
interaction of cells and tissues with synthetic materials and 2) the difficulties of gaining 
                                                     
13 Nanobiotechnology is defined "as any application of nanotechnology in biological research, drug 
discovery and drug delivery devices, diagnostic tools, therapeutics or novel biomaterials" [Paull et al, 
2003]. Thus the term includes more applications than the term nanomedicine but has a strong medical 
focus. 
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regulatory approval for novel drugs and medical devices. This can lead to a situation 
that scientists put much effort in the early development of materials that generally are 
considered as too risky to invest in by major pharmaceutical companies because these 
materials e.g. have no clinical history. Moreover, according to experts, European start-
ups have management teams that are generally less market experienced than 
management teams of US start-ups. This often leads to an underestimation of 
difficulties to enter the market with new nanotechnology-based products. To improve 
commercialisation efforts at universities in the EU three measures are considered useful:  
• Universities should offer business courses that provide scientists with the 
essential know-how to run a start-up company, 
• Senior management personnel should be involved in the management teams or 
the advisory panels of start-ups at an earlier stage than it is currently the case, 
• Establishment of more, and more professionally managed technology transfer 
centers at universities. 
 
Uptake by Pharmaceutical and Medical Device Industry 
Crucial for the commercialisation of nanomedicine products, particularly for 
nanotechnology-based drugs but to a lesser extent also for medical devices, is the 
investment of major pharmaceutical and medical device corporations. Only these 
companies have the means to finance clinical trials for novel drugs and diagnostic 
devices and they are also needed for providing the distribution networks. As there is a 
strong start-up scene in the USA and Europe sparking novel nanomedicine technologies 
the limiting factor for commercialisation is currently seen by experts in the very 
cautious investment by the big players. Scientists claim that their technologies are ripe 
for commercialisation whereas representatives from pharmaceutical corporations 
caution that many of the novel technologies are not yet in a stage that justifies major 
investment. Thus the situation is similar to the initially very slow uptake of recombinant 
biotechnology by the pharmaceutical industry. According to experts pharmaceutical 
corporations will wait with significant investments in nanomedicine until a 
nanotechnology-enabled blockbuster has shown the potential of this technology.  
 
Intellectual Property Landscape 
Patents are crucial for nanomedicine start-ups to protect their technology but also to 
attract investors. Patent experts anticipate that intellectual property (IP) protection will 
have a great impact on the success of companies in commercialising their technologies. 
The IP landscape for nanomaterials is seen as complex and fragmented as these 
materials are of multidisciplinary nature, situated at the borderline between physics, 
chemistry and biology, which makes categorisation particularly difficult. 
Nanomaterials, such as quantum dots, dendrimers or carbon nanotubes, can potentially 
be used for a broad range of medical applications just by modifying the core nanoscale 
component. Hence these nanomaterials can be seen as platforms allowing the 
development of different drugs or diagnostics based on just one core building block. 
There is a risk that patents on the core nanomaterial could be broad enough to prevent 
development of any possible medical application by competitors. Examples for 
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companies that have very strong patent portfolios and broad claims are Starpharma, 
Australia, for pharmaceutical applications of dendrimers, Quantum Dot (now 
Invitrogen), USA, for biological imaging applications of quantum dots and C Sixty, 
USA, for fullerenes as building blocks of novel drugs. Whether the claims are broad 
enough to prevent competitors from investing in these materials and using them for 
medical applications remains to be seen. However, experts see the risk that companies 
might be able to stop competitors from entering the market of certain nanoenabled drugs 
or diagnostics in a similar way as Affymetrix was able to prevent companies from 
manufacturing high density DNA chips. Generally, experts agree that it is of paramount 
importance for companies to check the IP landscape before starting activities in the field 
of nanomedicine.  
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4 Nanomedicine – Research and Development14 
 
4.1 Publications and Patents  
Nanomedicine is an emerging, very dynamically growing technology field with its 
beginnings more than twenty years ago. The number of nanomedicine publications 
surged from about ten per year in the late 1980s to more than 1200 in 2004 (Fig. 4.1). 
The rise in patent filings since the year 2000 is even more pronounced with a total of 
nearly 2000 patents filed in 2003. Drug delivery is the technology sector that dominates 
nanomedicine, contributing 76% of the publications and 59% of the patents. The second 
largest field is in vitro diagnostics accounting for 11% of the publications and for 14% 
of the patent filings (Table 4.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Nanomedicine publications and patents worldwide 
Publication and patent searches only include technologies covered in this report and was conducted using 
specific keywords that allow for a clear classification of the document content as nanomedicine or 
nanomedicine-related (see Appendix). Source: EPO, VDI Technologiezentrum GmbH 
 
 
Clustering the publications according to the three geographical areas USA, EU25 and 
Asia (Japan, China, South Korea, Taiwan, Singapore and India) reveals that the EU25 is 
leading with 36% of the worldwide publications, followed by the USA with 32% and 
Asia with 18% (Fig. 4.2). With regards to the different application fields of 
nanomedicine the share of EU25 publications varies between 37% for drug delivery 
and, at the lower end, 27% for active implants (Tab. 4.1). The USA is leading with 
regards to patent applications with a share of 53%, followed by the EU25 with 25% and 
Asia with 12%. There is a consistent trend for all nanomedicine application fields that 
the contribution of the EU25 to the worldwide patent activity is significantly lower than 
the publication share.  
                                                     
14 Information in this chapter is based on Work package 1 - Current status of medicinal 
nanobiotechnology in Europe, V. Wagner, VDI Technologiezentrum GmbH, 2005. 
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Table 4.1 Publications (1980-2004) and patents (1993-2003) in nanomedicine: Breakdown for 
medical sectors 
 
 Publications 
 % 
Publications 
Share of EU25
Patents 
 % 
Patents 
Share of EU25 
Drug Delivery 6332 76.3 37 % 5884 58.8 23 % 
Drugs & Therapies 150 1.8 32 % 342 3.4 32 % 
In vivo Imaging 352 4.2 39 % 1267 12.7 29 % 
In vitro Diagnostics 915 11.0 29 % 1400 14.0 26 % 
Biomaterials 487 5.9 28 % 801 8.0 35 % 
Active Implants 52 0.6 27 % 319 3.2 22 % 
Sum /average 8288 100 36 % 10013 100 25 % 
 Source: VDI Technologiezentrum GmbH 
 
Fig. 4.3 shows publication and patent activity since the 1990s for the 15 EU countries 
with the highest research activity. The three leading countries with regards to 
publications and patents are Germany, the UK, and France with more than 400 
publications each. Within Europe the nanomedicine patent activity of Germany is 
outstanding with more than 700 filed patents in the period between 1993 and 2003. 
Although the publication activity in the UK and France is comparable to Germany (87% 
and 72%, respectively), patent numbers are about a factor of three lower. In addition to 
Germany, Sweden and Denmark show high patent activities compared to the publication 
output, indicating commercially highly relevant research activities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Area breakdown for nanomedicine publications (1980-2004) and patents (1993-2003) 
Asia includes Japan, China, South Korea, Taiwan, Singapur and India. 
Source: EPO, VDI Technologiezentrum GmbH 
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Figure 4.3 Nanomedicine in Europe: Publications (1980-2004) and patents (1993-2003) for the top 
15 EU25 countries 
Source: VDI Technologiezentrum GmbH, EPO 
 
To obtain some information on the relative importance of nanomedicine research in 
EU25 countries we have calculated the share of nanotechnology publications that focus 
on medicine out of all nanotechnology publications since the 1970s. The results (Fig. 
4.4) show that The Netherlands, Portugal, the UK, Finland and the Czech Republic have 
a comparatively strong focus on nanomedicine with more than 7% of their 
nanotechnology publications covering medicine related research whereas for countries 
such as France, Germany and Sweden, the share of nanomedicine publications is only 
about 4%. On average 5.2% of EU25 nanotechnology publications cover nanomedicine 
topics, te share is 6.3% for the USA and 4% for Japan.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Share of nanotechnology publications since the 1970s that focus on nanomedicine for the 
top15 EU25 countries 
Source: VDI Technologiezentrum GmbH  
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Figures 4.5 and 4.6 show the geographical distribution of companies and leading 
academic research groups as identified in this study for the USA and Europe. Though 
fairly crude, this provide an indication for emerging nanomedicine clusters worldwide. 
In the USA activities in the areas of Boston, New York, San Francisco and Los Angeles 
are outstanding. Furthermore, many start-ups are founded in the States in the North 
Eastern part of the USA such as Illinois, Indiana, Michigan, Ohio and Pennsylvania. 
Research activities in Houston, Austin and Dallas are also significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Nanomedicine companies and leading research groups in the USA identified in this 
study 
Source: VDI Technologiezentrum GmbH 
 
 
In Europe much of the activity is centered in Germany, Switzerland, France and the UK. 
Remarkable is the concentration of start-up companies in Berlin, South East England 
(London, Oxford and Cambridge) and the Paris area. 
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Figure 4.6 Nanomedicine companies and leading research groups in the EU identified in this study 
Source: VDI Technologiezentrum GmbH 
 
 
4.2 Public Funding and Strategic Initiatives 
Nanotechnology has become one of the most heavily funded research areas, receiving 
about EUR 3 billion per year worldwide. In recent years the USA has run the biggest 
nanotechnology research programme funded with EUR 740 million in 2004, followed 
by Japan with EUR 480 million. The European Commission in 2004 spent about EUR 
370 million on nanotechnology research and the EU25 countries all together EUR 960 
million. In the EU25, the biggest governmental nanotechnology programmes are 
currently run by Germany (EUR 293 million), France (EUR 224 million), The 
Netherlands (EUR 120 million) and UK (EUR 100 million) (Fig. 4.7).  
Interviews with representatives from funding agencies have revealed, that there are no 
data available on public funding of nanomedicine research for any of the major players 
in this field such as the USA, Germany, the UK, and France. As nanotechnology is a 
cross-cutting technology, obtaining detailed data on governmental funding is already 
very difficult for most countries. A detailed breakdown of funding with regards to 
nanotechnology sectors seems to be an even more daunting endeavour that is not 
pursued by any of the countries reviewed in this report.  
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However, as an indicator the share of nanotechnology publications that focus on 
medical applications can be used. Based on this it is estimated that on average in the 
EU25 about 5% of the nanotechnology funding is spent on medicine-related research 
projects. A further 15% is probably funneled into other areas of nanotechnology such as 
biomedical research and related fundamental research so that life sciences related 
research is likely to account for about 20% of nanotechnology activity and funding 
[Paschen, 2003].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Nanotechnology public funding of EU25 countries in 2004 
Source: [European Commission 2005] 
 
While concrete figures on the public spending on nanomedicine do not exist for the 
major nanomedicine players in the EU25, there is information available on research 
programmes and funding initiatives that reflects the governmental funding activities in 
this field: 
France: The investment of INSERM (the French national medical research institute) 
into nanotechnology, that might be indicative for the French nanomedicine funding, was 
EUR 6.5 million in 2004. Further, in 2005 a decision was taken to create a center 
dedicated to micro- and nanotechnologies for health and biology in Grenoble that will 
be supported with EUR 23,5 million public funding for new equipment and facilities.  
Germany: The German Federal Research Ministry supports a specific 
nanobiotechnology research programme including nanomedicine projects since 2000 
over a period of six years with a total of EUR 50 million. To specificly promote R&D 
activities in nanomedicine (drug delivery, molecular imaging, and medical 
implants/regenerative medicine) the lead innovation initiative "NanoforLife" was 
established in 2004, a funding programme for four to five years that started end of 2005. 
Total funding will be up to EUR 30 million intended to leverage a similar amount of 
money from industry. Nanobiotechnology clusters were established in Rhineland-
Palatinate/Saarland and Munich to tighten contacts between research groups and 
companies.  
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United Kingdom: Nanotechnology research funded by UK Research Councils (the 
Biotechnology and Biological Sciences Research Council, BBSRC; the Engineering and 
Physical Sciences Research Council, EPSRC, and the Medical Reserach Council, MRC) 
includes two Interdisciplinary Research Collaborations (IRC) that focus on research in 
nanotechnology and life sciences and that are supported by EUR 56 million over a 
period of six years. As the UK biotechnology and pharmaceutical sector enjoys 
internationally a very strong position combined with a strong medical and science base, 
nanomedicine is anticipated to have a particular great synergy potential in the UK. 
Therefore, it is planned that future phases of the Department of Trade and Industry 
funded Micro- and Nanotechnology Initiative (MNT, about EUR 40 million per year) 
have a strong focus on nanomedicine. 
The European Union: Within The Sixth EU Framework Programme for Research and 
Technological Development (FP6, 2002-2006) an expected average spending on 
nanotechnology related projects is EUR 250 million per year. Of those 129 
FP6nanotechnology projects on which information is publicly available there are seven 
that can be classified as nanomedicine. At present several initiatives are on-going to 
strengthen European nanobiotechnology and nanomedicine research: 
Nano2Life is a network of excellence funded via FP6 with the objective to 
coordinate and bring together existing European expertise and knowledge in the 
field of nanobiotechnology in order to make Europe a leader in commercialising 
nanobiotechnology research in 5 years time. Nano2Life aims to develop the 
basis for a virtual European Nanobiotechnology Institute. Research of this 
virtual institute is targeted at nanotechnology applications in the areas of sensor 
technology, health care, pharmaceuticals, environment, defence and food safety.  
A European Technology Platform (ETP) on NanoMedicine was launched in 
autumn 2005. It aims to bring together stakeholders to develop a long-term 
vision for nanomedicine that should result in a strategic research agenda. It 
further aims to identify priority research areas, to mobilise public and private 
investment and to overcome fragmentation in the European nanomedical 
research community. The ETP will focus on the following three topics: drug 
delivery, regenerative medicine and nanodiagnostics including sensors and 
medical imaging [ETP Nanomedicine, 2005]. 
The European level initiative, Forward Look Nanomedicine, a foresight process 
conducted by the European Science Foundation, brought together over a period of 2 
years (2003-2004) over 100 international experts from academia, industry and 
governmental agencies to review the field and to deliver recommendations regarding 
funding priorities and organisational and research infrastructures needed in Europe. The 
report was recently published [ESF, 2005].  
USA: In the USA the multiagency efforts in nanotechnology research are coordinated 
by the National Nanotechnology Initiative (NNI). The US Department of Health and 
Human Services (HHS) contributed EUR 62 million (8%) to the total budget of the 
NNI. Though there is normally considerable thematic overlap between different funding 
domains, this could be an indication for the share of the budget that is spent on 
nanobiotechnology/nanomedicine research. The field of nanobiotechnology has been 
further strengthened by the US National Science Foundation that increased the budget 
for biological sciences within the NNI from EUR 4 million in 2004 to EUR 36 million 
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in 2005. Additionally, the National Institutes of Health (NIH) made three major 
commitments to a focused support of health related nanotechnology research in the year 
2004/2005: 
The National Cancer Institute's Alliance for Nanotechnology in Cancer, a EUR 112 
million five-year initiative to develop and apply nanotechnology to cancer, that was 
launched in September 2004 [NCI, 2005]. 
The Program of Excellence in Nanotechnology of the National Heart, Lung and 
Blood Institute to fund four research centers (EUR 42 million between 2005-2009) 
that develop nanotechnology solutions for the diagnosis and treatment of 
cardiovascular, pulmonary, blood and sleep disorders [NHLBI, 2006]. 
The Nanomedicine Roadmap Initiative, a broad programme that seeks to measure 
and characterise molecules and use this data to understand molecular pathways and 
networks [NIH, 2005]. 
China: Within the five-year plan 2001-2005 China spent EUR 150-230 million on 
nanotechnology research. It is estimated that about five percent of the funding is spent 
on nanobiotechnology and nanomedicine related research projects [RAM, 2004; ATIP, 
2003].  
Japan: Japan pursues an ambitious research programme “Nanotechnology & Material 
Science” with a total funding of EUR 600 million in 2004, of which about 80% (EUR 
480 million) are earmarked for nanotechnology. About 16% (EUR 100 million) of the 
budget is spent on the priority life sciences. In the year 2002 the Ministry of Health, 
Labour and Welfare initiated a Nano Medicine Research Project that provides funding 
of about EUR 7 million per year for 23 projects between 2002 and 2006. Thematically 
the projects cover a broad range of technologies including drug delivery, molecular 
imaging, biosensors and medical implants. 
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5 Impact of Nanomedicine Applications on Health Care Costs15 
In most industrial countries today, rising health care expenditures are a major concern 
for health care sytems. The most prominent explanations for this development are 
demographic changes and high costs of health care innovations. Thus future health care 
innovations will not only be required to be of high quality, safety and efficacy – they 
will, in addition, be assessed with respect to the costs at which they deliver health 
benefits. Consequently, high costs are likely to increasingly impede the diffusion of 
health innovations in the market. Against this background, nanomedicine innovations 
were analysed regading potential impacts on future health care costs and their cost-
effectiveness. 
 
5.1 Trends in Health Care Systems 
In the past, health innovations were mainly assessed with respect to efficacy and 
improved quality of life of patients, whereas cost considerations were not of prominent 
importance. Nowadays, the situation has changed: health care costs do matter. National 
health care expenditures are expected to increase significantly if the current practice is 
also pursued in the future: while in 2002, EU15 member states spent 6.2% of their gross 
domestic product on health care, this share is likely to rise to 8.9% in 2050 [Surcke et 
al., 2005]. The main drivers are demographic changes towards an ageing society 
(decreasing birth rates, increasing life expectancy), and medical innovations which alter 
the patterns of the most prevalent diseases towards an increase of complex and chronic 
diseases.  
The changing age structure of the society together with an increase in health care 
expenditure challenges the sustainability of the health care systems, because most of 
these systems are based on a pay-as-you-go financing mode. Population ageing 
unbalances the relation between health care expenditures and health care contributions, 
as fewer people of working ag will have to support those in retirement. This is reflected 
by the indicator of old-age dependency ratio, which is expected to rise in EU15 from 
24.3 in 2000 to 53.2 in 2050 [European Commission, 2006].  
Therefore, present health care systems will no longer be affordable in the medium to 
long term and require significant changes. Several options can be taken into 
consideration, among them  
• Structural reforms such as a change in the financing mode, reduced coverage, or 
a reduction in institutional inefficiencies in health care delivery, 
• Investments into the health of the population,  
• Cost reduction in sectors identified as main cost drivers. 
With respect to health innovations, it can be concluded that efficacy and improved 
quality of life will remain a necessary prerequisite, but will no longer be sufficient. In 
addition, health innovations will increasingly be assessed with respect to the costs at 
which the improvements come. For this reason, cost aspects of nanomedicine are 
considered in the following paragraphs. 
                                                     
15 This chapter is based on Work package 3 - Potential socio-economic impacts of medicinal 
nanobiotechnology applications, B. Hüsing and S. Gaisser, Fraunhofer Institute for Systems and 
Innovation Research, 2005. 
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5.2 Cost Considerations for Nanomedicine Applications 
Based on model calculations for Germany performed by Farkas et al. [2004], major 
drivers for future health care costs were identified: In addition to demographic changes, 
cancer, cardiovascular, neurodegenerative and musculo-sceletal diseases are expectd to 
be the major cost-causing diseases. Further, personnel-intensive care (e.g. days in 
hospital) is very cost intensive. Taking this into account, nanomedicicine innovations 
are likely to reduce future health care costs if they  
• Aim at major cost-causing diseases, and at the same time, 
• Reduce personnel costs, for example by reducing the required days of inpatient 
care, 
• Contribute to "healthy ageing" via raising the health status of the population.  
On the other hand, nanomedicine innovations are likely to have no major effect or even 
increase future health care costs if they  
• Aim at diseases of minor cost relevance such as infections or diseases with low 
prevalence and incidence, or 
• Come as add-on technology, which offers only a small health effect at 
significant costs so that the cost-benefit-ratio is unfavourable, or 
• Result in additional procedures without substantial health effects (e.g. more 
diagnostic procedures). 
For the major cost-causing disease groups cancer, cardiovascular, neurodegenerative 
and musculo-skeletal diseases, technology dependent costs account for a maximum of 
20% of the total costs [Farkas et al, 2004]. Thus nanotechnology innovations are likely 
to have a particularly strong impact on health care costs if they reduce personnel costs 
by reduction of the number of days in hospital. Other savings may be realised in 
ambulatory care costs, i.e. for diagnostic tests or for pharmaceutical therapies. In the 
following, examples are given how nanotechnology could impact future health 
expenditures:  
Cardiovascular disease is with 30% of the projected deaths the leading cause of death 
worldwide. Due to the high number of patients with cardiovascular diseases, even small 
cost effects (positive or negative) on an individual case basis will result in large cost 
impacts, if the whole affected population is taken into consideration. Main cost drivers 
are intensive care for chronic patients and rehabilitation for stroke patients. Some 
nanotechnology-based diagnostic tests may offer a potential for cost reductions. An 
example for nanotechnology innovations with potentially high impact in this field are 
contrast agents developed by Kereos, USA, in cooperation with Bristol-Myers Squibb 
Medical Imaging, USA. These are developed to detect unstable plaques with MRI to 
early identify those patients at high risk of heart attack. Effective prevention strategies 
for these high risk patients could result in reduced costs for intensive care and 
rehabilitation for stroke patients. The contrast agent is based on nanoscale 
perfluorocarbon emulsion particles and is currently in a preclinical development stage. 
Diseases of the nervous system: In the diagnostic group of nervous system diseases, 
nanotechnology-based drug delivery systems (NDDS) are in development that are able 
to transport drugs across the blood-brain barrier. Furthermore, novel nanoscale materials 
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are developed that possess much stronger antioxidant properties than any of the 
traditionally drugs for treatment of neurodegenerative diseases. However, none of the 
these products has reached late stage clinical trials so that possible cost impacts are 
difficult to assess. In conjunction with an early detection of neurodegenerative diseases 
before the onset of clinical symptoms, it is hoped that the period without the need for - 
expensive - custodial care can be prolonged and that the savings in care exceed the costs 
for additional diagnostics and medication.  
Cancer therapy requires an average stay in hospital of 10 days in Europe. For cancer 
diagnostics and treatment, novel nanotechnology-based in vivo diagnostic approaches 
and NDDS are under development. For example, nanotechnology-based cancer 
diagnostics are developed that aim at monitoring the therapeutic effects of drugs. Such a 
therapy-specific monitoring is expected to prove the efficacy of a drug within days 
compared to weeks or months with currently available diagnostic methods. As cancer 
therapies cost up to several thousand euros per month and it often takes several months 
until an effective drug treatment is found, nanotechnology-based molecular diagnostics 
are expected to improve the efficiency of disease treatment. Another important research 
direction in nanomedicine is the development of NDDS for anticancer drugs that result 
in drug accumulation at the tumour site and in that way reduce side effects. In case a 
reduction of treatment costs due to less side effects overcompensates the additional 
costs for the drug delivery system, an overall reduction in treatment costs could be 
achieved (see also below case study on liposomal doxorubicin). Furthermore, novel 
nanotechnology-enabled therapies are developed, such as iron nanoparticle-based 
hyperthermia, that are expected to have the same efficacy as traditional therapies but at 
significantly lower costs. Therefore experts expect these methods to have great potential 
to reduce health care costs. 
However, there is an important general consideration that is relevant for all life-
prolonging anticancer medicines. A global cost calculation has to take into account that 
tumour patients who survive their first tumour might require additional treatments due 
to the occurrence of secondary tumours. This scenario would eventually result in higher 
health care costs for any anticancer drug that is not able to eradicate cancer completely.  
Infectious diseases currently do not present a significant economic problem for the 
health care systems of industrialised countries. However, as the number of opportunistic 
infections increases due to the rising number of aggressive tumour therapies and 
transplantations (both are therapies that weaken the immune system), the spectrum of 
morbidity could change in the future. A certain improvement of drug therapies can be 
expected as nano-encapsulated drugs could be applied site directed and in higher 
concentrations. The case study of liposomal amphotericin B will describe this in more 
detail (see below).  
Musculo-skeletal diseases: Model calculations based on data for Germany show that 
this diagnostic group will cause the highest health care costs due to high costs for 
personnel in care and physiotherapy but also for drugs and implants [Farkas et al., 
2004]. A nanotechnology-based increase of the lifespan of implants from 15 years to 25 
years could be beneficial particularly for younger patients. However, in Germany only 
12% of all patients that undergo hip replacement are younger than 55 years. Therefore 
the potential of implants with longer lifespans to reduce treatment costs seems to be 
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limited. However, this situation might change taking into account the steadily increasing 
life expectancy and the high costs of revisions.  
 
The number of studies that cover economic aspects of nanomedicine products is very 
small. Up to now only for liposomal amphotericin B, an antifungal drug, and pegylated 
liposomal doxorubicine, an anticancer drug, sufficient data is available that allows a 
first analysis of cost-effectiveness. 
Case Study: Liposomal Amphotericin B (AmBisome®) 
Amphotericin B is an antifungal drug which is mainly used against fungal infections in 
transplant recipients, patients suffering from HIV/AIDS or in cancer patients. The major 
drawback of this drug is its kidney toxicity. To reduce the nephrotoxic side effects the 
company Gilead (USA) has developed AmBisome®, a liposomal formulation of 
amphotericin B. Several clinical studies came to the conclusion that AmBisome® has a 
higher efficacy than conventional amphotericin B [Sharon et al., 2002; Hann and 
Prentice, 2001; Cagnoni et al., 2000]. The costs of AmBisome® are substantial: A 
standard therapy against aspergillosis with AmBisome® costs EUR 26.000 to EUR 
53.000, whereas a standard therapy with amphotericin B costs EUR 107 to EUR 214. 
Depending on the infection, the high cost of AmBisome® may be counterbalanced by 
reduction of hospitalisation duration and absence of side effects. Owing to the much 
lower price amphotericin B is used as a standard therapy for treating fungal infections. 
Only if kidney problems occur, or if the patient is at high risk for developing severe 
kidney damage, AmBisome® is recommended as first-line therapy [Sharon et al., 2002; 
Dupouy-Camet 2004]. For these reasons sales of AmBisome® are moderate with EUR 
164 million in 2004. There is no information available about the price strategy of 
Gilead. However, experts assume that the high costs do not reflect the production costs 
but more the medical value of the drug. AmBisome® is a first generation liposomal 
product and it is assumed that the development and production costs of liposomal 
formulation will decrease with further scientific progress.  
 
Case Study: Pegylated liposomal Doxorubicin (Doxil®/Caelyx®) 
To reduce the cardiotoxic effects of the anti-cancer drug doxorubicin, pegylated 
liposome formulations (Doxil®/Caelyx®) were developed and launched beginning of the 
1990s. They are used to treat HIV/AIDS related Kaposi sarkoma or ovarian carcinoma. 
First-line therapy against ovarian carcinoma are platinum based drugs. In case patients 
do not respond to this therapy, the gold standard for the second-line therapy is 
topotecan. Approximately 150 clinical studies have been performed worldwide in order 
to assess the cost-effectiveness of liposomal doxorubicin in comparison with topotecan 
[Forbes et al. 2002; Thigpen et al. 2005; NICE 2005]. Both, topotecan and liposomal 
doxorubicin show similar clinical effectiveness in the treatment of ovarian cancer, but 
differ significantly in their pattern of side effects and incidence of adverse events. 
Treatment costs of liposomal doxorubicin tend to be slightly lower owing to a different 
pattern in side effects [Capri et al., 2003; Ojeda et al., 2003], but its overall cost-
effectiveness in terms of quality-adjusted life-years still remains to be established 
[Forbes et al. 2002]. Currently, treatment with liposomal doxorubicin costs 20 times 
more (about EUR 10.000 per treatment) than standard doxorubicin. Therefore liposomal 
doxorubicine is only administered to risk patients that suffer from cardiac diseases and 
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drug sales are moderate (EUR 112 million in 2004) with European uptake of less than 
three percent.  
 
Both drugs show similar or better clinical effectiveness and less side effects than the 
gold standard treatment, but differ in the cost at which this health benefit comes. They 
are cost-effective only for the small group of risk patients and are recommended only 
for this group. Therefore market uptake of these drugs remains low. 
Apart from the technological development, the future framework for approval and 
reimbursement is a key issue for the economic impact of nanotechnology on health care 
systems. The extent to which innovative technologies are added to the list of 
reimbursement by insurances or the national health care systems is a political question; 
facing the financial shortage in the health care systems, prices and cost-effectiveness 
ratios will be very crucial. Only cost-effective health technologies are likely to be 
reimbursed. This is a chance to focus nanomedicine research on medical technologies 
that aim at reducing health care costs.  
Looking at the multitude of options to apply nanotechnology to medicine, it becomes 
clear that at present no general assessment can be given, in which way nanotechnology 
will eventually impact health care costs. Generally, the development of novel 
pharmaceuticals with added functions such as drug delivery systems will be more costly 
than the drug alone, though eventually indirect cost reduction, such as less side effects, 
shorter recovery times and less costs for patient care (particularly regarding 
neurodegenerative diseases) will be decisive for the overall cost effect. With regards to 
analytical methods there are nanotechnology-based applications in the pipeline that 
promise early detection of diseases. Should this make an earlier and more effective 
intervention possible, costs could be reduced.  
According to experts, nanomedicine indeed has the potential to reduce health care costs, 
provided that the proper incentives to exploit these potentials are effective in the health 
care systems. One prerequisite would be the integration of health technology 
assessments in the development process of nanomedicine products. However, many 
more nanotechnological products and analyses of their cost-effectiveness are needed to 
be able to deliver a general assessment of the impact of nanomedicine on future health 
care costs.  
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6 Social and Ethical Issues in Nanomedicine16 
It has been widely recognised that there is a need to address social and ethical issues of 
nanotechnology in addition to scientific, economic and political issues [e.g. European 
Commission 2004, 2005]. Moreover, the ethical and sociological reflection should 
rather not be considered as an "add-on" which follows scientific-technological research 
and development, but should accompany it as an integral part (Schummer, 2004). It is 
hoped that a better understanding of the interaction and mutual interdependence of 
science, technology and society could lead to better informed decisions about how to 
shape the development of nanotechnology, and that mistakes that have been made with 
other technologies, such as biotechnology and genetic engineering, might be avoided by 
dealing proactively with the social and ethical embedding of nanotechnology [see e. g. 
Lewenstein 2005; Macnaghten et al. 2005]. 
However, the systematic exploration of social and ethical issues of nanotechnology 
started a few years ago. Due to the early stage development of nanotechnology, these 
are mainly deliberations about possible social and ethical issues for nanotechnology in 
general. The majority of these analyses relates to nanotechnology in their entirety, the 
differentiated analysis of certain application areas or subfields of nanotechnology (e.g. 
to nanomedicine) or of specific product lines (e.g. drug delivery) has only started 
recently (e.g. within the FP6 funded network of excellence Nano2Life the Ethics Board 
works on a wider assessment of ethical and social implications on new nanotechnology 
applications in addition to the ethical evaluation of research projects; Bruce, 2006). 
Moreover, because the development of nanotechnology applications is a rather long-
term endeavour, the exploration of social and ethical issues is hampered by the inherent 
uncertainty of this process and by the uncertainty about the future social contexts into 
which the use of the respective applications might be embedded.  
Issues raised by nanotechnology applications have, in part, been dealt with in depth in 
other technological contexts, so that the analysis of ethical and social issues of 
nanotechnology can establish links with this work [MacDonald, 2004]. For example, 
nanotechnology-enabled diagnostics may have close links with aspects of genetic 
testing, and enhancement of body functions raise similar issues as performance 
enhancing drugs in sports [UNESCO 2006]. But even if the ethical and social issues are 
not genuinely new or exclusively specific for nanotechnologies, this does not render 
them less valid. Rather, due to the enabling nature of nanotechnology some issues may 
become (even) more critical, and there may be shifts in emphasis. In addition, new and 
specific issues may arise [Baumgartner 2004]. Moreover, many potential applications 
and visions explicitly refer to the convergence of nanotechnologies, biotechnology, ICT 
and cognitive sciences [National Science Foundation 2002; Roco 2003], which seems to 
be a specific feature of the nanotechnology discourse. 
The expectation that nanotechnology applications in medicine will lead to positive 
health impacts for individual patients as well as the public is a major driving force for 
this field, and also characterises the prevailing view in the general public. However, 
                                                     
16 This chapter is based Work package 3 - Potential socio-economic impacts of medicinal 
nanobiotechnology applications, B. Hüsing and S. Gaisser, Fraunhofer Institute for Systems and 
Innovation Research, 2005. 
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possible health benefits must be carefully balanced against possible adverse health 
effects and social and ethical issues need to be addressed. 
 
6.1 Health risks of nanoparticles 
It is known that the exposure to ultrafine dust particles poses health risks for humans. 
This implies that exposure to engineered nanoparticles could pose health risks too. 
Particularly because of their mobility across biological barriers, size related chemical 
activity effects and their ability to penetrate cells, nanoparticles show properties that 
could result in increased toxicity compared to bulk materials. Nanoparticle sources are 
natural (e.g. salt spray from the ocean), unintentionally produced (e.g. cooking, material 
fabrication, diesel exhaust) or, relatively new, engineered nanoparticles. Presently, it is 
not known how significant the increase in exposure due to these engineered 
nanoparticles is and will be in the future [European Commission, 2006a]. Generally two 
forms of application of nanoparticles need to be distinguished with respect to exposure 
and possible health risks: 
• Nanoparticles bound into a chemical matrix, such as a polymer or a metal. 
Unless nanoparticles are released due to chemical processes or wear, these 
materials are generally considered as safe.  
• Free nanoparticles in the air or in fluids that can be taken up by the body via the 
lung, skin or the intestinal tract.  
Nanoparticle emission, intentionally or unintentionally, can occur during research and 
development activities, manufacturing, use, and after use/during disposal, and after their 
dispersion in the environment. Potentially exposed groups comprise staff in R&D, 
manufacturing, diagnosis and treatment, disposal, recycling, remediation and cleaning, 
transport and trade, and accidents, patients, and the general population. Additionally, 
ecosystems might be affected. Therefore toxicologists warn that health and 
environmental effects of nanoparticles and exposure of workers need to be investigated. 
There is consensus among stakeholders that the present level of knowledge is 
insufficient for risk assessments. The need to  
• Develop harmonised nomenclature and criteria for nanoparticle characterisation, 
• Develop methodologies for routine measurements, 
• Develop equipment and methods for the determination of the environmental fate 
of nanoparticles and for the detection in the environment, and for exposure 
assessment to nanoparticles, 
• Understand toxicity and ecotoxicity of nanoparticles, 
• Conduct epidemiological studies 
is broadly recognised [European Commission, 2006a]. 
 
6.2 Changes in health care delivery 
Several changes in health care delivery can be expected from the scientific-
technological developments outlined in Chapter 2: 
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o Personalised medicine. By providing diagnostic systems (e. g. for screening), 
nanotechnology will be an enabler for extended risk specifications on the level of 
the individual, which may open up the possibility to adopt preventive risk 
management strategies and to choose the most appropriate intervention for the 
affected individual. Therapeutic interventions (e.g. dosing of drugs) could be 
tailored to the individual response, if nanotechnology-enabled monitoring of 
disease progression and of effects of therapeutic interventions could be applied. 
This trend towards personalised medicine could increase the available options for 
patients to exert more self-determination and self-responsibility on their health, 
but on the other hand this option may also turn into a duty.  
o Convergence with ambient intelligence. The applications of nanotechnology are 
expected to support the introduction of telemedicine into health care delivery 
through nanotechnology-enabled devices such as sensors, which include ICT 
components. These devices will increasingly be interconnected, leading to a 
convergence of telemedicine/e-health with ambient intelligence. This will lead to 
changes in work and information flow in health care, and in the tasks that have to 
be performed by medical staff. 
o Shift of (chronic) diseases to older age. Earlier diagnosis and risk specification 
before clinical symptoms become manifest, coupled with preventive measures and 
improved therapies are expected to shift chronic disease states to older age. This 
should allow a higher quality of life until older age, but could have significant 
impacts on demographic development, and the need for social support systems for 
the elderly.  
o "Exchange of spare parts". Nanotechnology is seen as an enabler for the provision 
of interventions which compensate disabilities and impaired motor, sensory and 
cognitive functions. This could lead to a notion of medicine as providing "spare 
parts" which are exchanged in case of disease or accident in order to "repair" 
defects, with significant impacts on the role of the body for personal identity, and 
also on our understanding of health and disease (see also Chapter 6.4). 
 
6.3 Access to and availability of nanomedicine  
Fairness is one of the key principles of biomedical ethics which translates into the goal 
that there should be equal access to nanotechnology-enabled medical diagnostics, 
therapies and services for all those in need of it. However, the concern is often brought 
forward regarding the danger of inequal access to nanotechnology and a resulting 
"nano-divide". This term implies that there are winners with access to nanotechnology 
and losers who lack this access. This divide can take shape on different levels 
[Mnyusiwalla et al, 2003; Baird and Vogt, 2004; Invernizzi and Foladori, 2005]: 
o Between developed and developing countries in the way that the unequal access to 
scientific-technological know-how and use of nanotechnology is further 
increasing the wealth gap between these two parts of the world. The priorities of 
R&D efforts play a major role for realising the benefits of nanomedicine while 
avaoing the risks. Furthermore, research agendas of developed countries could 
also be targeted at developments beneficial for developing countries (see e.g. 
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Global Dialogue on Nanotechnology and the Poor: Opportunities and Risks17). 
Nanomedicine products could also be so expensive that poorer countries could be 
prevented from access to much needed medication. 
o On a company and cluster level, e.g. through the development of patent 
monopolies which allow the patent owner significant influence over certain 
trajectories of nanomedicine developments, and hinder the market entry of other 
players.  
o On a health care level in case nanomedicine products are so costly that they are 
not covered by health insurances and only the privileged get access to them. A just 
allocation of resources in health care requires the integration of health technology 
assessments and cost-effectiveness studies in the development of these new 
interventions. 
 
6.4 Specific characteristics of nanotechnology-based diagnostics  
In the following specific features of nanotechnology-base diagnostics will be analysed 
in more detail, also taking into account that thse applications seem to be comparatively 
close to the clinical application.  
It is expected that nanotechnology-enabled diagnostics will enable a significant 
extension in various dimensions of present capabilities to analyse and diagnose. These 
features, in their sum, can only be achieved by a convergence of nanotechnology with 
biotechnology and ICT: 
o Range of testable conditions. It is expected that the range of testable conditions 
(e.g. body functions and states, diseases or disease predispositions) will 
significantly expand, and that tests at the cellular or molecular level will become 
available.  
o Time and frequency. Testing will become possible at earlier disease states (i.e. 
before clinical symptoms become manifest) and even before an elevated 
individual risk is suspected (i.e. screening), resulting in an increase in predictive 
testing. It is likely that also the frequency of testing will increase, in order to 
monitor the progression of disease or the effects of therapeutic or preventive 
interventions, and even continuous surveillance and control can be expected. 
o Occasions for testing. New occasions for testing are likely to emerge: general 
screening for preventive purposes, for specification of individual risk, for 
monitoring of health status if a higher individual risk has been identified, and 
continuous surveillance. 
o Sites of testing. In addition to specialists, testing will also be performed by non-
specialist doctors and laboratories, by the care staff or the patient himself, with an 
increase in point-of-care and home testing. 
o Populations tested. Broader segments of the population will be subjected to 
testing, e. g. healthy people without clinical symptoms, children, newborns and 
unborns, but also tissues and gametes. 
                                                     
17 http://www.meridian-nano.org/ 
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o Data acquired. Both the quantity of data acquired will increase, but also the 
quality will change including data on behaviour, activity profiles and life style. 
Moreover, the risk of incidental findings, i.e. information about conditions where 
there was no intention to obtain them, will increase [see e.g. Illes et al. 2002, 
2004].  
o Linking diagnostics to intervention. Especially in surveillance applications, 
deviations from normal conditions will trigger interventional procedures. 
 
Overview of relevant privacy issues and measures to guarantee privacy 
The issue of privacy is especially relevant for nanotechnology applications in medical 
diagnostics (in vivo imaging and in vitro diagnostics). With respect to social impacts 
and ethical deliberations, one can build on an extensive analysis in the genetic testing 
and pharmacogenomics/pharmacogenetics field [see e.g. CIOMS Working Group on 
Pharmacogenetics 2005; The Royal Society 2005; Kollek et al. 2004] as well as the 
telemedicine/ambient intelligence field [see e.g. Friedewald and Da Costa 2004; 
Friedewald et al. 2005]. Despite these links, a nano-specific analysis is nevertheless 
desirable for the following reasons: 
o The nanotechnologies community is – at least in part – not fully aware of and 
familiar with the debate in the above-mentioned fields, 
o Nanotechnologies-enabled diagnostics have specific features and imply both a 
new quality as well as new contexts of diagnostic procedures, which make certain 
social implications and ethical consideration even more important and/or mean a 
shift in emphasis.  
The major concern regarding privacy is the potential misuse of the very sensitive and 
personal data obtained by diagnostic procedures. The increase in quantity and quality of 
highly sensitive personal data that can be expected due to improved and new diagnostic 
possibilities and the increasing abilities to interlink and process them makes the need for 
privacy and data protection even more pressing.  
The main issues are  
o Free and informed consent before a diagnostic procedure is performed. However, 
the scope and use of the data the consent relates to should be clear. The case of 
genetic testing showed that although extensive information and counselling of the 
person to be tested is required, the provision very often is of substandard quality 
and quantity [Ibarreta et al. 2004]. Patients could see themselves exposed to 
perceived or factual social pressure and discrimination if they wish to make use of 
their right not to know and do not make use of the predictive testing and risk 
specification options available. 
o Purpose of tests. Nanotechnology-enabled diagnostic procedures bear the 
potential to be used for a broad variety of purposes, including defined medical 
purposes, research involving human beings, criminal investigations as well as 
national security, surveillance and control, testing for workplace and for insurance 
purposes. Against this background, there is a clear need for political control and 
legitimation for which purposes personal data may be collected and analysed in 
order to avoid discrimination, social control and to ensure civil rights. 
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o Data access and use. Data access and use should be appropriately confined, 
especially if personal data can be increasingly interlinked. There is concern that 
information may be concentrated in the hand of those with the resources to 
develop, run and control such networks. 
There may be a requirement to establish whether current regulatory frameworks and 
institutions provide appropriate safeguards to individual or group privacy [The Royal 
Society & The Royal Academy of Engineering 2004]. 
 
Quality assurance of tests and related counselling 
Given the likely rapid expansion of testable conditions and diagnostic test systems, 
there is a clear need for validation and quality assurance of the diagnostic tests, 
especially if they will increasingly be applied outside specialists' facilities and 
increasingly provide predictive information. This does not only relate to genetic testing, 
but also to the testing of disease conditions in presymptomatic stages of the disease. 
Moreover, medical staff must be qualified to appropriately understand and interpret the 
results of the tests, which often only give a probability for a disease condition, in terms 
that are understandable by the patients and can be transformed into appropriate (changes 
of) behaviour. 
 
Dealing and coping with information from diagnostic procedures 
Many concerns related to expanded options for diagnosis are not directed at the testing 
procedures themselves, but relate to the knowledge that is acquired in this way:  
o Gap between diagnostic and therapeutic capabilities. While the diagnostic 
capabilities expand, this is not necessarily the case for the abilities to treat and 
cure the respective disease or disorder. In case of herediatary disorders, the 
diagnosis might also affect family members. 
o Interpretation of test results. Many diagnostic tests, especially if they are of 
predictive character, only give a specification of the individual risk in terms of 
increased probabilities. Whether the increased risk will, in the future, become 
manifest as clinical symptoms in the individual case, has inherent prognostic 
uncertainties. If a predisposition for a severe disorder or disease is diagnosed, this 
also bears the risk of (perceived or factual) discrimination, even if the disorder 
never becomes manifest in the individual case.  
o Predictive testing information. Nanotechnology-enabled diagnostic and 
therapeutic interventions will provide extended options for self-determination 
with respect to one's health, especially through predictive testing and risk 
specifications in early, asymptomatic stages of disease. In order to use these 
options for one's benefit, certain skills and abilities will be required [Rohr and 
Schade, 2000] such as the willingness and means to care for one's future life.  
o Right not to know. The more diagnostic tests are performed, the more the notion 
could prevail that people have a duty to perform (predictive) diagnostic tests, 
resulting in social pressure or discrimination if such tests are refused. Against this 
background, a broader debate is required about the question to which extent man 
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can be held responsible for his own life and health, and how this responsibility 
can in practice be balanced with the right not to know and with patient's 
autonomy. 
o Incidental findings. The more diagnostic tests are performed, the higher the 
probability of incidental findings, i.e. information about conditions where there 
was no intention to obtain them, and, because of the unintentional character, there 
are often no appropriate structures and provisions available or consistently 
enforced to deal with these findings, thus increasing the risk that privacy, patient 
autonomy and the right not to know, as well as access to counselling and 
psychosocial support, and other interests of the patient are at risk. 
o Medicalisation of deviations from normal status. The more diagnostic tests are 
performed, the higher the likelihood that any deviations from a "normal" status are 
seen as pathologic and as requiring medical treatment. This poses the question 
what – in the light of the wide variability in living organisms – constitutes a 
"normal" condition and by whom and on what empirical basis this has been 
established, bearing also in mind that the definition of "normal status" has a clear 
cultural component. 
 
6.5 Human Enhancement 
Biomedical applications of nanotechnology can not only be used to treat and restore 
impaired body functions, but also for enhancing them. Enhancement is understood as 
interventions which aim at an improvement of human abilities and performance beyond 
"normal" levels - also in an excessive and undesired manner [Friele and Fulford 2004]. 
Enhancement is not at all new or specific to nanotechnology. Examples can be found in 
e.g. the use of growth hormones in paediatrics, plastic and cosmetic surgery, doping in 
sports, or genetic engineering [Fuchs et al. 2002], and it is also discussed in 
neuroscience for cognitive, motor and sensory enhancement [Kennedy 2004; McGuire 
and McGee 1999; Wolpe 2002; Farah et al. 2004; Chatterjee 2004; Hüsing et al. 2005]. 
Nevertheless, nanotechnology, especially in the convergence with biotechnology and 
ICT, are often seen as powerful potential enablers to perform such interventions into a 
broad variety of motor, sensory and cognitive functions with unprecedented precision 
[see e.g. National Science Foundation 2002]. A latent societal demand for enhancement 
of certain human functions (e.g. cognitive performance, alertness, mood, endurance) is 
not unlikely. Against this background, ethical deliberations and social debates are 
required whether there is a difference between helping someone whose capacities are 
below average to reach the average, and helping someone already above average to 
reach a still higher level of functioning [Friele and Fulford 2004].  
However, there is no fixed and clear definition of what can be considered as "healthy" 
or "normal", because of broad biological variation of human functions, abilities and 
performance, and social, cultural and subjective elements in the perception of what is 
"normal". As a consequence, the borderline between "health/enhancement/illegitimate" 
and "disease/treatment/legitimate" is blurred. This could also lead to the medicalisation 
of an increasingly wide range of aspects of human life. Interventions with an 
enhancement purpose also raise the health economic questions whether and under which 
conditions health care systems should provide and pay such interventions.  
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It is likely that nanotechnology-based enhancement would not be confined to the health 
care systems, and that access to enhancing interventions will not be equal, so that 
certain segments of the population will be favoured over others, thus leading to a further 
widening of socio-economic divide ("nanodivide"). This does not rule out the possibility 
that enhancement could be used by individuals to compensate for existing inequalities, 
and to narrow the socioeconomic gap that way. In this context, it is also argued that 
some forms of enhancement are not only chosen in order to achieve a competitive 
advantage, but for the sake of non-competitive, intrinsic benefits. If enhancement were 
rejected in order to avoid socio-economic inequalities, the achievement of intrinsic 
benefits would also be ruled out. 
 
6.6 Blurring the borderline between humans and technical artefacts 
The use of technical artefacts or interventions for restoring or substituting impaired 
functions of the human body is an integral part of human culture, as exemplified by 
glasses for impaired vision, limb prostheses, dental implants, pacemakers and organ 
transplants. Against this background, the use of nanomedicine applications poses the 
question whether such applications bring about a new quality in the foreseeable time 
which might push the – culturally defined – borderline between humans and technical 
artefacts further.  
Among the technical trends with the potential to blur the borderline between humans 
and technical artefacts are 
o Devices as replacements for or complementation of biological components, e.g. 
retinal or cochlear implants, artificial organs, 
o Intimate integration of miniaturised devices into the human body (e.g. sensors, 
pacemakers, artificial organs), 
o Interlinkage of humans with internal or external devices (e.g. remote surveillance 
and control, brain-computer interfaces), also hybrid systems of distributed action, 
i.e. interaction of humans with intelligent technical artefacts, 
o "Humanisation" of devices (e.g. "intelligent" devices, autonomously acting 
systems, futuristic visions of self-replicating and autonomous nanorobots). 
A new quality which may challenge human dignity, fundamental rights, integrity of the 
human body and non-instrumentalisation is especially seen in nanotechnology-enabled 
interventions if [EGE, 2005] 
o the devices cannot be removed easily (implants), 
o they influence, determine or change cognitive and psychic functions, thus 
influencing human identity as a species as well as individual subjectivity and 
autonomy, 
o they could be misused, due to their network capability, for all kinds of social 
surveillance and manipulation, 
o they serve military applications, 
o no clear distinction between therapeutic intervention and enhancement can be 
drawn, 
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o if technology by-passes normal sensory experience, 
o if implants influence future generations, biologically and/or culturally. 
 
In addition to earlier discussed concerns related to privay, informed consent, human 
enhancement, access and availability, technical artefacts raise furher issues 
[Baumgartner, 2004]: 
o Possible impacts on our understanding of what makes humans human (conditio 
humana). What makes humans human is a central question in philosophy and 
religion. It also comprises the question against what humans can be distinguished 
in order to define their identity. The technical trends described above could lead to 
the requirement to redefine the borderline between man and machine/technical 
artefacts. 
o Personal identity. Basic to personal identity is the intimate relationship between 
bodily and psychical functions. This personal identity may be challenged if a 
major proportion of bodily or psychical functions is performed or supported by 
technical artefacts. Autonomy is also considered a central characteristic of 
personal identity which would be, in hybrid systems of distributed action, be 
(partly) delegated to "intelligent" technical artefacts which act autonomously and 
adaptively, perhaps leading to emergent behaviour of the systems with properties 
that no individual component of the system has.  
o Free will. Our concept of a human being as well as human societies are based on 
the notion that human beings have a free will, a view that is currently being 
challenged by some in the view of recent findings from brain imaging studies [see 
e.g. Wegner 2002; Singer 2003] and is very controversially being discussed [see 
e.g. Pauen 2004; Raeymaekers et al. 2004]. If technical devices would interfere 
with the free will, then our ways of thinking about responsibility and blame would 
be challenged, with possible, yet disputed impacts on criminal law and justice 
[Hüsing et al. 2005]. This discussion from the neuroscience/philosophy-field 
could also extend to nanotechnology. 
o Moral status of "made" artefacts. The question is also raised whether "made" 
artefacts which fulfil important criteria of known forms of living organisms can 
claim the moral and normative status that is currently assigned to humans, animals 
or other life forms. 
 
6.7 Military Use 
Biomedical applications of nanotechnology bear the potential to be used both for civil 
as well as military purposes. In the USA, the Department of Defence funds major 
nanotechnology research projects that have a clear focus on military applications. The 
application of nanobiotechnology for military purposes includes [Paschen et al. 2003]  
o nanoscale encapsulation systems for the improvement of chemical and biological 
weapons  
o the enhancement of soldiers' performance in battles, e.g. by implants with 
nanotechnology components, or antimicrobial battle-suits,  
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o the development of nanosensors to detect biological and chemical weapons.  
Against this background, a US citizens' jury on nanotechnologies has recommended 
"that nanotechnology should not be used to develop weaponry" [Kleinman, 2005]. 
There are concerns that nanotechnology could trigger new forms of an arms race, and 
that new types of weapons could be developed which are not covered by existing arms 
control frameworks. As military nanotechnology projects are secret, they could spark 
and fuel public's distrust in military nanotechnology R&D which might also extend to 
civil developments.  
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7 Public Debate18 
 
7.1 Public Perception of Nanotechnology and its Applications in Medicine 
Mass media play a significant role in the shaping of public attitudes towards 
nanotechnology because they are a major source of information for the general public. 
Moreover, they have a role as agenda-setters for public discourse and as gatekeeper that 
confer status on issues, stakeholders, and policy makers. At present no studies have 
been carried out about the media coverage of nanomedicine. Therefore, studies on 
nanotechnology were analysed that represent the field as a whole including 
nanomedicine [Anderson et al., 2005; Gaskell et al., 2004, 2005; Gorss and Lewenstein, 
2005; Faber 2005; Stephens, 2005; Schummer 2004, 2005]. From these studies, mainly 
focussing on the USA and UK print media, the following general conclusions can be 
drawn:  
o Media interest in nanotechnology has grown significantly since 1999. In 2003, it 
began to spread from the opinion-leading elite press to the general press, thus 
addressing a wider public.  
o Media coverage of nanotechnology throughout the entire period analysed (1986 – 
2004) is overwhelmingly positive. Though there are articles about nanotechnology 
risks that are clearly negative in tone, they are less prevalent. 
o The media, in the majority of articles, present nanotechnology in terms of 
progress and economic prospects. 
Media coverage of nanotechnology follows very similar pattern in terms of salience and 
framing, as was the case for biotechhology in its early stages. However, biotechnology 
was presented even more positive and progress-oriented, as nanotechnology is presented 
today. This might reflect a learning process ("avoid the same mistakes"), the current 
public climate which could be more sensitive to possible impacts of new technologies, 
or just an inherent feature of nanotechnology. 
Since 2002, several surveys have been completed which aimed at elucidating the 
public’s knowledge of and attitudes towards nanotechnology [Gaskell et al., 2004, 2005; 
Eurobarometer 224 and 225; The Royal Society & The Royal Academy of Engineering 
2004; komm.passion GmbH 2004; Bainbridge 2002; Cobb and Macoubrie 2004; Cobb 
2005; Sheetz et al., 2005; Scheufele and Lewenstein 2005; Lee et al., 2005]. All in all, 
the combined findings from the surveys show that the public's awareness of 
nanotechnology and their factual knowledge are very low. Nevertheless, in the absence 
of relevant scientific or policy-related information, people form opinions and make 
judgements about nanotechnology. Their opinions are currently influenced by factors 
other than factual and nanotechnology-specific information. Among these influencing 
factors are attitudes towards science and technology in general, scientific literacy, 
emotions, and cognitive shortcuts (e.g. personal predispositions, such as religion, 
ideology) and heuristics which are often provided by the mass media. Overall, benefits 
and positive emotions prevail, in particular expected benefits of nanotechnology relate 
                                                     
18 This chapter is based on Work package 3 - Potential socio-economic impacts of medicinal 
nanobiotechnology applications, B. Hüsing and S. Gaisser, Fraunhofer Institute fore Systems and 
Innovation Research, 2005. 
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to medical progress, environmental protection and economic growth. Metaphors such as 
"grey goo" have not been taken up widely and significantly by the general public. 
Whether public perception will remain that positive depends strongly on the social and 
regulatory context in which nanotechnology is embedded. 
Public workshops and focus groups are sources that give further information about 
genuinely considered beliefs of the public towards nanotechnology instead of 
(currently) uninformed opinions as via surveys [The Royal Society & The Royal 
Academy of Engineering, 2004; Macoubrie 2005, 2006; Meridian Institute 2005; 
Nanojury 2005; Kleinman and Powell 2005; Katz et al. 2005]. These activities 
addressed nanotechnologies in their entirety and have not been specifically devoted to 
nanomedicine. They took place mostly in the USA and the UK19 with the following 
findings: All in all, assessments of nanotechnology are positive, and major benefits are 
anticipated, especially from health applications of nanotechnology. Aspects which are 
of concern for the layman are, among others, 1) how to deal with the inherent 
uncertainty regarding potential impacts and future developments, 2) low trust in 
governmental bodies as well as industry to take decisions for the benefit of the general 
population, 3) the potential risks of nanotechnology, particularly from nanoparticles, 
which the public believes should be proactively addressed. Against this background, 
there is a high demand by these groups for effective regulation and control. In addition, 
governance issues are stressed and transparency of and public involvement in 
technology decision-making are called for. Citizens’ juries are an instrument for public 
engagement in decision-making. Up to now one citizens' jury took place in the EU, the 
NanoJury UK20.  
 
7.2 Non-Governmental Organisations – Involvement and Positions 
At present only few non-governmental organisations (NGOs) have actively contributed 
to the public debate about nanotechnology. Greenpeace and the etc group have taken the 
most prominent and visible role in this debate [e.g. etc group 2003a, 2003b; Arnall, 
2003; Parr 2005]. The majority of potentially affected NGOs in the field of 
nanomedicine are still in an earlier stage of engagement: while the importance and 
relevance of nanotechnology and its possible impacts are acknowledged, many NGOs 
still concentrate on monitoring developments in nanotechnology21. Noteworthy is the 
early and prominent engagement of insurance companies, documented by several 
studies and position papers [Munich Re Group 2002; Swiss Re 2004; Allianz and 
OECD 2005]. 
The etc group has gained public awareness after publishing the report “The Big Down. 
From Genomes to Atoms” [etc group, 2003b] that called for a moratorium on 
commercial production of nanomaterials. In contrast to the etc group, Greenpeace takes 
a much more balanced position. In the report “Future Technologies, Today’s Choices - 
                                                     
19 Additional dialogues will be performed in EU countries within recently started EU-funded projects, e.g. 
Nanologue (www.nanologue.net), Nanobio-RAISE (http://nanobio-raise.org/), and NanoDialogue 
(www.nanodialogue.org). 
20 http://www.nanojury.org/ 
21 This relates mainly to consumer organisations, environmental organisations, civil society groups, and 
industry unions. No patient organisations was identified which had genuinely engaged in nanotechnology 
issues. 
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Nanotechnology, Artificial Intelligence and Robotics” [Arnall 2003] and subsequent 
publications [Arnall and Parr 2005; Parr, 2005], the potential of nanotechnology to be 
used for both, beneficial and detrimental purposes is acknowledged and a differentiated 
opinion is advocated, depending on the applications and taking the present uncertainties 
into account. Against this background, the process and the knowledge base, on which 
decisions about future trajectories of technology development are taken, are 
emphasised. There is a call for more research to investigate environmental and 
toxicological effects of nanoparticles and for upstream stakeholder and citizens' 
involvement in political decisions. As a consequence, Greenpeace UK has been one of 
the major initiators and supporters of the NanoJury UK. A moratorium is not supported 
by Greenpeace.  
According to the experts interviewed, other NGOs, if monitoring nanotechnologies at 
all, have not yet formed or published an "official" opinion, but may be in the process of 
doing so. The publications and positions by the etc group and Greenpeace are used as a 
major input in this process. 
 
7.3 Debate about Health and Environmental Impacts of Nanoparticles  
In the last years, a debate about possible health and environmental risks of engineered 
nanoparticles has developed. It is mainly an expert debate in which the relevant 
professionals such as toxicologists as well as representatives from industry, regulatory 
and governmental bodies as well as insurance companies are involved, both on national 
as well as international (EU, OECD) levels. Consumer and environmental groups 
monitor the debate, but have not yet taken an active part in it. 
According to the experts interviewed, there is consensus among the different players in 
both national as well as the international debate with respect to the following aspects:  
o Acknowledgement of both chances and risks of nanotechnology,  
o Need for action regarding standardisation, common nomenclature, and availability 
of reference materials,  
o Need for further research into potential risks of nanoparticles and exposure along 
all stages of the life cycle of products including the development of suitable test 
systems. 
However, different views prevail regarding the question whether and to what extent this 
requries regulation. Moreover, only few stakeholders know and reflect the interests of 
the other parties. In the following the main positions of the different stakeholders are 
summarised: 
o Industry: The main interest is the development and commercial exploitation of 
new nanotechnology products and services. Product and process safety in relation 
to liability claims play an important role for investments in R&D. Existing 
regulatory regimes are deemed sufficient. Transparency is supported as long as 
protection of economically important know-how is guaranteed.  
o Governmental agencies are in the process of defining their responsibilities and 
tasks with respect to nanoparticles and start developing strategies. They aim at 
supporting the further development of nanotechnology.  
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o Environmental, consumer and civil society groups aim at preventing or 
reducing risks for the environment, consumers and workers. They want to 
critically monitor the developments. They support the intensification of research 
into the identification and assessment of risks. Environmental and consumer 
groups aim at increasing the transparency for consumers and citizens and 
therefore support measures such as product labelling.  
o Academic scientists see themselves as service providers in order to close 
knowledge gaps. Moreover, they hope for more research funding.  
o Unions and occupational health professionals want to examine whether the 
existing precautionary and protective measures and regulations need amendment 
and adaptation. 
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8 Regulatory Issues22 
In the EU, medicinal products and medical devices are not allowed to enter the market 
unless their compliance with regulatory requirements has been shown convincingly. For 
medical devices, the regulatory requirements are laid down in three European 
Directives: Directive on Medical Devices 93/42/EEC23, Directive on Active Implantable 
Medical Devices 90/385/EEC24, and Directive on In Vitro Diagnostic Medical Devices 
98/79/EC25. For medicinal products, the Directive on Medicinal Products for Human 
Use 2001/83/EC26 and the Directive on Clinical Trials on Medicinal Products for 
Human Use 2001/20/EC27 apply.  
Nanomedicine products are regulated as medicinal products or as medical devices and 
there is currently no specific regulatory framework for nanotechnology-based products 
neither in the EU nor in the USA. NDDS are always approved in combination with the 
drug they deliver and they are regulated as drugs because the delivery system interacts 
with the drug and can change its efficacy and safety profile. Some therapies in which 
nanoparticles have no direct therapeutic effect are regulated as medical devices. 
Examples are hyperthermia with iron nanoparticles or cell therapy using nanoparticles 
for cell sorting. Nanoparticle-based contrast agents that are administered intravenously, 
on the other hand, are regulated as drugs.  
Additionally to the above-mentioned regulations, also principles of biomedical ethics 
require a careful balancing of the benefits of a medical intervention or diagnostic 
procedure with the risks, not only when placing such products on the market, but also in 
the research phase. This is especially important in the case of nanomedicine, because 
not all risks may be known or deducible from existing therapies. It cannot be ruled out 
that medical interventions based on nanotechnology could have unprecedented 
biological and adverse effects, which have not been encountered before due to the 
novelty of these interventions. This is due to the lack of knowledge regarding the 
behaviour of nanoparticles in the human body, due to the inherent properties of some 
drug delivery systems to move across biological barriers, if new therapeutic principles 
are to be established (e.g. gene therapy), and if complex systems which e.g. comprise 
biological, nanotechnological and IT components and/or for which not all relevant 
parameters of safety and quality can reasonably be tested beforehand (e.g. long-term 
effects, interference with other components or systems).  
 
8.1 Toxicological Aspects 
At present, possible health and environmental risks of nanoparticles are debated. In the 
directives which regulate market access for medicinal products and medical devices in 
the EU, a risk assessment and management is already required in order to obtain market 
approval. However, it may be challenging to carry out this assessment in practice, 
                                                     
22 This chapter is based on Work package 2 - Challenges and drivers for medicinal nanobiotechnoloy and 
its impact on the medical sector, V. Wagner, VDI Technologiezentrum GmbH, 2005 and 2) Work 
package 3 - Potential socio-economic impacts of medicinal nanobiotechnology applications, B. Hüsing 
and S. Gaisser, Fraunhofer Institute for Systems and Innovation Research, 2005. 
23 Official Journal L 169 12/07/1993, p. 1-43 
24 Official Journal L 189, 20.7.1990, p. 17–36 
25 Official Journal L 331, 7.12.1998, p. 1–37 
26 Official Journal L 311 28/11/2001, p. 67-128 
27 Official Journal L 121, 1.5.2001, p. 34–44 
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because the required knowledge about the behaviour and biological effects of 
nanoparticles is presently too patchy and assessment schemes are not specifically 
tailored to assess nanoparticle-specific questions and might require amendment in order 
to take the specificities of nanotechnologies into account appropriately. A dedicated 
nanotoxicological risk assessment might be necesssary for novel nanomedicine products 
which should take into account  
o The biological fate of nanoparticles inlcuding distribution, accumulation and 
metabolism,  
o Medication-specific uptake routes related to the different routes of administration 
and the types of nanomaterials used,  
o Possible side effects, caused by the interaction of nanoparticles with living matter 
or their transport across biological barriers [De Jong et al, 2005].  
The SCENIHR28 in its opinion on the appropriateness of existing methodologies to 
assess the potential risks associated with engineered and adventitious products of 
nanotechnlogies, came to the conclusion that appropriate and nano-specific test systems 
and assessment schemes still have to be developed. It also stated, that depending on 
results of future research on the toxicological potential of nanoparticles, regulation 
might need to be adapted [European Commission, 2006a]. This also implies the 
development of specific guidance documents at a European level for the safety 
evaluation of nanotechnology products applied in medical technology and the need for 
an appropriate labelling and safety sheets [De Jong et al., 2005].  
With respect to the production process of nanomedicine products, new workplace 
standards might be required, taking into account the specific toxicological relevant 
properties of nanoparticles. Because classical toxicity testing does not account for 
nanoparticle specific properties it has been questioned whether nanoparticulate 
materials should fall within chemicals legislation, such as REACH29 [European 
Commission, 2006a; The Royal Society & The Royal Academy of Engineering, 2004]. 
So far, the chemicals legislation does not have specific provisions or testing 
requirements for substances on a nanoscale. In March 2006, the European Commission's 
Directorate General Environment requested the SCENIHR to assess the current risk 
assessment methodology, as laid down in the Technical Guidance Documents of the 
chemicals legislation, to provide an opinion on their appropriateness and to make 
suggestions for improvements where appropriate30. The assessment is due at the end of 
2006. 
The European medicines Agency (EMEA) recently published a reflection paper on 
nanotechnology-based products for human use, outlining the currnet thinking and 
initiatives by EMEA related to nanotechnology. An Innovation Task Force was created 
that coordinates EMEA-wide scientific and regulatory competence for emerging 
therapies and technologies, including nanotechnology. EMEA encourages potential 
                                                     
28 SCENIHR is the European Commission's Scientific Committee on Emerging and Newly Identified 
Health Risks 
29 REACH stands for Registration, Evaluation, Authorisation and Restriction of Chemicals, COM(2003) 
644 
30 See European Commission, DG Health and Consumer Protection, Public Health,  
http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_q_008.pdf 
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applicants to contact the agency early on in the product development process [EMEA, 
2006]. Also in the USA, the appropriateness of current legislation for nanotechnology is 
being discussed. Recently, the US Food and Drug Administration (FDA) set up an 
internal Nanotechnology Task Force to identify and recommend ways to address any 
existing knowledge or policy gaps with the aim to enable FDA to evaluate possible 
adverse health effefts of FDA-regulated nanotechnology products [FDA, 2006].  
 
8.2 Classification of Nanomedicine products 
"Borderline products" which do neither clearly fall into the scope of the medicinal 
products nor the medical devices regulation are known e.g. from the field of tissue 
engineering [Bock et al. 2003, 2005]. Nanotechnology-enabled products combining 
diagnostic and therpeutic activities, so-called theranostics (e.g. implantable drug 
delivery systems that release a certain amount of a drug according to specific body 
signals), or cell-free scaffolds for tissue regeneration, that release pharmaceutically 
active substances) could be difficult to categorise. Other cases could be 
nanotechnology-based cosmetic or functional food products with health claims. Against 
this background, "clearing house mechanisms" in regulatory authorities may be required 
in order to properly deal with such "borderline products" and which may involve 
nanotechnology in their manufacturing. However, the "borderline character" is inherent 
to these specific products, but is not specifically conveyed to them by nanotechnology. 
 
8.3 Regulation versus innovation 
Only if nanomedicine products are available and commercially viable, their potential 
health benefits can be realised. However, the higher the requirements to prove safety, 
quality, efficacy, and possibly also superiority over existing products and services in 
terms of costs or quality of life gains, the higher the barriers are for innovative products 
and services. Many of the more innovative NDDS and nanoparticle contrast agents 
focus on diseases that occur in comparatively small patient groups, e.g. brain or liver 
cancer. The regulatory requirements for these novel therapies are the same as for 
conventional drugs. According to experts, many novel therapeutic products based on 
NDDS will not enter the market simply because the costs for achieving regulatory 
approval are too high compared to expected sales. Other hurdles relate to the 
development of nanomedicine by relatively resource-poor SMEs, or the difficulty to 
prove superiority in certain characteristics, such as long-term effects (e.g. avoidance of 
frequent relapse). In the regulatory approval of medicinal products, provisions are 
established to reduce these barriers, e.g. the orphan drug regulation31 granting market 
exclusivity for a duration 10 years for treatments for rare diseases, or according to the 
Directve for Medicinal Products, possibilities for reduced fees and administrative 
assistance for SMEs, or conditional marketing authorisations. It might be necessary to 
evaluate the performance and appropriateness of these provisions with respect to 
nanomedicine products.  
Further, many experts anticipate that regulatory authorities might adapt the approval 
process for nanomedicine products due to safety concerns and e.g. request a more 
rigorous testing of the potential toxicity of nanoparticles. The ESF nanomedicine report 
                                                     
31 Official Journal L 18, 22/01/2000, p. 1-5 
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[ESF, 2005] comes to the conclusion that with an increasing number of 
nanotechnology-based drugs there is also a need to review or define appropriate 
regulatory guidelines for each new class of nanomedicine products. It further states that 
there is a need for preclinical and clinical test standardisation and an evaluation of the 
environmental impact of these products in the context of academic research and 
industrial development. According to expert opinion a more vivid and close information 
exchange between the scientific community and the regulatory authorities would be 
helpful to reach soon clarification whether regulation needs to be adapted. This could 
start with an open exchange of views at conferences and workshops. European scientists 
also point to the USA where regulatory authorities join the discussion process earlier 
and also attend conferences and workshops more frequently than their European 
colleagues. Experts believe that many pharmaceutical companies will be cautious with 
investments in nanotechnology-based medicines as long as it remains unclear to which 
extent the regulatory framework will be adjusted for nanomedicine products. Once this 
point is clarified industry can take strategic decisions and decide which nanomedicine 
products might be economically viable under the specific regulatory regime. Experts 
also see two important issues that should be addressed by regulatory authorities with 
regards to nanomedicine products: 
1) For nanotechnology-based drugs for small patient groups, scientists suggest the 
option of a conditional approval for drugs after clinical trial phase II so that they can be 
applied by trained experts to informed patients.  
2) Particularly for nanoscale imaging agents experts suggest to create a regulatory 
framework that supports the development of nanoscale delivery platforms. They believe 
that in many cases where novel products are just combinations of an already approved 
delivery system and an approved contrast agent, the approval process should be less 
rigorous than for new substances. Such a procedure would reduce the development costs 
and make the development of nanoscale contrast agents economically more viable and 
interesting for the pharmaceutical industry. 
 
8.4 Reimbursement  
In most health care systems, reimbursement by statutory and private health insurances 
plays a major role for market access of medical products. Health economic assessments 
will play an increasingly important role in reimbursement decisions. Many experts also 
see price controls as an important parameter in nanomedicine commercialisation. In the 
USA prescription drug prices are largely unregulated. That differs from most other 
countries, where prices are regulated either directly through price controls (e. g. France 
and Italy) or indirectly through limits on reimbursement (e. g. Germany and Japan). 
Particularly for drug delivery systems that are likely to increase the cost of a drug, 
reimbursement regulation is an important issue. Whereas US companies see little 
problems getting their more expensive nanotechnology-enabled drugs placed on the US 
market, companies that focus on the European market have a competitive disadvantage 
and less incentives for investment in the costly development of NDDS. Particularly 
American experts interviewed for this study state that the more cost regulated European 
pharmaceutical markets are an important reason for the widening innovation gap 
between the European and American pharmaceutical markets.  
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9 Conclusions 
In recent years nanomedicine has emerged as one of the most prominent application 
fields of nanotechnology, although publication-wise it currently accounts only for 5% of 
nanotechnology publications worldwide. It still is at an early stage development with 
few products on the market. Also the large share of start-up companies and SMEs 
(80%) within the companies worldwide that openly develop nanomedicine products 
reflects the early development stage of nanomedicine. However, not all large 
pharmaceutical and medical device companies make their engagement in nanomedicine 
R&D public.  
Table 9.1 shows a qualitative comparison of key aspects of the different nanomedicine 
application fields that were covered in this study. The application fields are in different 
development stages regarding research activity, patenting and products. 
 
Table 9.1 Qualitative comparison of nanomedicine applications in different medical sectors 
( = very high,  = high,  = medium,  = low) 
a) “Share of nanotechnology” assesses how much of the system actually consists of nanotechnology.  
Source: VDI Technologiezentrum GmbH 
 
 Drug 
Delivery 
Drugs & 
Therapies 
In vivo 
Imaging 
In vitro 
Diagnostics 
Bio-
materials 
Active 
Implants 
Research activity            
Commercialisation 
efforts 
             
Development status            
Target market               
Importance of 
nanotechnology for 
the sector as a whole 
                 
Share of 
nanotechnology a) 
                
EU25 
competitiveness, 
science 
                   
EU25 
competitiveness, 
commercialisation 
                
 
Nanotechnology-based drug delivery is by far the most advanced field of nanomedicine. 
More than 50% of research activities and commercialisation efforts as well as 
companies are targeted at NDD. The importance of nanotechnology for drug delivery is 
expected to increase in the future: Two thirds of the experts surveyed in the 
NanoRoadMap project32 agreed that nanotechnology will impact 25-50% of the drug 
                                                     
32 NanoRoadMap is a FP6 project funded by the European Commission. Its main objective is to produce a 
long term (10 years) forecasting exercise aiming to highlight the applications of nanotechnology in three 
important industrial fields: Materials, health and medical services, and energy (www.nanoroadmap.it). 
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delivery market until 2015 [Hartwig, 2005]. One of the drivers is the extension of a 
drug’s patent life cycle by a new drug delivery approach. Interestingly, Europe holds the 
leading position with regards to scientific output (37% of drug delivery publications 
compared to 30% of the USA), but has failed to translate this strength into products. 
This trend is documented by a lower number of patents than the USA (23% compared to 
55%), less companies involved in developing nanotechnology-based drug delivery 
systems (23% compared 52%) and less products on the market (29% compared to 74%). 
The position of the EU is below average compared to other nanomedicine application 
fields, however, the NDDS field is the most advanced regarding commercialisation. In 
general, the USA accounts for higher shares of patents, companies, products on the 
market and in development (45-55%) compared to the EU (35%). One reason for this 
could be the more restricted private funding situation in Europe. 
Nanotechnology-based drugs and therapies is probably the technology field that is most 
genuinely nanotechnolgy, as the therapies are based on the use of nanoparticles or 
nanoscale molecules. In all other sectors, nanotechnology has more of an enabling 
function. However, research activity is comparatively low and the impact of 
nanotechnology on the pharmaceutical sector as a whole will be small for the 
foreseeable future.  
The use of nanotechnology for in vivo imaging is still in a very early development 
stage. Most of the engineered nanoparticle contrast agents are currently developed by 
US companies. For in vitro diagnostics nanotechnolgy plays mainly an enabling role 
and most of the sensor systems that are under development for clinical applications are 
considered microsystem technology. Implant materials are a further field in which 
research activity and commercialisation efforts of nanotechnology-based devices are 
still in a fairly early stage. Particularly the market for orthopaedic implants is very 
mature and leaves only little room for innovation. Nanotechnology is of least 
importance for active implants. If at all, nanotechnolgy will only be used for the 
improvement of certain components such as implant housings or electrode surfaces.  
Within the EU, Germany, the UK and France are the countries with the highest research 
and commercial activity in nanomedicine. Noteworthy is the large difference between 
Germany, France and the UK regarding the number of patents in relation to publication 
numbers: France and the UK have much less patents than publications, whereas 
Germany has slightly more patents than publications.  
Development and commercialisation of nanomedicine products is faced with a number 
of challenges:  
• Pharmaceutical and medical device industry shows still a very moderate interest in 
this emerging technology. Start-ups currently pursue a plethora of ideas how to 
improve disease treatment and diagnosis with nanotechnology, but it seems to be 
difficult for them to find major pharmaceutical or medical device companies that 
licence their technology or partner with them to bring their novel nanomedicine 
products or diagnostic methods through the regulatory approval process.  
• Due to safety concerns regarding nanoparticles, the need for new or adapted 
regulation is currently discussed in the EU but also worldwide. This seems to 
create uncertainty concerning future regulatory requirements and results in a 
current cautiousness by the companies regarding investments in nanotechnology.  
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• Nanotechnology-based diagnostics and therapies are expected to address smaller 
patient groups, due to targeting less frequent diseases (e.g. liver or brain cancer), 
risk patients (e.g. the anticancer drug pegylated liposomal doxorubicin is applied 
to patients suffering from cardiac diseases), and due to the possibility of targeting 
subtypes of diseases (e.g. cancer tissue exhibiting specific marker proteins). This 
follows the trend of “personalised medicine” which is currently discussed in the 
context of pharmacogenetic approaches33. Therapies are expected to be more 
focussed on specific patient groups, implying smaller markets and resulting in a 
challenge for the blockbuster business model, which is currently followed by the 
pharmaceutical industry. A similar issue exists for the diagnostics industry, as 
more specific diagnostic approaches also meet a smaller market which might lie 
well blow the estimated EUR 80 million market size that is deemed necessary to 
receive a positive return on investment for a new diagnostic test [Batchelder and 
Miller, 2006]. This dilemma can only be solved if development costs can be 
reduced [FDA, 2004]. Nanotechnology-based diagnostics could play a role in cost 
reduction by supporting the R&D process and the establishment of faster and safe 
regulatory approval protocols (e.g. real-time assessment of the efficacy of 
therapeutic regimens by in vivo molecular imaging, better patient stratification for 
clinical trials based on detection of also low levels of specific biomarkers [Ferrari, 
2005; Ferrari nad Downing, 2005]).  
• Already today there are some companies that have a strong patent portfolio and 
consequently broad claims for certain applications of nanomaterials. There is a 
risk, that broad claims on nanomaterials result in a monopol, as seen for 
Affymetrix and high density DNA chips.   
• Nanotechnology applications in medicine include only few applications with 
breakthrough potential. Nanotechnology rather has the function of an enabling 
technology, which, however, has the potential of contributing considerably to 
meet medical needs and improved health care. However, the increasing cost 
pressure of health care systems will emphasise cost-effectiveness considerations 
in the future and might limit reimbursement. Currently, cost-effectiveness of 
nanomedicine products cannot be judged, as only few products are on the market 
and even fewer have been evaluated in this respect. Nevertheless, there are 
indications that nanomedicine approaches could result in cost-effective treatments 
with a potential to decrease health care costs, which to a significant extent are 
personnel costs.  
It has been widely recognised that there is a need to address social and ethical issues of 
nanotechnology early in the process, involving the public in an informed and 
interdisciplinary debate. Additionally, these reflections should not be considered as an 
“add-on” but rather as an integral part of scientific-technological research and 
development. Initiatives to explore and discuss social and ethical issues of 
nanotechnology have only begun recently, and most of the initiatives focus on 
nanotechnology in general. Lately, initiatives targeting for example nanobiotechnology 
                                                     
33 Pharmacogenetics is based on the observation that genetic factors can modify drug action. A prominent 
example is the breast cancer drug Herceptin for individuals which tumours overexpress the human 
epidermal growth factor receptor HER2. The drug use is linked to HER2 testing [The Royal Society, 
2005].  
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have emerged, amongst other several EU-funded projects such Nano2Life, where an 
Ethics Board is analysing ethical issues relating e.g. to medical applications of 
nanobiotechnology and respective research projects, or NanoBioRAISE, a project aimed 
at involving the public in the discussion on ethical and social issues.   
Many of the ethical and social issues raised in the context of nanotechnology and 
nanomedicine are not genuinely new, but known from other contexts (human 
enhancement – doping in sports, nanotechnology-based clinical diagnostics and 
monitoring – privacy and predictive diagnoses in genetic testing). However, 
nanotechnology might introduce a different or stronger emphasis on certain aspects. For 
example, the abundance of data that could be collected in the future through 
nanotechnology-based sensors facilitating continuous monitoring of the body, poses 
serious questions regarding data handling, data access, informational self-dertemination, 
and the “medicalisation” of life.   
Social and ethical analyses of nanotechnologies also deal to a substantial extent with the 
potentially disruptive character of nanotechnology, among them also futuristic visions 
of nanotechnology-enabled autonomous systems capable of replication and of 
nanotechnology-enabled human enhancement (e.g. through "intelligent implants") 
which are seen as "unrealistic" by the scientific community in the foreseeable future. As 
a consequence, the challenge should be met by the ethics and social sciences in the 
coming years, and initiatives are already emerging, to complement the necessary 
analysis of the potential disruptive character of nanotechnologies by a differentiated 
view for nanomedicine where the majority of innovations "in the pipeline" will most 
likely not be disruptive and revolutionary (but could nevertheless have disruptive 
aspects), but will predominantly lead to stepwise and incremental innovations.  
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Appendix 
 
Methodology Applied 
 
Nanomedicine R&D - Literature and Patents: Publications were searched in the 
Science Citation Index database, using discrete key words indicative for the 
Nanomedicine subtechnologies as they are presented and described in this report (see 
Box 12.1). Data is statistically analysed to retrieve rankings by country and number of 
publications per year. The patent search was conducted by the European Patent Office 
using the EPODOC database which covers patents worldwide. Nanomedicine patents 
were identified with a combined key-word and patent classification search. A 
crosscheck of the publication and patent analysis for this report with publicly available 
bibliometric and patent data in the field of nanobiotechnology show reasonable 
consistency, so that we are confident that the patent and literature data in this report is 
conclusive. 
 
Box 1 Search fields and terms for literature and patent search 
Drug Delivery: 
Liposomes 
Polymeric Drugs 
Drug Polymer Conjugate 
Protein Polymer Conjugate 
Pegylated Proteins 
Nanoparticles 
Nanocapsules 
Nanosuspensions 
Nanocrystals 
Solid lipid nanoparticles  
Dendrimers 
Gold nanoparticles 
Colloidal gold 
Silicate nanoparticles 
Calcium nanoparticles 
Biosilicon 
Titanium dioxide nanoparticles 
 
Drugs and Therapy 
Fullerene drugs 
Dendrimer drugs 
Nanoshells and phototherapy and hypothermal 
therapy 
Magnetic nanoparticles and hyperthermal therapy 
 
In vivo Imaging 
Superparamagnetic iron oxide 
Ultrasmall superparamagnetic iron oxide 
Monocristalline iron oxide nanoparticles  
Cross-linked iron oxide nanoparticles 
Liposome and ultrasound 
Nanoparticles and nuclear imaging 
Nanoparticels and optical imaging 
Nanoshells and optical imaging 
Quantum dots and optical imaging 
 
Medical Biosensors 
Surface plasmon resonance 
Cantilever biochips 
DNA Chips and electrical detection 
Nanoarrays 
Quantum dots and diagnostics 
Gold nanoparticles and diagnostics 
Magnetic nanoparticles and diagnostics 
 
Biomaterials 
Bone cements and nanostructures 
Dental implants and nanocomposites 
Orthopedic implants and nanostructures 
Cardiovascular implants and nanostructures 
Tissue engineering and nanostructures 
Silver nanoparticles and implants and wound 
dressings 
 
Intelligent Implants/ Neural Prothesis 
Electronic drug delivery systems and 
nanotechnology 
Neural prothesis and nanotechnology 
 
Cosmetics 
Sunscreens and nanoparticles 
Nanoparticles 
Nanocapsules 
Lipid nanoparticles 
Liposomes  
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Structure of the Industry: The analysis of industrial development of Nanomedicine is 
based on expert interviews and the collected bibliometric and business information. 46 
questionnaire guided interviews were conducted with leading experts from academia 
and industry. The interview partners were either professors or group leaders at 
universities (30 %) or management staff of companies (44 %) or start-ups (26 %). 52 % 
of the interviews were conducted with European experts, 33 % with experts based in the 
USA and 15 % of the interviewees came from other countries such as Australia, Canada 
and Israel. 
 
Companies, Products and Market Data: The most direct strategy to identify 
companies that produce a certain class of products are searches in company and product 
databases, that cover business activities worldwide. Unfortunately, in the case of 
nanomedicine, this is not a feasible strategy as the product classification schemes in 
these databases do not include nanotechnology or nanomedicine products. Therefore, 
currently it is not possible to get a complete survey of business activity in the field of 
nanomedicine by the usage of business databases.  
In order to compile a list with companies worldwide that work in the field of 
nanomedicine other sources than business databases were analysed for this report such 
as: business reports, various internet data bases and fora, including Nanovip and 
Nanoforum, patent data and interviews with experts. With this strategy we expect to 
cover about two third of the business activities in the field of nanomedicine. Data on 
products on the market and in clinical trials was retrieved by analysing review papers 
and business press. Further, expert interviews and searches in the Pharmaproject 
database provided valuable information. Sales numbers for products were taken from 
business press, company reports, and business databases or are estimates based on 
experts interviews. Comprehensive lists of nanomedicine products on the market and 
nanomedicine companies can be found in the appendix. Foreign currencies are 
calculated into Euro taking the following exchange rates:  
 
  1 USD  =   0.772 EUR 
1 GBP  =     1.47 EUR 
  1 RS     = 0.0177 EUR 
  1 FRF   =   0.156 EUR 
  1 CHF  =   0.661 EUR 
  1 GBP  =   1.477 EUR 
 
 
Methodology Chapter 5 
Literature Review: To identify cost effectiveness, cost benefit studies and general cost 
analyses in the field of nanobiotechnological applications literature searches were 
carried out in the MEDLINE database, in the Scopus database, in the Cochrane Library, 
the NHS Centre for Reviews and Dissemination Database (NHS CRD), and the 
database of the German Agency for HTA.  
In MEDLINE, a total of 717 articles were identified. Because this number was too high 
to be scanned manually, only the most recent articles, published between 2000 and 
2005, were analysed (346 articles). In the Cochrane Library 167 articles had to be 
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scanned manually. After reviewing the abstracts, 23 articles from MEDLINE, 10 from 
the Cochrane Library and a few from the other sources were analysed in depth. 10 
articles dealt with pegylated liposomal doxorubicin, six with liposomal amphotericin B, 
10 articles dealt with other cases, especially drug delivery and microarrays. The two 
cases with a significant number of detailed publications (pegylated liposomal 
doxorubicin, liposomal amphotericin B) were chosen as case studies, the results of the 
remaining publications were integrated in the overall description of the indications.  
 
Expert interviews: In order to validate the results from our literature analysis, 25 
experts with a health economy background from 10 European countries were chosen to 
comment on the results of the literature survey. Addressing the experts via email and 
personal communication, they were asked to comment on the results of the German 
analysis as presented by Farkas et al. 2004, on the results of the literature analysis and to 
compare the described effects with their national situation and personal assessment of 
the European situation. Helpful comments were received from four experts from the 
Netherlands, Switzerland, Ireland and Italy. Seven did not feel competent to answer the 
questions, four were under time restrictions that hindered them to answer, 10 did not at 
all reply to the questionnaire. The poor response rate shows the difficulty in gathering 
health economic data in the very early stage of development in which Nanotechnology 
in the medical sector still is.  
 
 
Methodology Chapter 6 
As an emerging technology, the discussion about social and ethical issues in the context 
of Nanotechnology is just emerging. Reports that focus on ethical issues do not yet 
discuss single application fields of Nanotechnology, such as Nanomedicine. A further 
difficulty is, that a definition of Nanomeidicine has just been emerging over the past 
couples of years and it becomes clear that Nanomedicine is largely an enabling 
technology that is more part of than driver of trends in medicine. We have analysed 
reports covering ethical issues of Nanotechnology and extracted those issues that are of 
relevance for Nanomedicine. Reports analysed include Paschen et al. 2003; The Royal 
Society & The Royal Academy of Engineering 2004; Malsch et al. 2004; Wood et al. 
2005; Türk et al. 2005a and Türk et al. 2005b. A further source of information are 
interviews conducted with 13 interview partners from NGOs, Unions, environmental 
and health administrations, insurances and consumer associations.  
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Research and Commercialisation Efforts in Nanomedicine 
 
 
Publications 
(cumulative 
until 2004) Publications % 
Patents 
(1993-2003) Patents% Companies Companies % Products Products % 
Drug Delivery 6332 76.3 5884 58.8 113 56.5 23 60.5 
Drugs & Therapies 150 1.8 342 3.4 7 3.5 0 0.0 
In vivo Imaging 352 4.2 1267 12.7 11 5.5 3 7.9 
In vitro Diagnostics 915 11.0 1400 14.0 33 16.5 2 5.3 
Implants 487 5.9 801 8.0 30 15 9 23.7 
Active Implants 52 0.6 319 3.2 6 3.0 1 2.6 
Sum  8288 100 10013 100 200 100 38 100 
 
 
 
Products in  
Pipeline 
Products in
Pipeline % 
Market 
Nanomedicine 
2004, Billion € 
Market 
% 
Drug Delivery 98 61.9 4.2 77.7 
Drugs & Therapies 7 4.5 0 0.0 
In vivo Imaging 8 5.8 0.015 0.2 
In vitro Diagnostics 30 18.7 0.6 11.3 
Implants 9 5.8 0.05 0.9 
Active Implants 5 3.2 0.5 9.9 
Sum  157 100 5.4 100 
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Nanomedicine Products on the Market.  
NA means that information is not publicly available. Sales numbers for many products were estimated based on information from experts and companies and can not be shown 
owing to data confidentiality. However estimates of total sales for Nanotechnology based products in the different medical sectors are calculated based on this information (see Tab 
3.3). 
Therapeutic  
agent/Medical Device 
Nanotechnology 
component 
Indication Company Country Sales 
2003/2004 
million $ 
Medical 
Sector 
Available in 
at least one 
EU25 
country 
Drug Delivery        
Abelcet Liposomes Fungal infections Enzon USA 58 Drug Delivery Yes 
Ambisome,  Liposomes Fungal infections Gilead, Fujisawa USA/Japan 212 Drug Delivery Yes 
Amphotec, Amphocil Liposome Invasive pulmonary 
infection 
InterMune Australia NA Drug Delivery Yes 
DepoCyt Liposomes Cancer SkyePharma, Enzon UK/USA 5 Drug Delivery Yes 
Doxil/Caelyx Liposomes Cancer (Kaposi's sarcoma,  
Ovarian) 
ALZA, Schering 
Plough 
USA 145 Drug Delivery Yes 
Daunoxome Liposomes Cancer (Kaposi’s sarcoma) Gilead USA 2 Drug Delivery Yes 
Epaxal Berna Liposomes Vaccine against Hepatitis A Berna Biotech AG Switzerland NA Drug Delivery Yes 
Estrasorb Liposomes Hormone Therapy Novavax USA 2 Drug Delivery N.A 
Inflexal Berna Liposomes Vaccine against Influenca Berna Biotech AG Switzerland NA Drug Delivery Yes 
Myocet Liposomes Cancer (Breast) Elan Ireland NA Drug Delivery Yes 
Visudyne Liposomes Wet macular degeneration  
in conjuction with laser 
treatment 
QLT, Novartis Canada/ 
Switzerland 
445 Drug Delivery Yes 
Adagen Polymer-Protein Conjugate Immunodeficiency disease Enzon USA 16 Drug Delivery N.A. 
Macugen Pegylated-Aptamer Age-related macular 
degeneration (eye diseases) 
Eye Tech 
Pharmaceuticals, 
Pfizer 
USA Approval 
End 2004 
Drug Delivery No 
Neulasta Polymer-Protein Conjugate Febrile Neutropenia Amgen USA 1600 Drug Delivery Yes 
PEGASYS Polymer-Protein Conjugate Hepatitis C Hoffmann-La 
Roche,  
Switzerlan/ 
USAd 
1000 Drug Delivery Yes 
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Therapeutic  
agent/Medical Device 
Nanotechnology 
component 
Indication Company Country Sales 
2003/2004 
million $ 
Medical 
Sector 
Available in 
at least one 
EU25 
country 
Nektar 
PEG-Intron Polymer-Protein Conjugate Hepatitis C  Enzon, Schering-
Plough 
USA 570 Drug Delivery Yes 
Oncaspar Polymer-Protein Conjugate Leukemia Enzon, Sanofi-
Aventis 
USA/ France 8 Drug Delivery Yes 
Somavert Polymer-Protein Conjugate Acromegaly Nektar, Pfizer USA 5 Drug Delivery Yes 
Copaxone Polymeric Drug Multiple Sclerosis TEVA 
Pharmaceuticals 
Israel 940 Drug Delivery Yes 
Renagel Polymeric Drug Kidney Failure Genzyme USA 350 Drug Delivery Yes 
Rapamune Nanosuspensions Immunosuppressant Elan/Wyeth Ireland/USA 240 Drug Delivery Yes 
Emend Nanosuspension Anti-emetic Elan/Merck & Co., 
Inc 
Ireland/USA 29 Drug Delivery Yes 
Abraxane (ABI-007) Nanoparticle (Albumin) Cancer American 
Pharmaceutical  
USA 23 Drug Delivery No 
Imaging   
Feridex/Endorem Iron Nanoparticles Liver tumors Advanced 
Magnetics/Guerbet 
USA/France NA Imaging Yes 
Gastromark/Lumirem  Iron Nanoparticles Abdominal diseases Advanced 
Magnetics/Guerbet 
USA/France NA Imaging Yes 
Resovist (Ferucarbotran) Iron Nanoparticles Liver tumors Schering Germany NA Imaging Yes 
In vitro Diagnostics   
cellsave/celltracks Magnetic nanoparticles and 
instrumentation 
Clinical cell separation Immunicon USA NA IVD N.A. 
CliniMacs Magnetic nanoparticles and 
instrumentation 
Clinical cell separation Milenyi Biotec Germany NA IVD Yes 
Colloidal Gold Gold nanoparticles for 
lateral flow tests 
e. g. pregnancy British Biocell UK NA IVD Yes 
Collloidal Gold Gold nanoparticles for e. g. pregnancy Amersham UK NA IVD Yes 
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Therapeutic  
agent/Medical Device 
Nanotechnology 
component 
Indication Company Country Sales 
2003/2004 
million $ 
Medical 
Sector 
Available in 
at least one 
EU25 
country 
lateral flow tests 
Colloidal Gold  Gold nanoparticles for 
lateral flow tests 
Alzheimer Nymox USA NA IVD N.A. 
Dynabeads Magnetic nanoparticles Clinical cell separation Dynal/Invitrogen Norway/USA NA IVD Yes 
Biomaterials   
Acticoat (TM) Silver Nanoparticle based 
wound dressing 
Antimicrobial wound care Nucryst USA 25 Implants Yes 
Ceram X duo Nanoceramic restorative Dentistry Dentsply UK NA Implants Yes 
Filtek Supreme Nanocomposite dental 
restorative 
Dentristy  3M Espe Germany/ USA NA Implants Yes 
Mondial Nanoparticle containing 
dental prosthesis 
Dentistry Heraeus Kulzer Germany NA Implants Yes 
Ostim Nano-hydroxyapatite Bone defects Osartis Germany NA Implants Yes 
PerOssal Nano-hydroxyapatite  based 
bone substitute 
bone defects Coripharm Germany NA Implants Yes 
Premise Nanocomposite dental 
restorative 
Dentistry Sybron Dental 
Specialities 
USA 4 Implants N.A. 
Tetric EvoCeram Nanocomposite denta 
restorative 
Dentistry Ivoclar Vivadent Liechtenstein NA Implants Yes 
Vitoss Nano-hydroxyapatite Bone defects Orthovita USA 7.8 Implants Yes 
Active Implants   
Fractal Electrodes Fractale electrodes for 
pacemaker 
Heart failure Biotronik Germany NA Active 
Implants 
Yes 
Cosmetics (Examples)        
Capture Liposomes Anti-Aging Christian Dior Frnace NA Cosmetics Yes 
Dermo-Expertise Liposomes Anti-Aging L'Oreal France NA Cosmetics Yes 
Hydra Zen Liposomes Anti-Aging L'Oreal France NA Cosmetics Yes 
Hydrazone Liposomes Anti-Aging Guinot France NA Cosmetics Yes 
Liftosome Liposomes Anti-Aging Guinot France NA Cosmetics Yes 
Liposome Lotion Liposomes Anti-Aging Cali USA NA Cosmetics Yes 
Nanobase Solid Lipid Nanoparticles Moisturiser Astellas Japan NA Cosmetics N.A. 
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Therapeutic  
agent/Medical Device 
Nanotechnology 
component 
Indication Company Country Sales 
2003/2004 
million $ 
Medical 
Sector 
Available in 
at least one 
EU25 
country 
(Yamanouchi)  
Plentitude Nanocapsules Anti-Aging L'Oreal France NA Cosmetics Yes 
Primordiale Intense Eye Nanocapsules Anti-Aging L'Oreal France NA Cosmetics Yes 
Re-Surface Nanocapsules Anti-Aging L'Oreal France NA Cosmetics Yes 
Extra Protective TiO2, ZnO Sunscreen Beiersdorf Germany NA Cosmetics N.A. 
Sun Age Defence TiO2 Sunscreen Beiersdorf Germany NA Cosmetics N.A. 
Sunblock SPF 15 TiO2 Sunscreen Pevonia Botanica USA NA Cosmetics N.A. 
Suncare TiO2 Sunscreen Cellex-C Canada NA Cosmetics N.A. 
Ti.Silc SPF45 TiO2 Sunscreen Sheer Spain NA Cosmetics N.A. 
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Companies with Nanomedicine Activities 
Explanation of abbreviation and categories:  
1) Company size: Start-ups = spin-offs from universities or companies; SME = companies with less than 500 employees mostly profitable at least mature status of product 
development; Corporation = companies with more than 500 employees.  
2) Development status of most advanced Nanotechnology enhanced product: M = Market, CP = Clinical Phase, PC = Preclinical Phase, Dev = Development status for sensors 
3) Nanomedicine involvement: Core = company focuses on Nanomedicine applications, Partly = company pursues several business segments including Nanomedicine, Peripheral = 
Company has minor activities in the field of Nanomedicine that are of little or peripheral importance for its business activities 
4) IVD = In vitro Diagnostics, NA= Not available 
 
Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
Drug Delivery         
Access 
Pharmaceuticals 
Dallas, TX USA Start-up Drug Delivery  Polymer-Drug Conjugates CP Partly Drug Delivery 
Activery Barcelona Spain Start-up Drug Delivery Development of nanostructured 
DDS 
NN Core Drug Delivery 
Acusphere Watertown, MA USA Start-up Speciality Pharmaceuticals Drug Nanoparticles CP Partly Drug Delivery 
Advanced Magnetics Cambridge, MA USA SME Biopharmaceuticals Iron Nanoparticles M Core Drug Delivery 
Alnis Biosciences Emeryville, CA USA Start-up Biopharmaceuticals Polymer Nanoparticles NN Core Drug Delivery 
Altair Reno, NV USA Start-up Nanotechnology Inorganic Nanoparticles PC Partly Drug Delivery 
ALZA Mountain View, 
CA 
USA Corporation Drug Delivery Liposomes, Doxil, Caelyx M Partly Drug Delivery 
American 
Pharmaceutical 
Partners 
Los Angeles USA Corporation Pharmaceuticals Nanoparticles, Nanosuspensions M Partly Drug Delivery 
Amgen Thousand Oaks, 
CA 
USA  Corporation Biopharmaceuticals Liposomes CP Peripheral Drug Delivery 
Anosys Evry Cedex Fr / USA Start-up Biopharmaceuticals Dexoxomes, Vaccines CP Core Drug Delivery 
Antigenics New York USA SME Biopharmaceuticals Liposomes CP Partly Drug Delivery 
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Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
Aphios Woburn USA SME Biopharmaceuticals Polymer Nanospheres NN Partly Drug Delivery 
Baxter Deerfield, IL USA Corporation Pharmaceuticals, Medical 
Products 
Nanosuspensions CP Peripheral Drug Delivery 
Bayer Healthcare Lerverkusen Germany Corporation Pharmaceuticals Liposomes CP Peripheral Drug Delivery 
Berna Biotech AG Bern Switzerland Corporation Biopharmaceuticals Liposomes M Partly Drug Delivery 
Bioalliance Pharma Paris France Start-up Biopharmaceuticals Polymer Nanoparticles CP Partly Drug Delivery 
Biodelivery Sciences Newark, NJ USA Start-up Speciality 
Biopharmaceuticals 
Phospholipid Nanotubes NN Partly Drug Delivery 
Biofontera Lerverkusen Germany Start-up Speciality Pharmaceuticals Nanocolloids, Phototherapy CP Partly Drug Delivery 
Biomira Edmonton Canada SME Biopharmaceuticals Liposomes CP Partly Drug Delivery 
Biosante Lincolnshire, IL USA Start-up Biopharmaceuticals Nanosuspensions, Inorganic 
Nanoparticles 
CP Partly Drug Delivery 
Callisto 
Pharmaceuticals 
New York USA SME Biopharmaceuticals Liposomes CP Partly Drug Delivery 
Capsulution Berlin Germany Start-up Polymer Capsules Polymer Nanocapsules NN Core Drug Delivery 
Cell Therapeutics Seattle USA SME Pharmaceuticals Polymer-Drug Conjugates CP Partly Drug Delivery 
Celltech Slough UK Corporation Biopharmaceuticals Polymer-Protein Conjugates CP Peripheral Drug Delivery 
Celmed Saint-Laurent Canada SME Biopharmaceuticals Drug Nanoparticles CP Partly Drug Delivery 
Celsion Columbi, MD USA Start-up Pharmaceuticals, Medical 
Equipment 
Liposomes CP Partly Drug Delivery 
Chugai Tokyo Japan Corporation Pharmaceuticals Liposomes CP Peripheral Drug Delivery 
Copernicus 
Therapeutics 
Cleveland USA SME Biopharmaceuticals Gene delivery with liposomes NN Partly  Drug Delivery 
CritiTech Lawrence, KN USA Start-up Drug Delivery Submicron drug nanoparticles NN Core Drug Delivery 
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Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
Cytimmune Rockville, MD USA Start-up Biotechnology, DDS Gold Nanoparticles NN Core Drug Delivery 
Cytokine 
PharmaSciences 
King of Prussia, 
PA 
USA Start-up Biopharmaceuticals, DDs Nanosuspensions PC Partly Drug Delivery 
Dabur Pharma New Delhi India SME Pharmaceuticals Polymeric Micelles CP Partly Drug Delivery 
Daiichi 
Pharmaceutical  
Tokyo Japan Corporation Pharmaceuticals Liposomes NN Peripheral Drug Delivery 
Delex Therapeutics Mississauga Canada Start-up Biopharmaceuticals, DDS Liposomes CP Partly Drug Delivery 
Dendritic 
Nanotechnologies 
Mount Pleasant, 
MI 
USA Start-up Nanotechnology Dendrimers PC Partly Drug Delivery 
Do-Coop 
Technologies 
Or-Yehuda Israel Start-up  Life Sciences Hydrated Nanoparticles  NN Core Drug Delivery 
Eiffel Technologies North Ryde Australia SME Drug Delivery Drug Nanoparticles NN Partly Drug Delivery 
Elan Dublin Ireland Corporation Pharmaceuticals / 
Biotechnology 
Liposomes, Nanosuspensions M Partly Drug Delivery 
Endovasc Montomery, AL USA SME Biopharmaceuticals Liposomes CP Partly Drug Delivery 
Enzon Bridgewater, NJ USA SME Biopharmaceuticals Liposomes, Polymer-Drug 
Conjugates 
M Partly Drug Delivery 
Esteve Barcelona Spain Corporation Pharmaceuticals/Chemicals Polymer Nanoparticles PC peripheral Drug Delivery 
Eurand Milan Italy SME Drug Delivery Polymer-Drug Conjugates NN Partly Drug Delivery 
EyeTech 
Pharmaceutical 
New York USA Start-up Biopharmaceuticals Polymer-Aptamer Conjugates CP Partly Drug Delivery 
Flamel Venissieux France SME Biotechnology, DDS Poly-aminoacid Nanoparticles CP Partly Drug Delivery 
Fujisawa Osaka Japan Corporation Pharmaceuticals Liposomes M Peripheral Drug Delivery 
Genzyme Cambridge, MA USA Corporation Biotechnology Polymeric Drugs M Peripheral Drug Delivery 
Gilead Foster City, CA USA Corporation Biopharmaceuticals Liposomes M Peripheral Drug Delivery 
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Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
Hoffmann-La Roche Basel Switzerland Corporation Pharmaceuticals Polymer-Protein Conjugates M Peripheral Drug Delivery 
IDEA München Germany Start-up Biopharmaceuticals Transfersomes CP Core Drug Delivery 
INEX 
Pharmaceuticals 
Corp 
Burnaby Canada SME Drug Delivery Liposomes CP Core Drug Delivery 
Insert Therapeutics Pasadena, CA USA SME Drug Delivery Polymer-Drug Conjugates NN Core Drug Delivery 
Intermune Brisbane Australia SME Biopharmaceuticals Liposomes M Partly Drug Delivery 
Intradigm Rockville, MD USA Start-up SiRNA Therapeutics Synthetic Nanoparticles  PC Partly Drug Delivery 
Introgen Austin, TX USA SME Biopharmaceuticals Nanoparticle DDS CP Partly Drug Delivery 
Labopharm Laval, Quebec Canada SME Speciality Pharmaceuticals Polymer Micelles PC Partly Drug Delivery 
LiPlasome Pharma Lyngby Denmark SME Biotechnology, DDS Lipid Based Nanocarriers PC Core Drug Delivery 
Liquids Research 
Limited 
Bangor UK SME Ferrofluids Magnetic nanoparticles as DDS NN Partly Drug Delivery 
MaganMedics Aachen Germany Start-up Speciality Pharmaceuticals Iron Nanoparticles PC Partly  Drug Delivery 
MAP 
Pharmaceuticals 
Mountain View, 
CA 
USA Start-up Drug Delivery Nanoparticle DDS CP Partly Drug Delivery 
Medigene Martinsried, San 
Diego 
Ger/USA SME Biotechnology Liposomes CP Partly Drug Delivery 
Medinova 
(Nanopharm) 
Magdeburg Germany Start-up Pharmaceutical Technology Polymer Nanoparticles PC Core Drug Delivery 
Meiji Seika Kaisha 
(Tedec Meiji) 
Tokyo Japan Corporation Pharmaceuticals, Food, 
Consumer 
Liposomes CP Peripheral Drug Delivery 
Merck & Co Inc. Whitehouse 
Station, NJ 
USA Corporation Pharmaceuticals Nanosuspensions M Peripheral Drug Delivery 
Merck KGaA Darmstadt Germany Corporation Speciality Chemicals, Liposomes CP Peripheral Drug Delivery 
Appendix  
 
 
103
Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
Pharmaceuticals 
Mountain View 
Pharmaceuticals 
Menlo Park, CA USA SME Biopharmaceuticals, DDS Polymer-Drug/Protein 
Conjugates 
CP Core Drug Delivery 
Nanobio Corp. Ann Arbor USA Start-up Biopharmaceuticals Nanoemulsions CP Core Drug Delivery 
Nanobiomagnetics Edmond, OK USA Start-up Nanobiotechnology Magnetic Nanospheres PC Core Drug Delivery 
Nanocarrier Chiba Japan Start-up Drug Delivery Polymer-Micelles CP Core Drug Delivery 
Nanocure Ann Arbor USA Start-up Biopharmaceuticals, DDS Dendrimers PC Core Drug Delivery 
NanoCyte Inc. Jordan Valley Israel Start-up Biotechnology Nanotubes  NN Partly Drug Delivery 
Nanodel Magdeburg Germany Start-up Drug Delivery  Polymeric nanoparticles DDS NN Core Drug Delivery 
Nanomed 
Pharmaceuticals 
Kalamazoo, MI USA Start-up Drug Delivery Nanoparticles, Nanotemplate 
Engineering 
NN Core Drug Delivery 
NanoMedica Newark USA Start-up Speciality Pharmaceuticals Nanoscale DDS NN Core Drug Delivery 
Nanopharmacology Plymouth, MN USA Start-up Nanomedicine Nanoshells PC Core Drug Delivery 
Nanotherapeutics Alachua, FL USA Start-up Nanomedicine Nanosuspensions NN Core Drug Delivery 
Nektar San Carlos, CA USA Corporation Drug Delivery Polymer-Protein Conjugates M Partly Drug Delivery 
Neopharm Lake Forest, IL USA SME Biopharmaceuticals Liposomes CP Partly Drug Delivery 
Nippon Kayaku Tokyo Japan Corporation Chemicals/Pharmaceuticals Polymeric Micelles CP Peripheral Drug Delivery 
Nippon Oils & Fats Tokyo Japan SME Chemicals Liposomes NN Partly Drug Delivery 
Nippon Shinyaku Kyoto Japan Corporation Pharmaceuticals Gene delivery with lipoplexes NN Peripheral Drug Delivery 
Nobex Research 
Triangle Park 
USA Start-up Drug Delivery Polymer-Protein Conjugates CP Partly Drug Delivery 
Novagali Evry France Start-up Drug Delivery/Drug 
Development 
Cationic Emulsions CP Core Drug delivery 
Novartis Basel Switzerland Corporation Pharmaceuticals Liposomes M Peripheral Drug Delivery 
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Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
Novavax Malvern, PA USA SME Biopharmaceuticals Micellar Nanoparticles M Partly Drug Delivery 
Novosom Halle Germany SME Liposomes Liposomes NN Core Drug Delivery 
Nucryst Wakefield, MA USA Start-up Pharmaceuticals Nanosuspensions CP Partly Drug Delivery 
OSI Pharmaceuticals Melville, NY USA SME Biopharmaceuticals Liposomes CP Partly Drug Delivery 
OZ Biosciences Marseille France Start-up Drug Delivery Magnetic nanoparticles for 
transfection  
M Core Drug Delivery 
PAR 
Pharmaceuticals 
Spring Valley, 
NY 
USA Corporation Generic Pharmaceuticals Nanocrystal CP/
M 
Peripheral Drug Delivery 
Pfizer New York USA Corporation Pharmaceuticals Polymer-Protein Conjugates M Peripheral Drug Delivery 
Pharmasol Berlin Germany Start-up Drug Delivery Nanosuspensions CP Core Drug Delivery 
Phoenix 
Pharmacologics 
Lexington, KY USA SME Biopharmaceuticals Polymer-Protein Conjugates CP Core Drug Delivery 
pSivida Perth Australia/U
K 
Start-up Biopharmaceuticals BioSilicon, Nanopores CP Core  Drug Delivery 
QLT Vancouver Canada SME Biopharmaceuticals Liposomes M Partly Drug Delivery 
Regeneron 
Pharmaceuticals 
Tarrytown, NY USA Corporation Biopharmaceuticals Polymer-Protein Conjugates CP Partly Drug Delivery 
Sanofi-Aventis Strasbourg France Corporation Pharmaceuticals Polymer-Protein Conjugates, 
Nanosuspensions 
NN Peripheral Drug Delivery 
Savient 
Pharmaceuticals 
East Brunswick, 
NJ 
USA SME Speciality Pharmaceuticals Polymer-Protein Conjugates CP Partly Drug Delivery 
Schering Plough Kenilworth, NJ USA Corporation Pharmaceuticals Liposomes, Polymer-Protein 
Conjugates 
M Peripheral Drug Delivery 
Shire 
Pharmaceuticals 
Basingstoke UK Corporation Pharmaceuticals Inorganic Nanoparticles CP Peripheral Drug Delivery 
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Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
SkyePharma London UK SME Drug Delivery Liposomes, Nanosuspensions M Partly Drug Delivery 
Soliqs Ludwigshafen Germany SME Drug Delivery Nanosuspensions NN Partly Drug Delivery 
Solubest Ness Ziona Israel Start-up Drug Delivery Polymer Nanoparticles NN Core Drug Delivery 
Spherics Lincoln, RI USA Start-up Drug Delivery  Polymer Nanospheres NN Partly Drug Delivery 
Supergen Dublin, CA USA  SME Pharmaceuticals Nanosuspensions CP Partly Drug Delivery 
Supratek Dorval, Quebec Canada Start-up Drug Delivery Polymer Micelles CP Partly Drug Delivery 
Terumo  Tokyo Japan Corporation Medical Devices, 
Pharmaceuticals 
Liposomes NN Peripheral Drug Delivery 
Teva Pharmaceutical 
Industries 
Petach Tikva Israel Corporation Healthcare, 
Pharmaceuticals 
Polymeric Drugs M Peripheral Drug Delivery 
Transave Monmouth, NJ USA SME Biotechnology Gene delivery with liposomes NN Partly  Drug Delivery 
Transgenex 
Nanobiotech 
Tampa, FL USA Start-up Nanomedicine Polymer Nanoparticles PC Core Drug Delivery 
Valentis Burlingame, CA USA SME Biotechnology Gene delivery with cationic 
lipids 
NN Partly Drug Delivery 
Wyeth-Ayerst Madison, NJ USA Corporation Pharmaceuticals Nanosuspensions M Peripheral Drug Delivery 
Xstalbio Glasgow UK Start-up Advanced Drug Delivery Nanostructured DDS NN Core Drug Delivery 
Zilip-Pharma Amsterdam The 
Netherlands
Start-up Biotechnology Liposomes CP Core Drug Delivery 
Drugs & Therapies         
C Sixty Houston, TX USA Start-up Nanomedicine Fullere Drugs and DDS PC Core Drugs/Therapies 
ImaRx Tucson, AZ USA Start-up Nanomedicine Lipid Nanospheres CP/
M 
Core Drugs/Therapies 
Magforce 
Nanotechnologies 
Berlin Germany Start-up Nanotechnology Iron Nanoparticles, 
Thermotherapy 
CP Core Drugs/Therapies 
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Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
Nanobiotix Labege France Start-up Nanotechnology Magnetic Nanoparticles PC Core Drugs/Therapies 
Nanospectra 
Bioscience 
Houston, TX USA Start-up Nanotechnology Nanoshells, Thermotherapy NN Core Drugs/Therapies 
Starpharma Melbourne Australia SME Dendrimers Dendrimer Drugs CP Core Drugs/Therapies 
Triton Biosystems Chelmsford MA USA SME Speciality Pharmaceuticals Magnetic Nanoparticles PC Core Drugs/Therapies 
Imaging         
BioCrystal Westerville, OH USA Start-up Bioanalytics/Biopharmaceu
tics 
Nanocrystal Probes, 
Flowcytometry 
M Core Imaging 
Chemicell Berlin Germany Start-up Magnetic Nanoparticles Magnetic nanoparticles DDS and 
imaging agents 
M Core Imaging 
Ferropharm Berlin Germany Start-up Diagnostic Imaging Nanoparticle MRI contrast 
agents 
M Core Imaging 
Guerbet Roissy France SME Diagnostic Imaging Nanoparticle MRI contrast 
agents 
M Peripheral Imaging 
Philips Medical 
Systems 
Best The 
Netherlands
Corporation Diagnostic Imaging Imaging modalities/contrast 
agents 
Dev Peripheral Imaging 
Schering Berlin Germany Corporation Pharmaceuticals  
and Diagnostics 
Nanoparticle MRI contrast 
agents 
M Peripheral Imaging 
Siemens München Germany Corporation Diagnostic Imaging Imaging systems, Electrical 
Biochips 
Dev Peripheral Imaging 
Visen Medical Woburn, MA  USA Start-up  Diagnostic Imaging Nanoparticle fluorescence 
contrast agent 
PC Partly Imaging 
Kereos Saint Louis, MO USA Start-up Nanomedicine Perfluorocarbon Emulsions PC Core Imaging 
Luna Nanomaterials Blacksburg, Va USA SME Technology/Engineering Metal Encapsulating Fullerenes NN Partly  Imaging 
Amersham/GE Little Chalfont UK Corporation Medical Diagnostics and Colloidal gold for diagnostic M peripheral Imaging 
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Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
Life Sciences applications 
In vitro Diagnostics         
Akubio Cambridge UK Start-up Nanobiotechnology Acoustic Biosensors Dev Core IVD 
Ambri Chatswood Australia SME Nanobiotechnology Biosensor, Biochips Dev Core IVD 
Aurion Wageningen The 
Netherlands
SME Immuno Gold Colloidal gold M Core IVD 
Bioforce 
Nanoscience 
Ames, IA USA Start-up Nanotechnology AFM, Nanoarrayer Dev Core IVD 
Biogenon Oulu Finland Start-up Nanobiotechnology Sensors Nanotechnology Biosensors  Dev Core IVD 
Biognostic Berlin Germany Start-up Diagnostics Nano-encapsulated dyes for 
immuno tests 
Dev Partly IVD 
British Biocell Cardiff UK SME Colloidal gold Colloidal gold for lateral flow 
tests 
M Core IVD 
Cantion Lyngby Denmark Start-up Nanotechnology Cantilever Biochips NN Core IVD 
CombiMatrix Corp Mukilteo USA SME Drugs and Diagnostics, 
Technology 
Biochip with electrochemical 
detection, nanostructured 
Dev Partly IVD 
Concentris Basel Switzerland Start-up Cantilever Sensors Cantilever Sensors for chemical 
and biochemical sensing  
NN core IVD 
Dynal/Invitrogen Oslo Norway SME Biomagnetic Separation 
Technology 
Superparmagnetic particles M Partly IVD 
eBiochip Itzehoe Germany Start-up Biochips Nanoelectrodes for biochips NN Core IVD 
Evident 
Technologies 
New York USA Start-up Nanotechnology Quantum Dots Dev Partly IVD 
Evotec Technologies Hamburg Germany SME Technology Provider for 
Life Sciences 
 GMI biosensor Dev Peripheral IVD 
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Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
Genefluidics Monterey Park USA Start-up Bioanalytics Microchips with nanotech 
components 
Dev Partly IVD 
Immunicon Monterey Park USA SME Nanobiotechnology 
Microfluidics 
Magnetic nanoparticles for cell 
separation, cancer diagnostic 
M Core IVD 
Maxwell Sensors Santa Fe Springs USA  Start-up Medical Sensors Quantum Dot beads NN Partly IVD 
Micromod Rostock Germany SME Bioanalytics Nanoparticles for bioanalytics M Partly IVD 
Miltenyi Biotec Bergisch 
Gladbach 
Germany SME Biotechnology, Cellular 
Technologies 
Superparamagnetic nanoparticles 
for cell separation 
M Partly IVD 
Nanoco Manchester UK Start-up Nanotechnology Quantum dots for healthcare 
applications 
NN Partly IVD 
Nanomix Emmeryville USA Start-up Nanotechnology CNT based Sensors for medical 
applications 
Dev Partly IVD 
Nanoplex Menlo Park, CA USA Start-up Nanotechnology Nanobarcode Particles Dev Partly IVD 
Nanoprobes Yaphank, NY USA SME Bioanalytics Gold Nanoparticles M Core IVD 
Nanosphere Northbrook IL USA Start-up Bioanalytics Gold Nanoprobes Dev Core IVD 
Nomadics Stillwater, OK USA SME Sensor Technology SPR Sensors NN Partly IVD 
Nymox Maywood USA SME Biopharmaceutical 
Company 
Colloidal gold for Alzheimer 
diagnostic 
M Partly IVD 
Orasure Bethlehem USA SME Medical Diagnostics Upconverting Phosphor 
technology 
NN Partly IVD 
QuantumDot Hayward, CA USA Start-up Bioanalytics Qdot-Nanocrystals Dev Core IVD 
Ademtech Pessac 
(Bordeaux) 
France Start-up Magnetic Microbeads Nanomagnetical materials for 
diagnostics  
M Core IVD 
Oxonica Kidlington UK SME Nanomaterials Nanoparticles for diagnostics M Partly IVD 
Sensia Madrid Spain Start-up Life Science Analytics SPR and cantilever sensors incl. NN Partly IVD 
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Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
for diagnostic applications 
Solexa Cambridge UK UK Start-up Bioanalytics Nanotechnology based DNA 
Biochips  
Dev Core  IVD 
Sphere Medical 
Limited 
Cambridge UK Start-up Diagnostic Products Nanoimprinted receptor 
materials for diagnostic sensors 
NN Partly IVD 
Implants         
MIV Therapeutics 
Inc 
Vancouver Canada Start-up Biomaterials Nano-film Hydroxyapatite Dev Partly Implant 
 Fidia Advanced 
Biopolymers 
Abano Terme Italy SME Biomaterials Nanotechnology applications for  
regenerative medicine 
NN Peripheral Implants 
3M Espe St. Paul, MN USA Corporation Dental Materials Nanocomposite dental restorative M Peripheral Implants 
Alchimer Massy  France Start-up Coatings  Nanostructured (electrografted) 
surfaces for medical implants 
NN Core Implants 
Alcove Gladbeck Germany Start-up Surface Technology  Nanoporous coatings for stents NN partly Implants 
Angstrom Medica Woburn, MA USA Start-up Biomaterials Nanocrystalline Calcium 
Phosphate 
M Core Implants 
Blue Membrane Wiesbaden Germany Start-up Nanostructured Composite 
Materials 
Nanotechnology based coatings 
for implants and medical devices 
Dev Partly Implants 
Coripharm Dieburg Germany SME Biomaterials for Bone 
Repair 
Bone substitute materials based 
on nanocrystalline 
hydroxyapatite  
M Partly Implants 
Debiotech Lausanne Switzerland SME Medical Devices Nanoporous coatings for stents NN Peripheral Implants 
Dentsply Weybridge UK Corporation Dental Products Nanoceramic restoratives M Peripheral Implants 
DePuy Orthopedics Warsaw, Indiana USA Corporation Orthopedic Care Nanoapatite coatings for 
orthopedic implants 
NN Peripheral Implants 
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Erothitan Suhl Germany SME Implant Technology Nanoparticle based HA coatings 
for titanium implants 
Dev Partly Implants 
GfE Medizintechnik 
GmbH 
Nürnberg Germany SME Surface Technology for 
Medical Implants 
Nanoscale titanized plastic 
implants 
Dev Core Implants 
Hemoteq GmbH Wuerselen Germany Start-up Medical Devices Supplier Nanocoatings NN Core Implants 
Heraeus Kulzer Hanau Germany Corporation Dental Prothesis Nanopearls, inorganic 
nanomaterials for dental 
prothesis 
M Peripheral Implants 
Inframat Corp Farmington CT USA Start-up Nanotechnology Research  Nano-apatite coatings for 
implants 
Dev Partly Implants 
Ivoclar Vivadent Schaan Liechtenstei
n 
Corporation Dental Materials Nanocomposite dental restorative M Peripheral Implants 
Nano Interface 
Technology, Inc. 
Lorton, VA USA Start-up Medical Devices nano-hydroxyapatite NN Core Implants 
Nanomatrix Dallas TX USA Start-up Medical Devices Collagen nanofibers NN Core Implants 
Nucryst Wakefield MA USA SME Medical Devices Antimicrobial dressing based on 
silver nanocrystals 
M Core Implants 
Orthovita Malvern, PA USA SME Biomaterials Nanoparticle based bone 
replacement 
M Peripheral Implants 
Osartis Obernburg Germany SME Biomaterials Nanocrystalline hydroxyapatite M Core Implants 
PlasmaChem Berlin Germany SME Plasma Ultra-Thin Tilm 
Technology 
Nanoscale coatings for stents NN Partly Implants 
QuantumSphere Costa Mesa USA Start-up Nanomaterials Nanosilver for medical/cosmetic 
applications 
M Partly Implants 
Raymor Industries Montreal Canada SME Advanced Materials, Nano-sized titanium powder for M Partly Implants 
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Nanomaterials biomedical markets 
Stryker Kalamazoo USA Corporation Orthoaedics Use of nano-sized titanium 
powder for implants 
NN Peripheral Implants 
Sustech Darmstadt Germany Start-up Nanotechnology Research 
Company 
Nano-apatite for dental 
applications 
M Partly Implants 
Sybron Dental 
Specialities 
West Collins 
Orange 
USA Corporation Dental Products Nanocomposite dental restorative M Peripheral Implants 
Bio-Gate Nürnberg Germany Start-up Silver Nanoparticles Silver nanoparticles for medical 
devices 
M Partly Implants 
Sarastro Quierschied-
Goettelborn 
Germany Start-up Nanocoatings Antimicrobial nano-coatings NN Partly Implants 
Active Implants         
iMedd Columbus, OH USA Start-up Biomedical Nanoporous membranes Dev Partly Active Implants 
Microchips Cambridge, MA USA Start-up Medical Devices Nanomembranes  Dev Partly Active Implants 
Biophan West Henrietta, 
NY 
USA Start-up Medical Devices Nanoparticle Coatings,  Dev Core Active Implants 
Biotronik Berlin Germany Corporation Biomedical Technology 
Company 
Fractal coatings for pacemaker 
electrodes 
M Peripheral Active Implants 
Med-EL Innsbruck Austria SME Cochlear Implants Nanotechnology applications in 
screening status 
Dev Peripheral Active Implants 
Retina Implant AG Reutlingen Germany Start-up Retina Implants Nanoporous thinfilm electrodes Dev Peripheral Active Implants 
Second Sight Sylmar USA Start-up Retina Prosthesis Nanostructured diamond 
coatings for retina implants 
Dev Peripheral Active Implants 
Cosmetics 
(Examples) 
        
Appendix 
 
 
 
112
Company  Town Country Size Business Segment Nanotechnology Stat
us 
Nano-
medicine 
Medical Sector 
Beiersdorf Hamburg Germany Corporation Consumer Goods TiO2 Nanopowders M Peripheral Cosmetic 
BioSpectrum Yongin City Korea SME Life Science / Skin Care Liposomes M Partly Cosmetic 
Cali New York USA NA Cosmetics Liposomes M NA Cosmetic 
Cellex-C Toronto Canada NA Cosmetics TiO2 M NA Cosmetic 
Chenyin Technology Shenzhen China SME Hightech Materials TiO2 Nanopowders M Partly Cosmetics 
Christian Dior Paris France Corporation Cosmetics Liposomes M Peripheral Cosmetics 
Engelhard/Coletlica Iselin, NJ USA Corporation Surface and Material 
Science 
Nanoencapsulation M Partly Cosmetics 
Guinot Paris France Corporation Cosmetics Liposomes M Peripheral Cosmetics 
L’Oreal Paris France Corporation Cosemtics Liposomes, Nanocapsules M Partly Cosmetics 
Pevonica Botanica Daytona Beach, 
FL 
USA NA Cosmetics TiO2 M NA Cosmetics 
Sheer Sant Boi de 
Llobregat 
Spain NA Cosmetics TiO2 M NA Cosmetics 
Astellas Pharma 
(Yamanouchi) 
Tokyo Japan Corporation Pharmaceutics Solid Lipid Nanoparticles M Peripheral Cosmetics 
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nanobiotechnology applications and products 
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